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ABSTRACT  
 
Exposure to milk caseins beyond the normal weaning age in rats (21 days) was shown to impact 
the development of the opioid system, a key player in emotional regulation. Further, milk alters 
the gut microbiome and evidence suggests the gut microbiota can modify brain function and 
behaviour. Given such evidence, it is hypothesised exposure to milk casein and its bioactive 
breakdown product, beta casomorphin-7 (BCM-7) beyond weaning age in rats results in 
disruptions to brain neurochemistry and behaviour via a microbiome-gut-brain axis 
mechanism. This work aimed to investigate this hypothesis using in vivo behavioural, 
neurochemical, gut microbial and metabonomic studies.  
The behavioural results showed that exposure to casein from postnatal day 21-26 resulted in 
an increase in ‘depressive-like’ behaviour as measured by the forced swim test (FST) and that 
BCM-7 is not the only casein derived product driving such behavioural impairments. 
Quantitative autoradiography revealed the casein induced depressive phenotype was 
concomitant with changes to oxytocin and opioid receptors in regions of the brain associated 
with mood. Fluorescence in situ hybridization showed an increase in Clostridium Histolyticum 
in the gut suggesting a microbiome-gut-brain axis role in the casein induced changes reported. 
In line with this, antibiotic knock-down of gut microbial activity not only prevented the 
development of the casein induced depressive phenotype, but also caused a casein independent 
antidepressive-like effect as assessed by the FST. Lastly, metabonomic analysis revealed an 
increase in gut microbial metabolites and disruptions to choline and energy metabolism in 
response to prolonged casein exposure, which have been implicated in mood disorders.  
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Collectively, these findings suggest casein exposure beyond weaning age results in 
neurochemical and emotional impairments via a potential microbiome-gut-brain axis 
mechanism. This indicates that prolonged breastfeeding periods may cause mood disorders in 
humans and highlight the need for more comprehensive guidelines regarding an appropriate 
weaning age. 
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1.1 Early Life Development and Weaning 
 
Early childhood represents a period in which the most rapid development occurs in humans. 
The years from conception through to eight years of age are critical for healthy, cognitive, 
emotional and physical growth of children. The cell precursors of the brain and spinal cord, 
which compose the central nervous system (CNS) begin to develop early in embryonic life and 
extend into the postnatal period. By two years of age the human brain reaches 80-90% of its 
adult size (Clancy et al., 2007). Therefore, during this period of rapid growth and development, 
the CNS is in a state of constant change and plasticity and hence a stage at which it is sensitive 
to both genetic and environmental influences (see Rice and Barone 2000). 
Research has shown that environmental determinants such as early nutrition, stress, levels of 
stimulation and social interaction all exert a critical impact on the maturation of brain structure 
and behavioural function (see Loman and Gunnar, 2010; Lucassen et al., 2013). The ability of 
the CNS to change and adapt to both internal and external stimuli is an important characteristic 
which allows it to generate a range of phenotypes suitable for different environments. However, 
developmental plasticity can also play a role in the generation of psychiatric disorders (see 
Borre et al., 2014). 
The concept of early life nutrition as a key environmental factor influencing brain development 
and subsequent adult behaviour is fast gaining credence (for a review see Sachser et al., 2011; 
Sachser, et al., 2013; Pryce and Feldon 2003). Unlike other environmental factors, nutrition 
can directly influence brain development by providing the specific molecules, which enable 
genes to exert their targeted effects on brain growth and development. For example, normal 
brain development requires adequate concentrations of certain nutrients such as choline, folic 
acid, iron, zinc and special fats which enable genes to exert their effect on brain development 
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and are obtained through the diet (Bryan et al., 2004). Therefore factors influencing dietary 
intake in early life will subsequently effect normal brain development. 
One of the most important nutritional events in the early stages of life in all milk-producing 
mammals is weaning. The term weaning comes from the Anglo-Saxon word “wenian” meaning 
“to become accustomed to something different”. Weaning can be generally defined as a gradual 
process involving a progressive reduction in rate of milk transfer from the mother to her young, 
accompanied by an increasing intake of solid food by the offspring, or for the purpose of this 
thesis, as the complete cessation of milk transfer from mother to young (abrupt or final wean).  
After weaning the young mammals become nutritionally and behaviourally independent from 
their mothers (Kikusui et al.,2008; Kikusui and Mori, 2009) . This weaning process is marked 
not only by a decline in maternal investment and offspring suckling but also a cascade of 
nutritional, immunological, microbiological, biochemical and psychological adjustments 
(Lawrence and Lawrence 1994). These changes which occur during weaning have very 
important influences on subsequent behaviours of the infants as they become adults (Kikusui 
et al., 2008). Therefore any manipulations to the weaning process are also likely to have an 
influence on behavioural development. 
1.1.1 Weaning in Rats 
 
The rat has long been used as the experimental species of choice in developmental research 
(Clancy et al., 2007). As a result the rat macro and micro neuroanatomy, neurophysiology and 
behaviour have become well mapped during development (see Raedler, Raedler and Feldhaus, 
1980; Bayer et al., 1993). As with humans, milk is the only source of nutrition for rat pups in 
early postnatal development (first two weeks of life in rats) (Thiels et al., 1990). Spontaneous 
weaning then begins around the third week of age and continues until around 30-34 days of 
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age when the pups cease milk intake (Kikusui et al., 2009). In rats, weaning occurs in nature 
with the birth of the next litter, circa 27 days. Although suckling can continue normally up until 
34 days of age, the time spent by offspring suckling reduces gradually and reaches adult levels 
well before, at or around 25 days of age (Thiels et al., 1990). For laboratory rats, females 
generally show postpartum oestrous and become pregnant again, which results in another 
delivery every 21 or 22 days. Therefore, to increase productivity, laboratory rats are generally 
weaned on postnatal day (PND) 21 (Kikusui et al., 2009). It should be noted that in laboratory 
settings “weaning” is defined as the day the mother is removed from her pups (Ferdman et al., 
2007; Curley et al., 2009) it reflects breakage of the bond between the dam and her offspring, 
which includes the cessation of suckling and physical separation from the dam and also the 
cessation of social protection (Kikusui et al., 2009). 
Several key differences between the laboratory rat and human brain maturation have been 
shown. Rat pups are born after a short gestation period of 22.5 days, compared to humans at 
280 days. Generally the new born rat CNS is equivalent approximately to a 24-week human 
foetus (Romijn et al.,1991). However the rat CNS maturation is much more accelerated in 
comparison to the human and is mature by three or four weeks (Clancy et al., 2007). 
Furthermore, it is estimated that the rat brain at PND1–10 equates to the 3rd trimester in humans 
and rat neurodevelopment at PND7 is equivalent to that of the human brain at birth (Clancy et 
al., 2007). Moreover, Quinn  (2005) has  provided details of age comparison between the rat 
and human in relation to weaning times in both species and have shown that a 42 day-old rat 
can be thought of as being equivalent to a 1 year-old human.  
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1.1.2    The Effect of Weaning Time on behaviour 
 
To date, there has been strong evidence from numerous laboratory models that experiences 
occurring in early life can have long term influences on neurobiology and behaviour during 
adulthood. In particular, studies in rodents show that variations in mother-infant interactions 
during the postpartum period leading-up to weaning can induce changes in gene expression in 
the brain leading to differences in stress reactivity, social and reproductive behaviour, cognition 
and reward mediated behaviour (Curley et al., 2009). Studies looking at the neurobehavioral 
consequences of manipulations to mother-infant interactions during the postnatal period have 
predominantly focused on maternal separation paradigms, more specifically focusing on “early 
weaning” in which mothers are removed between postnatal days 14 and 15 (early-weaned) or 
between postnatal days 20 and 25 (considered as normal or standard weaning), far less is 
documented on the effects of delayed weaning on offspring behavioural development.  
As summarised in Table 1.2 studies in mice have shown that removal of the dam prematurely 
at PND14 versus normal weaning at PND21, results in the early weaned animals being more 
aggressive (Kikusui et al., 2004), showing increased anxiety-like behaviour (Kikusui et al., 
Entire Life Span 
Weaning period 
Pre-pubertal period 
Adolescent period 
Adulthood 
Aged phase 
Average 
13.2 days 
42.4 days 
3.3 days 
10.5 days 
11.8 days 
17.1 days 
16.4 days 
= 1 Human year  
Table 1.1: Correlating a human year with rat days based on different phases of life. Taken and adapted 
from (Sengupta, 2013). 
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2005; Iwata et al., 2007) and increased general activity (Laviola et al.,1997; Kikusui et 
al.,2005). With respect to physiological and neural correlates, ‘early weaning’ was associated 
with an elevated neuroendocrine response to mild stress (Kikusui et al., 2006), decreased brain 
derived neurotrophic factor (BDNF) concentrations in the hippocampus (Kikusui et al., 2009) 
and altered myelin formation in the brain during the developmental period (Kikusui et 
al.,2007). Similar results were obtained in rats, where the removal of the mother at postnatal 
day 15 or 16 was also found to elevate levels of anxiety like behaviour and general activity 
(Kanari et al., 2005; Shimozuru et al., 2007). Moreover, male rats were found to be more 
vulnerable to early weaning induced stress than their female counterparts (Kikusui et al., 2006). 
Other changes seen in early-weaned female rodents include a reduction in maternal behaviour 
towards their own offspring, as well as producing offspring later in life (Kikusui et al., 2006). 
Together, these findings indicate that premature weaning exerts effects on later behavioural 
profile. 
As mentioned above, so far, relatively little is known about the effects of ‘late-weaning’ 
however studies summarised in Table 1.2 indicate that removal of the mother at later time 
points during early development also induces changes in the behavioural profile of male and 
female offspring. For example, Farshim et al., (2016) showed that delay weaning male rat pups 
on PND25 resulted in increased depressive-like behaviour compared to rats normally weaned 
on PND21. Moreover, a study by Cook, (1999) tested four different weaning schedules, 
including abrupt weaning where pups were removed entirely from their mother at 21 days of 
age, self- weaning where pups were left with their mother until 30 or 40 days of age and gradual 
weaning where pups were removed from their mothers for an increasing number of hours each 
day starting with day 21 and finally having the mother removed permanently on day 30 (Cook, 
1999). It was found that the basal levels of corticosterone, an indicator of stress in rats, was 
significantly higher in the abruptly weaned and self-weaned rats compared to the gradually 
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weaned group. These tests were repeated again once the same animals had reached 12 months 
of age, and the same results were seen (Cook, 1999). Taken together, these studies suggest 
weaning age has both long term and short-term consequences on behaviour. 
Indeed, a recent study by Richter et al., (2016)  investigated the effect of late weaning  on the 
behavioural profile of male and female mice in adulthood. They reported at the group level, 
weaning mice on week 4 (late weaning) was associated with a reduction of anxiety-like 
behaviour and increased exploratory locomotion in adulthood compared to mice weaned on 
week 3. Stability of the reported behavioural profiles was also investigated by repeating 
behavioural tests at intervals of eight weeks during adulthood. Behavioural stability was found 
to be highly dependent on the combination of weaning age and sex in that females weaned after 
3 weeks of age were characterized by a high degree of behavioural stability, while this was not 
the case for females weaned at 4 weeks of age. In males, pups weaned at 4 weeks of aged 
expressed a high degree of behavioural stability in adulthood while those weaned at 3 weeks 
of age did not (Richter et al., 2016). Taken together these findings show weaning age and sex 
impact behavioural profiles overtime.  
The experience of weaning at different time points was also found to produce changes in social 
interaction in mice once they reached adolescence, with interesting differences observed 
between males and females (Terranova et al., 2001). In one study, varying weaning ages were 
tested: early weaning where the dam was removed on PND15, normal weaning where the dam 
was removed on PND20 and delayed weaning at PND25. When the dam was removed, each 
litter was split into males and females. A number of social behaviours were then tested for on 
PND30 including, social sniffing, social grooming and social following (Terranova et al., 
2001). Both males and females belonging to the early weaned group were much more involved 
in investigative social behaviours (sniffing of novel partners etc.) whilst spending less time in 
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self-directed behaviour such as self-grooming compared to their normally weaned counter 
parts. In females, increased social investigation was also found as a consequence of delayed 
weaning. These results were explained by sexual dimorphism in the development of opioid 
systems in the brain (Terranova et al., 2001). 
The effect of weaning on exploratory behaviour was also investigated using the open field test 
in two different studies. A study by Curley et al., (2009) showed only a gender difference 
irrespective of weaning age, where male mice spent more time in the centre in the open filed 
showing lower levels of anxiety compared to female mice (Curley et al., 2009). A study by 
Ferdman et al., (2007) assessed the combination of manipulations to weaning age and social 
isolation on exploratory behaviour in adult rats. It was found that in the late weaned group 
(PND 30) the males showed more exploratory behaviour than the females. This effect was only 
observed in the late weaned but group reared pups (Ferdman et al., 2007). Rats reared in 
isolation after weaning showed a reversed effect (i.e. females showing more exploratory 
behaviour). This shows that rearing conditions are another early life influence, which can have 
long lasting effects on behaviour (Ferdman et al., 2007).  
Altogether, these studies show that manipulations to weaning age, most markedly within the 
first 30 days of postnatal life, can produce significant and persistent behavioural changes.  
These changes could be attributed to maternal factors or to nutritional factors induced by 
changing the length of time animals are exposed to milk in early postnatal life.  
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Weaning Time Age of Testing 
days/weeks 
Species (strain) Behavioural 
Phenotype(s) 
Possible Mechanism (s) Reference (s) 
Early weaned (PND 
15) 
Normally weaned 
(PND21) 
Delayed weaned 
(PND27) 
>PND60 Male CD-1 mice Regular weaned- AMPH 
induced hyper-reactivity 
and conditioned 
locomotion 
Deleted weaned and 
Early weaned –no 
induction 
Weaning age (early life 
experiences) play a role 
in abuse of drugs 
(Adriani et al., 2002)  
Early weaned (PND 
21) 
Normally weaned 
(PND 28) 
PND50 and 
PND74 
Male and Female 
C57BL/6J and B6 mice 
Sexual dimorphism, 
females weaned on 
PND28 less active and 
less explorative 
compared to males. No 
difference in anxiety-like 
behaviour  
Oxytocin and 
Vasopressin 
(Curley et al., 2009) 
Early weaned (PND 
14) 
Normal weaned (PND 
21) 
3-26 weeks old Male and Female balb/CA 
ICR mice 
Increased level of 
aggression 
Increased anxiety 
Increased general 
activity 
Elevated corticosterone 
response to stress in 
early-weaned animals 
compared to normally 
weaned. 
Lower 5HT1B mRNA is 
hippocampus 
 
Changes in 
glucocorticoid mRNA 
expression 
(Kikusui et al., 2004; 
Kikusui et al., 2006; 
Iwata et al., 2007b; 
Nakamura et al., 2008) 
Early weaned (PND 
15) 
Normally weaned 
(PND 25) 
PND30 and 
PND70 
Male and female CD1 mice Increased locomotor 
activity and altered 
social play in early 
weaned compared to 
normally weaned. 
Dopaminergic and 
opioid systems 
Increased sensitivity to 
δ-opioid receptor 
agonists 
(Laviola et al., 1997; 
Terranova et al., 2001) 
Early weaned (PND21) 
Normally weaned 
(PND 30) 
 
14 weeks of age Male and female Wistar 
rats 
Early weaned- more 
active in open field test 
Regularly weaned- more 
explorative 
In early weaned low 
dendrite length and 
density in prefrontal 
cortex 
(Ferdman et al., 2007) 
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(late weaned rats avoid 
social interaction) 
Early Weaned ( PND 
17) 
Normal Weaned (PND 
23) 
 
PND30 Male C57BL/6 and 
DBA/2 mice 
Early weaned- increased 
anxiety in Elevated Plus 
Maze in both strains, 
increased depressive-like 
behaviour in D2, no 
change in BL6. 
Epigenetic (Carlyle et al., 2012) 
Normally weaned 
(PND 20) 
Milk formula fed or 
food pellets given to 
two groups 
10.5 weeks Male ddY mice Exploratory behaviour in 
milk fed mice lower than 
in pellet fed. 
Nutritional (Ishii et al., 2005) 
Normally reared 
Artificially reared with 
common milk 
Artificially reared with 
high protein (3g 
casein/100ml milk) 
PND18 Female Long-Evans 
Hooded rats 
Increased locomotion in 
normal weaned rats 
compared to two other 
groups. High protein rats 
had smaller brains 
Protein-enriched diet (Diaz et al., 1982) 
Early weaned (PND16) 
Normally weaned 
(PND 30) 
8 weeks Male and female wistar rats Early weaned males but 
not females showed 
lower frequency and 
duration in the open arm 
of elevated plus maze 
Mother-pup interaction 
(Stress) 
(Ito et al., 2006) 
Early weaned 
(injection of 
bromocriptine on 
PND28, 30 and 33) 
Control  (group kept 
with mothers, injected 
with saline ) 
PND30 and 
PND60 
Domestic cat (Felis Catus) Early weaned kittens 
showed increased 
frequency of social and 
locomotive play but not 
of object play compared 
to control 
Maternal milk 
supply/interaction 
(Martin and Bateson 
1985) 
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Table 1.2:  Summary of selective studies relating manipulations of weaning age and rearing conditions to behaviour with possible underlying 
mechanisms in various species. Abbreviations: AMPH: amphetamine; 5H-T;5-hydroxytryptamine; PND: postnatal day.
Early weaned (before 
PND 20) 
Regular weaned (PND 
20) 
PND20 Female and male Guinea 
pigs 
Early weaned showed 
depressive behaviour 
Proinflammatory activity (Schneider et al., 2012) 
Early weaned (PND16) 
Regular weaned (PND 
30) 
Weeks 4-7 Female and Male Wistar 
rats 
Early Weaned show 
lower playful 
interactions and 
increased anxiety in 
Elevated Plus Maze 
Mother-pup interaction (Shimozuru et al., 
2007) 
Early Weaning 
(breastfeeding time) 
Up to week 12 145 children diagnosed 
with infantile autism 
Early weaned (lower 
duration of breast 
feeding) may contribute 
to aetiology of infantile 
autism 
 
Duration of breast 
feeding 
(Tanoue et al., 1989)  
Delayed Weaning on 
PND25 
Control normally 
weaned PND21 
PND25 Male Wistar Rats Delayed Weaned 
(Housed with mother 
until PND25) showed 
increased depressive like 
behaviour compared to 
weaned on PND 21 
Duration of 
breastfeeding 
(Farshim et al., 2016) 
Delayed Weaning 
week 4 
Control normally 
weaned week 3 
Weeks 20 and 
28 
Male and Female 
C57BL/6J mice 
Group level: mice 
weaned week 4 less 
anxious and more 
explorative than W3 
animals. Sexual 
dimorphisim week 3 
females and week 4 
males higher behavioural 
stability in adulthood. 
Mother-pup interaction  (Richter et al., 2016) 
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1.1.3 Weaning in Humans and Milk Rich Diets 
 
Weaning can vary in onset and the length of time between species. Beliefs and practices 
surrounding weaning vary dramatically from culture to culture and are often also influenced 
by religious beliefs and the structure of a mother’s work activities and age amongst other 
factors (Macadam 1995). For example, mothers in Zulu societies have traditionally breastfed 
their infants until 12 to 18 months, at which point a new pregnancy would be anticipated. 
Ancient Hebrews completed weaning at about 3 years old, and most children in traditional 
societies are completely weaned between 2 and 4 years of age (see Mutch et al., 2004).  Due 
to such variations, the appropriate age at which weaning should occur in humans remains 
unclear, however The World Health Organisation (WHO) recommends infants should be 
exclusively breastfed for the first six months of life to achieve optimal growth, development 
and health, after which infants should receive complementary foods in order to meet their 
evolving nutritional requirements, while breastfeeding continues to two years and beyond 
(WHO, 2018). 
It is well established that breastfeeding is an unequalled method of providing optimal nutrition 
in infancy and boasts a wide range of health benefits for the developing child. Extensive 
evidence has shown that breastmilk contains a variety of bioactive agents that modify the 
function of the gastrointestinal tracts and the immune system, as well as in brain development 
(see Binns et al., 2016). Some of the key health benefits of breastfeeding are summarised in 
Table 1.3. As a result of such findings, prolonged breastfeeding periods and milk rich diets are 
widely promoted in infancy.  
 
 
36 
 
Area                                                          Health benefit                                             Reference  
Neurobehavioral                                                                                           McCrory and Murray, 2013; 
                                                                                                                              Julvez et al., 2007; 
 
 
Gastrointestinal                                                                                                          Kramer, 2002; 
                                                                                                                                Klement et al., 2004; 
 
Metabolic                                                                                                                 Harder et al., 2005; 
                                                                                                                                   Pettitt et al., 1997; 
 
Atopic                                                                                                                      Chiu et al., 2016; 
                       
Immunological                                                                                                  Demmelmair et al., 2006; 
                                                                                                                                Kwan et al., 2004; 
 
 
However, despite the health benefits associated with milk consumption in early life, the 
prolonged consumption of milk especially cow’s milk has come under scrutiny in recent years 
for its reported links to a number of disease states including diabetes, cardiovascular disease 
and neurological disorders such as autism and schizophrenia (see Bell et al., 2006) Some of 
these health effects have been linked to bioactive peptides liberated from milk proteins (see 
Section 1.3). 
Up until the 20th century, a wet nurse was the only safe alternative to breastfeeding infants. 
Since then, alternative milk sources have evolved to include the synthetic formulas used today, 
which are based on bovine milk as a protein source (Stevens et al., 2009). In the western world, 
the use of artificial feeding substances grew rapidly around the mid-1980’s and was 
significantly influenced by advertising campaigns aimed at the public. Such campaigns 
Reduced risk of diarrhoea. 
Reduced risk of inflammatory 
bowel disease. 
 
Reduced risk of obesity and 
type 2 diabetes.  
 
Reduced occurrence of 
Asthma and Allergic diseases.  
 
Increased cognitive ability or 
intelligence. Improved language and 
motor skills. Reduced attention deficit 
or hyperactivity disorders. 
Improved immune defence
Reduced risk of leukaemia.  
Table 1.3:  Key reported health benefits of prolonged breastfeeding in human infants and children 
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promoted infant and follow on formulas for their resemblance to mothers breast milk, boasting 
many of the same health benefits as breast milk as well as some additional benefits, such as 
being fortified (Stevens et al., 2009). As a result, many parents make the transition from 
breastfeeding to formula or cow’s milk when the infant is less than one year of age (Leung et 
al., 2003). Although breastmilk remains to be the medically preferred method of infant feeding, 
milk formulas and cow’s milk have provided a way of supplementing breastfeeding while also 
extending an infant’s exposure to milk rich diets beyond the ‘normal’ age of weaning. It is also 
important to note that in evolutionary terms, milk and dairy products are relatively new to 
humans, having begun with the domestication of diary animals (Ludwig et al., 2013). Therefore 
although today milk is considered to be essential for a balanced diet both in infancy and 
adulthood, it was not a part of the traditional hunter-gatherer diet. In many parts of the world 
such as china, milk is still a minor part of the diet (Ludwig et al., 2013). 
1.2 Milk as a Bio-messenger  
 
For centuries milk has been regarded as a mere nutritional provider. Milk proteins were 
extensively studied primarily as amino-acid donors and from a nutritional angle. Although this 
conventional concept of milk is still valid and accepted, accumulating evidence over the last 
three decades suggests that milk proteins and their by-products act as bioactive components 
and bio-messengers, which exhibit important physiological and biochemical functions.  
Milk was found to contain modulators of digestive and gastrointestinal functions, hormones 
and growth factors capable of influencing the development and growth of the CNS (McCrory 
et al., 2013), gastrointenstinal (GI) tract (Donovan, 2006), play a role in immunoregulation 
(Walker et al., 2014) and modulation of the gut microflora population (Jost et al., 2015). 
Among the bioactive constituents of milk (see Figure 1.1), this thesis will focus on the 
bioactive peptides derived from milk proteins and more specifically the bioactive peptides 
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derived from milk caseins. For an extensive review on the peptides encoded in and yielded by 
all milk proteins the reader is directed to Shah (2000). 
 
 
The identification of bioactive peptides in milk was first reported over 60 years ago, since then 
knowledge of bioactive peptides has rapidly increased and peptides with various functions 
including opiate, anti-hypertensive and immunomodulatory activities have been described 
(Meisel et al., 2000; Korhonen Hannu et al., 2006). This wide spectrum of biological activity 
predetermines the role of bioactive milk peptides in human health and disease states. Much of 
the experimental data to date indicate the positive effects of milk derived peptides on health 
during early infancy (Saito, 2008). However, during the last decade, a growing body of 
evidence linked bioactive peptides in milk with various adverse biological responses 
(Woodford, 2007) (see Section 1.3). 
Figure 1.1:  Major bioactive compounds derived from milk. Image adapted from (Park et al., 2015) 
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The bioactivities of milk proteins are latent within the sequence of the parent protein, and only 
during proteolytic cleavage of the parent protein are the active peptide fractions released; these 
peptides can be released in three ways: (i) through hydrolysis by digestive enzymes, (ii) through 
hydrolysis of proteins by proteolytic microorganisms, and (iii) through the action of proteolytic 
enzymes derived from microorganisms (Pihlanto-Leppälä, 2000; Korhonen et al., 2003). 
Therefore, given that milk is the main source of nutrition in early postnatal life, and it is known 
to release bioactive peptides which play crucial roles in the development of a number of 
systems in the body including the CNS, it is perhaps no surprise that manipulations to weaning 
time or periods of exposure to milk in early life are likely to result in alterations to normal brain 
development and subsequent behaviour. 
1.2.1 Constituents of Mammalian Milk  
 
Milk is introduced as the main source of nutrition in early postnatal life either in the form of 
mother’s breast milk or cow’s milk as a supplement/replacement for breastmilk. It is recognised 
as being nutritionally balanced and as a source of bio-messengers that support the growth and 
development of infants, it has therefore attracted a lot of scientific interest over the years. Milks 
are complex oil -in-water emulsions containing protein, fat, lactose, vitamins and minerals, as 
well as biological products such as enzymes, cells, hormones and immunoglobulins. The 
composition and profiles of milk vary amongst the mammalian species depending on the 
nutritional needs of the young (Miller et al.,1990). This thesis will focus on human and bovine 
milk as these are the most relevant milk types during early postnatal development in humans. 
 Human and bovine milk differ not only in protein quantities, but also in general profile, these 
differences are illustrated in Table 1.4. As shown, one of the major differences in composition 
between the two milk types is the total protein content. Total protein makes up 3.3% of bovine 
milk, compared to 1.22% found in human milk (Miller et al.,1990). 
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Constituents                                                  Human milk (%)                                     Bovine milk (%) 
Protein                                                                                                                                              
Lactose                                                                                                                                                
Fats                                                                                                                                                      
Ash (minerals)                                                                                                                              
Total solids         
 
 
 
There are two major protein groups in milk: Caseins which account for around 80% of the total 
protein content in bovine milk (Kamiński et al., 2007) and Whey proteins which account for 
the remaining 20% (Kamiński et al., 2007). Both of these major proteins in milk are known to 
release peptides with bioactive functions (see Figure 1.2). Whey protein gives rise to β-
lactoglobulin and α-lactalbumin while caseins breakdown to release beta casomorphins (see 
Nongonierma et al., 2015). This thesis will focus on casein and its bioactive breakdown 
products.  
In human milk, the casein to whey protein ratio varies throughout the lactation period. Early in 
lactation the concentration of whey proteins is higher than casein, with casein concentrations 
being very low or absent, resulting in whey/casein ratio of about 90:10 in early lactation (Kunz 
et al., 1990, 1992). Subsequently, casein synthesis in the mammary gland and milk casein 
concentrations increase, whereas the concentration of total whey proteins decreases, resulting 
in a 50:50 ratio in late lactation (Kunz et al., 1992). As a consequence, unlike bovine milk there 
is no fixed ratio of whey to casein in human milk. However it is clear that with lactation time, 
the compositional makeup of mother’s breastmilk changes along with the nutritional 
requirements of the infant, further highlighting the need to establish an appropriate weaning 
age.  
1.22 
7.0 
3.8 
0.21 
12.4 
3.3 
4.8 
3.7 
0.72 
12.8 
Table 1.4: The average composition of human and bovine milk. The various constituents are given 
as a percentage of whole milk  (Miller et al.,1990). 
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Infant formulas provided to developing human babies are designed to simulate the content of 
human breast milk and are often used as a replacement or supplement to breastmilk, however 
they are bovine milk based and therefore differ considerably from human breastmilk. For 
example, protein provides approximately 7% of the calories in human milk, whereas in cow’s 
milk proteins provide 20% of the calories (see Martin et al., 2016). Furthermore, cow’s milk 
contains six to seven times as much casein as does human milk  (see Martin et al., 2016). The 
high casein content in cow’s milk is undesirable for developing infants not only because of 
bioactive breakdown products liberated from milk caseins, but also casein forms a tough, hard 
to digest curd that is difficult for young infants to digest resulting in gastrointestinal 
complications (Leung et al., 2003). Recently, research has focused on better matching infant 
formulas to mothers breast milk, for example during the manufacturing process of cow-milk 
based infant formula, skim milk powder (high in casein) is mixed with whey protein 
concentrate in order to make the whey/casein ratio more similar to human milk (McMahon et 
al., 2008). However as milk is the main source of nutrition in early postnatal life, a period of 
rapid growth and development, more research into the health implications of prolonged 
exposure to milk rich diets either in the form of mothers breastmilk or cow’s milk in infants is 
required. 
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1.2.2   Milk Caseins and Beta-Casomorphins 
 
The caseins are a family of phosphoproteins synthesised in the mammary gland and secreted 
as large colloidal aggregates termed micelles, which are responsible for many of the unique 
physical properties of milk (Ginger et al., 1999). Bovine milk was found to contain 4 casein 
types: alpha S1 (39-46% of total casein) alpha S2 (8-11%) beta (25-35%) and kappa (8-
15%).There is also gamma casein which is a product of degradation of beta casein (Kamiński 
et al., 2007). Human milk contains three classes of caseins, namely alpha- S1, beta and kappa 
caseins (McMahon et al., 2008). These caseins are encoded by members of a multigene family, 
namely α β and κ. Among these, the beta casein gene has been studied extensively due to the 
potential influence of beta-casein variants on human health.  
Milk
Casein
Whey
α casein
Β casein
Ƙ casein
α-lactalbumin
β-lactoglobulin
• In vivo digestion by 
digestive enzymes
• In vivo digestion by 
microbial enzymes
• In vivo digestion by 
proteolytic 
microorganisms 
Bioactive
peptides
Cardiovascular system
Antihypertensive
Antithrombotic
Antioxidant
Anti-inflammatory
Nervous system
Opioid activity 
Metabolic heatlh
Glucose control 
Hypochloestrolaemic
Appetite control
Immune system
Immunomodulatory
Cytomodulatory
Anti-inflammatory
Antimicrobial Activity
Antibacterial
Antiviral
Antifungal 
Major proteins in milk Generation of peptides Bioactivities of milk derived peptides 
Figure 1.2: Schematic illustration of the generation of milk-derived bioactive peptides and their 
physiological functionalities. Taken and adapted from  (Mohanty et al., 2016) 
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Mutations in the bovine  beta casein gene (CSN2)  have led to 13 genetic variants of this gene, 
out of these  A1 and A2 are the most common forms in cattle breeds (Kamiński et al., 2007). 
These two variants contain 209 amino acids and differ by one amino acid in their sequence 
(See Figure 1.3). In position 67 of the beta casein chain, proline in variant A2 is substituted by 
histidine in variant A1 (Greenberg et al., 1984). This difference is also displayed between 
minor variants, which on the basis of this amino acid substitution and known digestion of beta 
casein variants A1 and A2, may be classified as ‘A1 like’ and ‘A2 like’. These variants include: 
A3, D and E which, like A2 contain a proline at this position; and B,C and F which, like A1 
contain a histidine at amino acid residue 67 (Kamiński et al., 2007). 
A2 beta casein is recognized as the original beta casein variant as it existed before a proline 67 
to histidine 67 point mutation caused the appearance of A1 beta casein in some European herds 
some 5000–10,000 years ago (Farrell et al., 2004). A1 beta casein has only been found in cattle 
of European origin. Pure bred Asian and African cattle produce milk containing only the A2 
beta casein type, although some cattle presenting phenotypically as Asian or African cattle may 
produce A1 beta casein as a consequence of cross bred ancestry (Farrell et al., 2004). In human 
milk, no such polymorphism was found in the beta casein gene (A2-Corporation 2006; 
Greenberg et al.,1984). 
Upon proteolytic cleavage in the gut, A1 beta caseins break down to release peptides with 
opioid effects similar to morphine, hence given the name beta casomorphins (BCMs) including 
BCM-7. BCMs can be released from both human and bovine milk and are typically 4-11 amino 
acids long (see Table 1.5), all starting with a tyrosine residue in position 60 in bovine beta 
casein and position 51 of human beta casein (Kamiński et al., 2007). They are yielded from A1 
beta caseins by digestion in the small intestine by pepsin, leucine aminopeptidase and elastase 
and are substrate for the enzyme dipeptidyl peptidase IV (DPP IV) which is a cell surface 
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protease, belonging to the prolyl oligopeptidase family. BCMs are hydrolysed by DPP IV to a 
mixture of Tyr-Pro, Phe-Pro-Gly, Phe-Pro and Gly (Kreil et al., 1983). 
Beta-casomorphin                                                                    Amino acid composition  
 
 
 
 
 
 
 
 
  
 
 
In contrast, proteolytic cleavage of the A2 variant of bovine beta casein does not yield BCM-7 
as the proline at position 67 hinders a split at this site under normal gut conditions (See Figure 
1.3) (Noni, 2008; De Noni et al., 2010; Boutrou et al., 2013). However,  it should be noted that 
under specific in vitro conditions relating to pH and enzyme combinations not found in the 
human gut A2 beta casein can indeed release BCM-7 (Cieślińska et al., 2012). 
 
Bovine BCM-4 
Bovine BCM-5 
Bovine BCM-6 
Bovine BCM-7 
Bovine BCM-8 
Bovine BCM-11 
Human BCM-7 
Human BCM-8 
Tyr-Pro-Phe-Pro 
Tyr-Pro-Phe-Pro-Gly 
Tyr-Pro-Phe-Pro-Gly-Pro 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn -Ser-Leu 
Tyr-Pro-Phe-Val-Glu-Pro-Ile 
Tyr-Pro-Phe-Val-Glu-Pro-Ile-Pro 
Table 1.5: Amino acid composition of naturally occurring betacasomorphins (BCMs) in human 
and bovine milk (Kamiński et al., 2007). 
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In human milk, beta casein is of the A2 type, with a proline at the equivalent position on the 
beta casein protein chain (Jarmołowska, Sidor, Iwan, Bielikowicz, Kaczmarski, Elżbieta 
Kostyra, et al., 2007). Thus, thermodynamics does not favour the yielding of BCM-7 from 
human beta casein. Indeed, Wada et al., (2015) examined non-digested and in vitro-digested 
human milk, and reported the presence of human BCM-9 but not human BCM-7 (Wada et al., 
2015). However, Jarmołowska et al., (2007) reported the presence of BCM-7 in colostrum (the 
mothers fluid produced in the first day after delivery), but at 2 months into the lactation period, 
the authors reported much lower quantities (Jarmołowska, Sidor, Iwan, Bielikowicz, 
Kaczmarski, Elżbieta Kostyra, et al., 2007). Furthermore, Kost et al., (2009) were able to detect 
substances with immunoreactivity of human BCM-7 in blood plasma of 3 month old breast fed 
infants  (Kost et al., 2009a). Human BCM-7 has a different amino acid sequence to bovine 
Amino Acid Sequence of β-casein  
Val – Tyr – Pro – Phe – Pro – Gly – Pro – Ile – X
Val – Tyr – Pro – Phe – Pro – Gly – Pro – Ile – Pro Val – Tyr – Pro – Phe – Pro – Gly – Pro – Ile – His
Βeta-casein A2 Βeta-casein A1
Tyr – Pro – Phe – Pro – Gly – Pro – Ile 
Beta-casomorphin 7
Pepsin
Pancreatic elastase
Leucine amino peptidase 
Elastase 
X= Pro in beta-casein A2
His in beta-casein A1
Figure 1.3: Diagram showing the amino acid sequence of A1 and A2 beta casein and how beta 
casomorphin-7 is released from the A1 variant. Taken and adapted from (Kamiński et al., 2007). 
 
46 
 
BCM-7,with homology in five of seven amino acids (differing amino acids at positions four 
and five) (Wada et al., 2015). BCM-7 has been the focus of much research due to its ability to 
act on opioid receptors found in the body and consequently eliciting a wide range of health 
effects (see ul Haq et al., 2014). 
1.3 The Influence of BCM-7 on Health and Behaviour 
 
BCM-7 was first isolated as a peptide having morphine-like activity in 1979 (Brantl, 1984). It 
contains the N-terminal amino acid sequence Tyr-Pro-Phe-Pro which possesses preferential μ 
opioid receptor (MOPr) agonist activity (Brantl, 1984; Sun et al., 1999) and moderate potency 
compared to morphine. Furthermore BCM-7 was shown to exhibit a low affinity for δ opioid 
(DOPr)  and almost no affinity for Ƙ-opioid receptors (KOPr)  (see Section 1.4.1) 
(Teschemacher et al. 1997). These pharmacodynamic characteristics of BCM-7 were 
elucidated alongside other BCMs in studies using radioligand binding assays and in isolated 
organ preparations from the guinea pig ileum or from the mouse vas deferens, which are 
typically used test systems for MOPr and DOPr activities, respectively. In general, these studies 
showed that human BCM-7 was 3-30 times less potent than bovine BCM-7, and 300-600 times 
less potent than morphine (Human BCM-7 IC50 = 29.00 µmol/l,  Bovine BCM-7 IC50 = 5.14 
µmol/l,  Normorphine = 0.05 µmol/l )(Koch et al.,1985). 
As an opioid receptor ligand, BCM-7 can be expected to act as  other opioids, i.e. to bind to 
opioid receptors and elicit effects in all cells or tissues in which opioid receptors are known to 
be expressed (Smotherman et al., 1992). The first physiological effects of BCMs take place in 
the gastrointestinal tract. Indeed it has been shown that BCMs bind to opioid receptors found 
in the luminal side of the gut and can affect gastrointestinal functions such as absorption, 
secretion and gut motility (Mahè et al., 1989). Daniel et al., (1990) have shown that 
casomorphins inhibit intestinal motility in isolated segments of rat ileum (Daniel et al., 1990). 
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Rats fed casein rich suspensions took longer in gastric emptying and gastrointestinal transit 
time than rats given a whey protein suspension (Daniel et al., 1990). These effects were found 
to be reversed when the opioid antagonist naloxone was administered, implicating the role of 
MOP receptors in eliciting these effects. Furthermore, Barnett et al., (2014) showed that 
feeding rodent’s milk containing A1 beta casein resulted in significantly delayed 
gastrointestinal transit time compared with milk containing the A2 beta casein variant. Again, 
this delay could be eliminated by the administration of opioid blocker naloxone suggesting a 
MOPr mediated effect. This group also demonstrated a 40% up regulation of the enzyme DPP4 
in the jejunum of A1- relative to A2 fed rodents (Barnett et al., 2014) suggesting BCM-7 in 
mediating these gastrointestinal effects, as it is known BCM-7 is a substrate for DPP4. BCM-
7 has also been shown to induce a strong release of gastrointestinal mucin secretion in rat 
jejunum through the activation of µ-opioid receptors (Zoghbi et al., 2006).  
Based on findings from Kost et al., (2009) who reported detecting substances with 
immunoreactivity to human BCM-7 in blood plasma of 3 month old breast fed infants. It is 
feasible to suggest BCM-7 can be transferred intact from the luminal side to the blood side of 
the gut where it can be transported to tissues and organs and can elicit further opioid mediated 
biological and physiological responses. Furthermore, bovine  BCM-7 immunoreactive material 
has been detected in the plasma of new born calves  following milk intake (Umbach et al., 
1985), and in new-born but not adult dogs (Singh et al., 1989). The absorption of large 
macromolecules such as BCMs from the GI to the blood seems to only occur in the case of 
immature neonatal mucosa (Weaver, 1992; Sun et al., 2003). New born mammals are known 
to have leaky guts as they need to be able to pass large molecules through the gut wall enabling 
them to absorb nutrients from mother’s milk (Zanardo et al., 2001). This could explain why 
BCM-7 is detected in new born infants and other mammals but not in adults, and also suggests 
infants may be exposed to higher levels of BCMs. In line with this, patients with “leaky gut” 
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syndrome have been shown to have high levels of BCM-7 in their urine compared to 
individuals with normal gut walls (Mulloy et al., 2010).   
Once in the blood, it has been suggested that  BCM-7 can act as a causative agent in 
cardiovascular disease, type 1 diabetes, sudden infant death syndrome as well as autism and 
schizophrenia (see minireview by Lister et al., 2015). 
1.3.1   Cardiovascular Effects 
 
The connection between beta casein A1 consumption and heart disease was first drawn 
following epidemiological studies. McLachlan (2001)noted a strong connection between milk 
consumption and coronary heart disease (CHD) mortality across countries (McLachlan, 2001) 
and from comparisons of the levels of antibodies to milk protein in cases of CHD and non-
affected controls (Davies et al., 1969). Later Elliott et al., (1999) published an epidemiological 
study concluding that A1 beta casein was significantly and positively correlated with CHD in 
20 affluent countries over a 20 year period (Elliott et al., 1999).  Supporting the early 
epidemiological work was the observation that casein in comparison to other milk proteins is 
a potentiator of heart disease or related conditions such as hypercholesterolemia, in rabbits 
(Terpstra et al., 1981) and monkeys (Barth et al., 1984). However this work did not identify 
which variants of milk caseins are atherogenic. A rabbit feeding study later showed a causative 
link between A1 consumption and the development and progression of arterial lesions (Tailford 
et al., 2003).  The proposed mechanism underlying the atherogenic properties of A1 beta casein 
stem from findings that the bioactive peptide BCM-7 released from A1 beta casein has been 
shown to catalyse the oxidation of low density lipoproteins (LDL) (Torreilles et al., 1995). The 
uptake of oxidised LDL by endothelium bound macrophages has been widely implicated in the 
pathogenesis of atherosclerosis  (Torreilles et al., 1995). Studies have also shown that cow’s 
milk infant formula fed infants raised antibodies to oxidised LDL at ten times the rate of infants 
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who were breast fed , highlighting a difference in the atherogenic properties of bovine BCM-7 
compared to human BCM-7  (Steinerová et al., 1999).  
1.3.2  Diabetes 
 
Type 1 insulin dependent diabetes mellitus (IDDM) also known as childhood onset diabetes  is 
an autoimmune disease affecting approximately 0.2 to 0.6% of the population of developed 
countries (see Chia et al., 2017). This form of diabetes is thought to result from an interaction 
of several genetic and environmental factors that activate immune cells capable of destroying 
the insulin-producing beta cells in the pancreatic islets. One of the environmental factors 
implicated in diabetes pathogenesis is exposure to certain types of food including cow’s milk. 
Studies have shown a strong correlation between early exposure to cow’s milk and the 
incidence of IDDM (Scott, 1990; Virtanen et al., 1998; Muntoni et al., 2000). Elliot et al., 
(1997) were amongst the first to demonstrate milk protein induced diabetes via an opioid 
receptor mediated mechanism.  Non-obese diabetic mice were fed a basal diet supplemented 
with either A1 or A2 beta casein. 47% of mice fed A1 beta casein diet developed autoimmune 
diabetes while mice fed A2 beta casein did not develop the disease. Co-administration of the 
opioid receptor antagonist naloxone attenuated the effects of A1 beta casein diet, suggesting 
the diabetogenic effects of the A1 beta casein diet were at least partly mediated via opioid 
receptors (Elliott et al., 1998). Two years later an association between the incidence of IDDM 
in children younger than 14 years of age and the consumption of beta caseinA1 was reported 
(Elliott et al., 1998; McLachlan, 2001). In addition a group in Iceland compared the incidence 
of type 1 diabetes across five  Nordic countries  with measured levels of a number of milk 
protein variants and concluded that beta casein variant A1 and not other milk proteins 
examined, may contribute to observed variation in the diabetogenicity of cow’s milk 
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(Thorsdottir et al., 2000). It was proposed that the diabetogenic effect of A1 beta casein was 
attributable to the release of BCM-7 during digestion (Elliott et al., 1998). 
Different mechanisms underlying the diabetogenic effect of BCM-7 have been suggested, with 
the immune system being a strong candidate (Chia et al., 2017). In humans, Padberg et al., 
(1999) reported that the ratio of A1 to A2 beta casein antibodies was higher in those with type 
1 diabetes than in controls. Indeed BCM-7 has been shown to influence the function of immune 
cells, for example two in vitro studies have shown BCM-7 alters lymphocyte proliferation via 
an opioid-dependent pathway (Elitsur et al., 1991; Kayser et al., 1996). The first of these 
studies showed suppressive effects of BCM-7 on lymphocyte proliferation at all concentrations 
tested while the second study showed suppressive effects at low BCM-7 doses and stimulatory 
effects at higher doses. However the full physiological relevance of the immunomodulatory 
effects of BCM-7 in animals and humans requires further investigation. 
Other proposed mechanisms for the pathogenesis of type 1 diabetes consider BCM-7 
interacting with the intestinal microbiota, increasing mucosal barrier permeability and 
intestinal immune response (Vaarala et al., 2008). Gut permeability abnormalities increase the 
risk of intestinal immune system exposure to dietary antigens such as proteins and peptides 
resulting in an altered immune activation and intestinal inflammation (Vaarala, 2008). Indeed 
studies in rats have shown the intestine is highly permeable before the onset of type 1 diabetes. 
(Neu et al., 2005). Intestinal myeloperoxidase activity are also higher in diabetes prone rats 
compared to control highlighting a concomitant early intestinal inflammatory response (Neu et 
al., 2005). This is notable because inflammatory mediators can compromise epithelial barrier 
function and further effect gut permeability. Indeed, elevated intestinal myeloperoxidase 
activity is reported in rodents fed A1 compared with A2 beta casein (Barnett et al., 2014). 
Suggesting BCM-7 may indeed mediate its diabetogenic effects via the immune system.  
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It has also been shown in rats that A1 beta casein stimulates the production of the enzyme 
DPP4 in the jejunum (Barnett et al., 2014). It is known that DPP4 degrades the gut incretin 
hormones rapidly (Drucker 2006); in humans incretin hormones modulate insulin and glucose 
metabolism (Holst et al., 2004). DPP4 inhibitors are now widely used in the management of 
type 2 diabetes due to their effects on incretin hormones. It is therefore likely that BCM-7 
induced up regulation of DPP4 could result in increased degradation of incretin hormones resulting 
in altered metabolism of insulin and glucose and thus contribute to the development of diabetes.   
1.3.3   Neurological disorders  
 
A growing body of literature has linked diet/nutrition to the development of neurological 
disorders (for a review see Liu et al., 2015) . Beta casein variant A1 and its bioactive breakdown 
product BCM-7 have been shown to aggravate some neurological disorders. Autism Spectrum 
Disorder (ASD) is a neurodevelopmental disorder characterized by abnormalities in social 
interaction, communication skills and restrictive repetitive behaviours (Cieslinska et al., 2015). 
The prevalence of ASD is estimated from 60 to 70 per 10,000 (Fombonne, 2009) and its 
aetiology remains unknown. However there are strong links to a variety of genetic factors 
(Hallmayer et al., 2011; Buie, 2013). The recent increase in prevalence of ASD suggests other 
factors are contributory including dietary factors (Buie, 2013; Cieslinska et al., 2015). In recent 
years, researchers have focused on the role of the opioid system in ASD and the “opioid excess” 
theory was developed. Many authors have reported that autistic children, and in some cases 
their mothers, displayed elevated levels of  both endogenous opioid peptides and exogenous 
opioid peptides such as BCMs in serum, urine, immune cells and the cerebrospinal fluid 
(Cazzullo et al., 1999; Tordjman et al., 2009; Sokolov et al., 2014). Researchers have strongly 
suggested that severity of autistic symptoms are correlated with the concentration of BCM-7 
in the urine (Sokolov et al., 2014). The opioid theory of autism has been further supported by 
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pharmacological studies which have demonstrated that the opioid receptor antagonist naloxone 
can improve the clinical symptoms of autism (Leboyer et al., 1993). According to this theory, 
genetic predisposition and/or early exposure to environmental stressors may lead to functional 
alterations in the gut, reduced proteolytic activity and the increased permeability of the gut 
mucosa. These factors, possibly in combination with low levels of circulating peptidases and 
increased blood-brain barrier (BBB) permeability, may cause hyperpeptidemia and 
accumulation of opioid peptides such as BCM7 in the blood and the brain. Thus, chronically 
elevated levels of exorphins in the brain may directly modulate the opioid and other 
neurotransmitter systems, leading to the development of ASD (Whiteley et al., 2002). Indeed, 
studies have demonstrated the presence of human or bovine BCM-7 in the blood of infants that 
were breast fed or received cow’s milk based infant formulas respectively (Kost et al., 2009). 
Out of these children those who displayed delayed psychomotor development expressed higher 
levels of bovine BCM-7 than children with normal psychomotor development, whereas the 
presence of human BCM-7 correlated with normal psychomotor development (Kost et al., 
2009).  This study suggests an association between the levels of circulating bovine BCM-7 and 
impaired early child development, setting the stage for autistic disorders. Furthermore, a 
number of studies have reported that autistic children on a gluten-free casein free diet displayed 
improved autistic symptoms, including improved gastrointestinal symptoms, concentration and 
attention as reported by their parents (Lange et al. 2015), suggesting casein and its bioactive 
breakdown products do indeed play a role in the exasperation of autistic like symptoms. 
Similarly, Dohan (1966) proposed a hypothesis for schizophrenia pathogenesis that stressed an 
interaction between genetic and dietary factors  (Dohan, 1966). It was suggested that a dietary 
overload of food exoprhins derived from casein and also gluten may produce schizophrenia-
like symptoms through their action on opioid receptors in certain genetically susceptible 
individuals (Zioudrou et al., 1979). Indeed, peptides with opioid activity were detected in the 
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urine (Hole et al., 1979) and plasma (Schmauss et al., 1985) of patients with schizophrenia. 
These peptides were found to induce prolonged behavioural abnormalities following 
intracerebroventricular (i.c.v) injection into rats (Schmauss et al., 1985). Furthermore, BCM-7 
injections in rats have been shown to cause other dramatic behavioural changes (Sun et al., 
1999). BCM-7 is capable of crossing the blood brain barrier and was shown to cause 
“explosive” behaviour, which entailed violent running and jumping. This was followed by 
withdrawn behaviour and eventually led to a state of complete inactivity (Sun et al., 
1999).These types of behaviours are often associated with mental disorders such as 
schizophrenia and autism (Sun et al., 1999). 
As with autism, gluten free casein free diets have been reported to improve the symptoms of 
schizophrenia (Singh et al., 1976; Okusaga et al., 2013). The underlying mechanism of benefit 
for such diets in improving neurological disorders remains unclear. However, recently an 
epigenetic mechanism for the beneficial effects of these diets has been proposed,  as it is known 
epigenetic programming during early postnatal development can influence lifelong disease risk 
(Bale et al., 2010; Reynolds et al., 2012) and can be modulated by nutritional factors especially 
factors effecting DNA methylation. 
DNA methylation is an important methylation reaction involving the addition of a methyl group 
to DNA and is a major factor for epigenetic changes in gene expression (see Trivedi et al., 
2014). Emerging evidence from biochemical investigations indicate that systemic oxidative 
stress also plays a strong role in ASD (Frustaci et al., 2012) and schizophrenia (Yao et al., 
2006) associated with significantly lower levels of the antioxidant glutathione (GSH) whose 
synthesis is limited by cysteine availability. Brain GSH levels are reported to be decreased in 
both autism (Melnyk et al., 2012) and schizophrenia (Do et al., 2000) strongly supporting the 
proposal that a deficit in GSH might contribute to neurodevelopmental disorders. 
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Oxidative stress and DNA methylation changes are metabolically coupled via the 
transsulfuration pathway. DNA methylation is carried out by a class of enzymes called DNA 
methyltransferases, which depend on the level of S-adenosylmethionine (SAM) (Trivedi et al., 
2014) , which in turn are dependent on the action of the enzyme methionine synthase (MS) and 
the redox status of the cell (Hondorp et al., 2004). SAM acts as a methyl donor for over 200 
methylation reactions and is then converted to S-adenosylhomocystine (SAH) an inhibitor of 
methylation reactions. In recent studies abnormal DNA methylation patterns have been 
reported in schizophrenia (Jakovcevski et al., 2012; Nishioka et al., 2012) and ASD (Schanen, 
2006). 
Indeed, it has been shown that human and bovine BCM-7 decreases excitatory amino acid 
transporter 3 (EAAT3) mediated cysteine uptake in cultured human neuronal and 
gastrointestinal epithelial cells via a MOPr mediated mechanism (Trivedi et al., 2014). An 
inhibition of cysteine uptake was observed following treatment of these two cell types with 
either human or bovine BCM-7 for 30 mins in a concentration dependent manner with bovine 
BCM-7 showing more potency in reducing cysteine uptake compared to human BCM-7. This 
decrease in cysteine uptake was associated with  changes in intracellular antioxidant GSH and 
also the methyl donor SAM, which plays an important role in DNA methylation and subsequent 
gene expression (Trivedi et al., 2014). Indeed Trivedi et al., (2014) also reported both human 
and bovine BCM-7 increased genome-wide DNA methylation with a potency order similar to 
their inhibition of cysteine uptake, i.e. bovine BCM-7 induced a higher increase in DNA 
methylation compared to human BCM-7. At the transcriptional level, human BCM-7 
significantly increased expression of nine genes including EAAT3. In contrast bovine BCM-7 
decreased expression of the same nine genes assessed (Trivedi et al., 2014) . Taken together, 
this study illustrates the potential of both bovine and human BCM-7 to exert antioxidant and 
epigenetic changes that may be particularly important during postnatal development. 
55 
 
Furthermore, the differences in the antioxidant and epigenetic effects of human versus bovine 
BCM-7 may contribute to the developmental differences observed between breastfed and 
formula-fed infants (Kost et al., 2009a). 
There is also strong evidence to suggest that opioid peptides in milk alter responses to stress. 
For example, acute administration of BCM-7 was found to reduces maternal separation distress 
responses in chicks (Panksepp et al., 1984). In contrast, it was found that chronic administration 
of BCM-7 during development impairs the development of behavioural responses to stressful 
stimuli (Panksepp et al., 1984). Furthermore, BCMs have been shown to cause analgesia, apnea 
as well as changes in the sleep of neonatal rats (Kamiński et al., 2007). Naloxone pre-treatment 
was found to reverse these effects, suggesting a MOPr mediated effect. These effects have been 
shown by intracerebral, intraperitoneal and intraventicular injections (Sun et al., 1999).  
 
1.4 The Effect of Weaning and Milk Rich Diets on Brain   
Neurochemistry 
 
1.4.1 The Opioid system 
 
The discovery of the endogenous opioid system stems from the use of opium extracted from 
the poppy seed (Papaver somniferum), which has powerful pain reliving properties as well as 
a euphoric effect. Morphine, named after the Greek god Morpheus, was isolated from opium 
in 1806 and remains the most widely used painkiller in contemporary medicine today. The 
existence of opioid binding sites in the brain was established in 1973 and were later MOPr, 
DOPr and KOPr. Since then the opioid system has been extensively explored and has proven 
to be an important neurotransmitter system critically implicated in the control of mood, 
motivation and pain. The opioid system also regulates numerous physiological functions, 
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including responses to stress, respiration, gastrointestinal transit, as well as endocrine and 
immune functions (for an extensive review on the opioid system see Bodnar, 2016).  
Soon after the discovery of the opioid receptors, a series of endogenous ligands were also 
discovered. Three pro-hormone precursors provide the parent compounds from which these 
endogenous ligands are derived. Preproenkephalin  (PENK) is cleaved to form met-enkephalin 
and leu-enkephalin which bind to DOP receptors. Dynorphin A and Dynorphin B are derived 
from preprodynorphin (PDYN) and are agonists for KOP receptor. Prepro-opioimelanocortin 
(POMC) is the parent compound for beta endorphin, an agonist at the MOP receptor, although 
beta endorphin is capable of displaying agonist activity at all three classical opioid receptors 
(McDonald et al., 2005; Corbett et al., 2009). In addition to beta endorphins, POMC precursor 
also encodes non-opioid peptides, namely adrenocorticotropic hormone (ACTH), α-
melanocyte-stimulating hormone (α—MSH) and β-lipotropic pituitary hormone (β-LPH) (see 
Bodnar 2016) All opioid peptides, both endogenous and exogenous, such as BCM-7, share a 
common NH2-terminal  Tyr-Gly-Gly-Phe signature sequence which allows them to interact 
with opioid receptors (see Table 1.6).  The genes encoding all three opioid receptors have been 
successfully cloned (MOR-1 DOR-1 and KOPr-1, as well as the gene for the non-opioid 
orphaninFQ/nocieptin receptor which is considered to be a non-opioid branch of the opioid 
receptor family). All opioid receptors were found to display a topology characteristic of G-
protein coupled receptors (Corbett et al., 2009), and found to have a high homology with their 
genomic organisation being virtually identical  (Kieffer et al., 2002).  
Opioid receptors and peptides are broadly expressed in different densities within the central 
nervous system and, to a lesser extent, throughout the periphery, occupying sites within the vas 
deferens, knee joint, gastrointestinal tract, heart and immune system, amongst others (Wittert 
et al.,1996). In the brain, opioid receptors are expressed primarily in the cortex, limbic system 
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and brain stem. Binding sites for the three receptors overlap in most structures, but some 
structure exhibit higher expression of one receptor more than others (see Le Merrer et al., 
2009). The highest MOP receptor densities are found in the amygdala (not including the central 
nucleus  of the amygdala), thalamus, caudate putamen, neocortex, nucleus accumbens, 
amygdala, interpeduncular complex, and inferior and superior colliculi (Mansour et al., 1987).  
Moderate densities of MOPr are found in the periaqueductal gray and raphe nuclei (Hawkins 
et al., 1988). These brain regions have well-established roles in pain and analgesia. Other 
physiological functions shown to be mediated by MOPr include respiratory and cardiovascular 
functions, intestinal transit, feeding, emotional regulation, reward, thermoregulation, hormone 
secretion and immune functions (Dhawan et al., 1996).  
DOPr receptor distribution is more restricted compared to MOPr, with a prominent gradient of 
receptor density from high levels in forebrain regions to relatively low levels in the most hind 
brain regions. The highest densities of DOPr in the mouse/rat are found in the olfactory tract 
(olfactory bulbs, anterior olfactory nucleus, TU, medial amygdala), neocortex, caudate 
putamen, nucleus accumbens and amygdala (Mansour et al., 1987) and also highly expressed 
in the striatum. In the spinal cord DOPr are present in the dorsal horn where they play a role in 
mediating the analgesic effects of DOPr agonists. The functional roles of DOPr are less clearly 
established compared to MOPr, however in addition to analgesia, DOPr may have a role in 
gastrointestinal motility, mood and behaviour as well as in cardiovascular regulation 
(Reinscheid et al., 1995).   
KOPr are located predominantly in seven brain regions that are part of the stress axis (including 
the claustrum, paraventricular hypothalamus, arcuate nucleus, supraoptic nucleus and pituitary) 
and have also been implicated in the regulation of nociception, diuresis, feeding, 
neuroendocrine and immune system functions (Dhawan et al., 1996).  
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Precursor                  Peptide                     Sequence                                                       Receptor affinity  
 
 
 
 
 
 
 
 
 
 
Prepro- 
Opioimelanocortin 
 
Unknown  
 
Pro-enkephalin 
 
 
Pro-dynorphin 
 
 
 
 
 
 
 
MOPr + DOPr 
 
 
MOPr 
 
DOPr 
 
 
KOPr 
 
 
β-endorphin 
 
 
Endomorphin-1 
Endomorphin-2 
[Met5]Enkephalin 
[Leu5]Enkephalin 
 
Dynorphin A 
 
Dynorphin B 
 
α-neomorphin 
β-neomorphin 
 
 
 
 
 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-
Thr-Pro-Leu-Val-Thr-LeuPhe-Lys-Asn-Ala-Ile-
Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
 
Tyr-Pro-Trp-Phe-NH2 
Tyr-Pro-Phe–Phe-NH2 
Tyr-Gly-Gly-Phe-Met 
Tyr-Gly-Gly-Phe-Leu 
 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Trp-Asp-Asn-Gln 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-
Val-Thr 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro 
Table 1.6:  Table summarising precursors, sequences and affinity of endogenous opioid peptides. 
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1.4.2 Role of the Opioid System in Emotional Regulation 
 
The role of the opioid system in emotional regulation has been elucidated using both 
pharmacological knock-out (KO) studies and selective opioid receptor drugs (for an extensive 
review see Lutz and Kieffer, 2013). Constitutive KO mice for MOPr, DOPr and KOPr were 
created almost two decades ago (see Kieffer and Gavériaux-Ruff, 2002) and characterized for 
mood states amongst other characteristics. In KO mice lacking all three opioid receptors, no 
obvious developmental defects were evident and all mice were fertile (see Kieffer and 
Gavériaux-Ruff, 2002). This suggests that the opioid system is not crucial for development, at 
least when animals are raised under home cage conditions. This produced the notion that the 
opioid system is primarily recruited under challenging situations (see Kieffer and Gavériaux-
Ruff, 2002).   
Data from MOPr KO mice are in agreement that this receptor represents a key molecular 
component in reward processing of both natural stimuli and drugs of abuse (see Lutz and 
Kieffer, 2013). MOPr agonists have been shown to have strong rewarding properties, which is 
likely to be linked to the well-known  antidepressant effect of opioids (Tenore, 2008). However, 
two studies reported both decreased anxiety and depressive-like behaviour in MOR KO mice, 
indicating that the MOPr play a paradoxical depressant role in regulating emotional responses 
(Filliol et al., 2000; Yoo et al., 2004). MOPr-mediated mechanisms of mood control are 
therefore complex and may relate back to the pharmacology of opioid receptors (see  Lutz and 
Kieffer, 2013). 
Genetic deletion of  DOPr  has been reported to result in a significant and consistent  increase 
in anxiety and depressive-like behaviours (Filliol et al., 2000), a phenotype also partly seen in 
PENK KO mice (König et al., 1996). Further studies have confirmed that the endogenous 
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activity of enkhephalin/DOR system positively modulates mood states (Pradhan et al., 2011). 
Unlike DOPr KO mice, KOPr KO mice did not differ from controls in behavioural models of 
depressive-like behaviours (Filliol et al., 2000). However, it is now well known KOPr receptor 
activity is initiated by stressors such as repeated forced swim and may play a role in stress-
induced psychopathology (Knoll et al., 2010). Taken together, these studies indicate that MOPr 
DOPr and KOPr play highly distinct roles in regulating emotional responses. 
Studies using selective MOPr DOPr and KOPr drugs have confirmed the differential roles of 
opioid receptors in emotional regulation.  The antidepressant activity of DOPr agonists is well 
documented (Naidu et al., 2007; Javelot et al., 2010; Saitoh et al., 2011; Yang et al., 2011) 
consistent with the increased depressive like behaviour seen in DOPr KO mice. Similar to 
DOPr but less well documented acute pharmacological activation of MOPr reduces depressive-
like behaviour in some behavioural models of depression (Tejedor-Real et al., 1995; Rojas-
Corrales et al., 2004; Yang et al., 2011) but not all (Zhang et al., 2006). Studies reporting the 
antidepressant like effect of MOPr agonists are in apparent contradiction with the decrease in 
depressive like behaviour seen in MOPr KO mice, further confirming the paradoxical role of 
MOPr in mood regulation. Systemic administration of KOPr drugs also produced mood altering 
effects in classical models of depressive-like behaviours. KOPr agonists showed depressive-
like behaviour while antagonists were associated with antidepressant-like behaviours (Mague 
et al., 2003; Beardsley et al., 2005). In summary, DOPr agonists and KOPr antagonists have 
antidepressant-like effects, in contrast data from MOPr investigations appear more complex.  
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1.4.3  Opioid Receptor Development  
 
Opioid receptors have been shown to have a marked differential development in the rat. The 
development of the opioid system has been extensively studied using selective ligands for each 
receptor subtype (see McDowell and Kitchen, 1987). MOPr were found to be present at birth 
in rat forebrain, and after an initial decline in concentration during the first few days they 
undergo a subsequent rapid increase (Spain et al., 1985). The number of MOPr sites continues 
to rise during the first week after birth, with the most pronounced rate of increase in their levels 
occurs during the second and third postnatal weeks.  A similar pattern of MOPr development 
is seen in the striatum. Unlike MOPr, DOPr are present in only very low levels, if at all during 
the first postnatal week. The DOPr protein in the brain is not detectable before birth (McDowell 
et al., 1986) and the expression of the DOPr gene is delayed (Leslie et al., 1998). From the 
second through the fourth week a near linear increase in their concentration occurs with 75% 
of the total DOPr population developing by the normal age of weaning at day 21 (McDowell 
et al., 1986), which correlates well with the rise in MOPr  sites (Spain et al., 1985; McDowell 
and Kitchen, 1987). The development of KOPr differs slightly in that these receptors can be 
found in the forebrain and hindbrain regions from birth, whereupon hindbrain levels rise 
substantially. After postnatal day 14 the density of forebrain KOPr increases and hindbrain 
levels decline.  Indeed, the second postnatal week appears to be of high importance for the rat 
brain maturation as the development of dopaminergic and cholinergic receptors are also 
increasing at this time (Spain et al., 1985). 
From studies carried out in human brains it is clear that the temporal aspects of the development 
of the opioid receptors observed in rats is mirrored in human brain ontogenesis. MOPr and 
KOPr were both found to be present and develop during gestation, whilst DOPr are not 
detectable up to birth (Magnan et al., 1989). Considering that the opioid system shows marked 
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postnatal development in both man and rodent, it is possible that environmental early life 
influences may be very important developmental determinants for this system. As milk is the 
main source of nutrition during early postnatal development, and both human and bovine milk 
have been shown to release opioid peptides upon digestion, manipulations to weaning time or 
periods of exposure to milk in early life could possibly effect the normal development of the 
opioid system as well as other developing neurochemical systems.  
 
1.4.4    Role of Weaning in Opioid Receptor Development  
 
The development of the opioid system has been shown to be vulnerable to changes when the 
process of weaning is delayed at least in the rat (Muhammad et al., 1993; Goody et al., 2001). 
A study carried out by Muhammad et al., (1993) was the first to demonstrate that weaning rat 
pups from their mothers was a critical process in regulating the postnatal development of δ-
opioid receptors (Muhammad et al., 1993). Animals left with their mothers after the normal 
age of weaning at day 21, showed delayed development of  DOP receptor mediated Stress-
induced antinociception (SIA) (Muhammad et al., 1993).  
Stress-induced analgesia in man or SIA in experimental animals, are adaptive physiological 
responses that can be provoked by a number of different stressors including immobilisation, 
cold, electroshock and swimming.  Depending on the environmental stimuli, it can be divided 
into opioid mediated and non-opioid mediated types (Bodnar, 1990). Swimming-SIA is 
particularly useful as it can differentiate between opioid and non-opioid forms by varying the 
duration and temperature of the swim session.  It has been shown that the opioid receptor 
subtype which mediates the opioid form of SIA differs in the neonate in comparison to the 
adult (Jackson et al., 1989; Kitchen et al., 1990). Studies using Naloxone (MOPr antagonist) 
and the DOPr selective antagonist ICI 174864 and naltrindole have shown that SIA is mediated 
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by μ-receptors in 20-day old rat pups, but by day 25 it is predominantly δ- sites which mediate 
this behaviour (Muhammad et al., 1993). It was then shown that weaning plays a critical role 
in this transition. Muhammad et al., (1993) showed this by testing for SIA responses in 
normally weaned (PND21) and delayed weaned pups (PND25).  To ensure that opioid SIA is 
induced, rats were forced to swim for 3 minutes and then tested for SIA responses by the tail 
immersion test on PND25. The results showed SIA to be partially reversed following pre-
treatment with the δ-selective antagonist naltrindole in pups weaned at PND21, which indicates 
an active DOPr component.  However, pups housed with their mother until PND25 and then 
tested continued to exhibit MOPr mediated swim SIA, which was insensitive to naltrindole 
(Muhammad et al., 1993). Therefore the delay of weaning is able to halt the MOPr to DOPr 
transition. When the delayed weaned pups were tested again at day 30, naltrindole was able to 
reversed swim SIA indicating that the DOP receptors were now mediating this response 
(Muhammad et al., 1993). 
The role of weaning on DOPr development has been further implicated by receptor binding 
studies analysing the number of labelled DOPr sites in the weaned and delayed weaned rats 
(Kitchen et al., 1995a). In this study,  rats were weaned on PND21 or delayed weaned on 
PND25 before being killed on PND25 (therefore considered non-weaned) (Kitchen et al., 
1995). Using the DOPr agonist, [H3] [D-Ala
2 ] deltorphin I (DELT I), it was found that levels 
of binding were significantly higher in weaned rats compared to their non-weaned/ delayed 
weaned counter parts. This difference in binding was localized to the deep layers of the frontal 
parietal cortex and the pontine nucleus (Kitchen et al., 1995). However, in-situ hybridization 
experiments showed no difference in DOPr mRNA density in the regions in which binding 
differences were observed between the two groups (Kitchen et al., 1995). These discrepancies 
might indicate the existence of different delta receptor subtypes expressed in those regions, 
which were not recognized by the cRNA probe used for the in-situ hyberdization. Also it is 
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possible that a subpopulation of delta receptors is coupled to another G-protein in those regions 
forming heterodimers and that weaning stimulates this coupling process which is then 
recognized by DELT 1. In either case, it is evident that the weaning stimulates the development 
of a subpopulation of DOPr. Taken together with the results from the SIA experiments it is 
clear that delaying weaning influences the development of the opioid system by preventing the 
MOPr to DOPr switch, and preventing the development of the final 25% of DOPr in the brain.  
Furthermore, a study by the same group went on to address whether loss of suckling, stress due 
to maternal removal or loss of a nutritional component is the crucial determinant of weaning-
induced activation of DOPr (Goody et al., 2001). By measuring the δ-receptor component in 
SIA responses, in animals provided with lactating and non-lactating surrogate mothers it was 
demonstrated that a nutritional component rather than maternal presence is the critical factor 
in this transition (Goody et al., 2001). 
1.4.5 Role of Milk Caseins in Opioid Receptor Development  
 
Following on from the set of experiments carried out by Goody et al., (2001) (see Section 
1.4.4) the group then went on to investigate the possible mechanisms underlying  the delayed 
development of DOPr mediated by weaning time. It was hypothesised that this delay could be 
caused either by a continuation of suckling/continued consumption of milk casein, or continual 
maternal presence, both of which are associated with delayed weaning (Goody et al., 2001).To 
determine the exact cause, the following groups were established and measured for the DOPr 
component in SIA responses: Weaned on PND21, delayed weaned on PND25 with either their 
own mother, a lactating surrogate mother or replacement with a non-lactating surrogate mother 
on PND21, and finally three groups in which the dams were removed on PND21 and replaced 
with either casein rich, casein spiked or casein free milk substitutes. The results showed that 
replacement with a non-lactating surrogate until PND25 did not delay the development of 
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DOPr, as antagonism of SIA by naltrindole was still present as seen in rats normally weaned 
on PND 21 (Goody and Kitchen, 2001). Therefore this indicated that the cause of the delayed 
DOPr development was not due to a continuation of suckling behaviour by the pups, which 
would have still occurred at the non-lactating nipple, indicating a nutritional component from 
maternal milk. Indeed, this was demonstrated with the group provided with a casein-free milk 
substitute. This group showed SIA was antagonised by naltrindole administration, 
demonstrating that DOPr had developed normally. In contrast the groups provided with casein-
rich and casein spiked milk substitutes did not show reversal of SIA upon naltrindole 
administration, hence indicating that DOPr development had been delayed (Goody et al., 
2001). 
In summary, the results of the casein containing diets mirrored the results of the groups which 
were delayed weaned with either their own mother or a lactating surrogate. Naltrindole was not 
able to antagonise SIA in these groups, indicating that DOPr development was hindered 
(Goody et al., 2001). In contrast, the results from the groups provided with casein-free diet, 
mirrored the results of the group normally weaned on PND21 and the group that was housed 
with a non-lactating surrogate until PND25. Naltrindole was able to antagonise SIA in these 
groups, indicating that DOPr development occurred normally (Goody and Kitchen, 2001). 
These findings strongly implicate milk casein in influencing the development of the opioid 
system with focus on the DOPr. Although the mechanism underlying this effect is unknown, 
some suggestions have been made including the involvement of the gut-brain axis (see Section 
1.5). 
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1.4.6    The Oxytocin System 
 
The neuropeptide oxytocin (OT) was first discovered in 1906 when it was observed that 
extracts from human posterior pituitary gland were able to induce uterus contractions in a 
pregnant cat. The name oxy, derives from the Greek words “ωκνξ τoκoxξ,” meaning “swift 
birth” (Romano et al., 2016). OT is a 9 amino-acid neuropeptide which is synthesised in the 
brain and in the periphery (Gimpl et al., 2001) and plays a key role in the modulation of 
emotional and social behaviours (see Neumann and Landgraf, 2012).  In the brain, the 
hypothalamic-neurohypophysical system represents the major OT neurosecretory system and 
consists of the paraventricular (PVN) and supraoptic (SON) nuclei (Gimpl et al., 2001). Within 
the PVN, two populations of OT neurons have been identified: “magnocellular” and 
“parvocellular” neurons. OT is mainly synthesised in the magnocellular neurons of the PVN 
and SON (Gimpl et al., 2001). Oxytocinergic magnocellular neurons terminate in the posterior 
lobe of the pituitary gland amongst other regions of the brain. Once activated, magnocellular 
oxytocinergic neurons release OT from the nerve terminals to the posterior pituitary from 
which OT is then released into the blood steam to elicit its effects on organs expressing OT 
receptors (OTr) (Gimpl et al., 2001). 
The OTr  belongs to the G-protein coupled receptor family with seven transmembrane domains 
(Kimura et al., 1992). OTr have been identified in several brain regions as well as peripheral 
organs. In the rat CNS, OTr are located in several regions including the olfactory system, 
cortex, thalamus, basal ganglia, ventromedial region of the hypothalamus, central amygdala, 
brain stem and spinal cord (Gimpl et al., 2001). Interestingly the expression density of OTr has 
been shown to change according to age. Tribollet et al., (1989) have shown that in male and 
female rats the distribution and number of OT binding sites undergo changes during 
development. From PND5 to PND16, the distribution of binding sites remained essentially 
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unchanged but differed significantly from that characteristic distribution seen in an adult. The 
change-over from the "infant pattern" to the "adult pattern" was reported to occur during two 
critical periods: the first change took place between PND16 and PND22, a time corresponding 
to the pre-weaning period; the second change occurred after PND35 and thus coincided with 
the onset of puberty. During the first transition period, binding was reduced or disappeared in 
several areas intensely labelled at earlier stages, in particular, in the cingulate cortex and the 
dorsal hippocampus. At the same time, binding sites appeared in the ventral hippocampus. At 
puberty, high densities of OT binding sites appeared in the ventromedial hypothalamic nucleus 
and the olfactory tubercle (Tribollet et al., 1989). Thus like the opioid system, the OT system 
appears to also have a differential ontogenic pattern that may be susceptible to insult from 
environmental stimuli during development. Indeed environmental stimuli (Bales et al., 2012) 
and experiences during early development  such as social, maternal care and stress are known 
to shape the OT system possibly through epigenetic modification of the OTR (Carter, 2003; 
Bales et al., 2011). 
1.4.7    Role of the Oxytocin System in Emotional Regulation  
 
OT is currently attracting considerable scientific attention as a result of its CNS functions. OT 
regulates a variety of behaviours including maternal care and aggression, pair bonding, sexual 
behaviour as well as anxiety-related behaviours and stress coping  (for a review see Romano 
et al., 2016).The role of OT in regulating these behaviours makes this neurotransmitter system 
of the brain a promising target for treatment of numerous psychiatric illnesses such as anxiety 
disorders and depression (Romano et al., 2016). 
The synthesis and release of OT within the brain was found to be driven by anxiogenic, stressful 
and notably social (both positive and negative) stimuli (Landgraf et al., 2004; Neumann, 2008). 
For example, exposure of male rats to novelty, forced swimming, or social defeat rapidly 
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increases OT release into blood but also within the PVN and/or SON and in other limbic brain 
regions, such as the central amygdala or septum (Engelmann et al., 2004; Neumann, 2007). 
Similarly, increased OT release into blood (Neumann et al., 2001) and within the PVN and 
central amygdala (Bosch et al., 2004) has also been found in female rats exposed to 
psychosocial stress (maternal defeat by an aggressive lactating resident dam). 
Once released in the brain regions involved in stress and anxiety regulation, OT exerts 
anxiolytic effects and modulates neuronal functions related to physiological stress responses, 
mainly at the level of the PVN and amygdala. Indeed pharmacological intervention studies 
have shown that acute or chronic central administration of synthetic OT exerts an anxiolytic 
effect both in female and in male rats and in mice (Ring et al., 2006; Blume et al., 2008). In 
order to elucidate the role of the endogenous brain OT in regulation of anxiety like behaviour 
in more detail, OTr antagonists were used to block these receptors, specifically within the 
central amygdala (Neumann, 2002). However, the effects of antagonist administration on 
anxiety were only observed in pregnant or lactating but not virgin female or male rats 
(Neumann et al., 2000; Lonstein, 2007). This indicates that endogenous OT does not seem to 
play a major role in the maintenance of a basal level of anxiety, but rather comes into play 
during psychosocial or physiological activation of the system as seen in periparteum period in 
females (Neumann et al., 2000; Lonstein, 2007). Behavioural data from transgenic mice 
lacking OT provide further support for the anxiolytic importance of brain OT in anxiety 
regulation, as female knockout mice show greater anxiety-related behaviour than their wildtype 
counterparts on the elevated plus maze (Amico et al., 2004).  
Due to the high degree of comorbidity between anxiety and depression disorders, common 
mediators are likely to underlie both conditions. Indeed, in addition to its anxiolytic effect, 
synthetic OT administration was shown to shift stress-coping in rodents towards a more active 
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coping style, after either central or peripheral administration indicating anti-depressive like 
effects (for a review see Neumann and Slattery, 2016). Furthermore there is also preclinical 
and clinical evidence that OT may also contribute to the improvement of other depression-
related symptoms including sexual dysfunction, sleep disturbances and anhedonia (Slattery et 
al., 2010). 
Given the importance of the oxytocinergic system in emotional regulation, combined with 
evidence that this system shows developmental changes, it is likely weaning age or duration of 
exposure to milk proteins may result in changes to the normal development of the oxytocinergic 
system, thus impacting emotional behaviour. 
1.4.8    The Role of Weaning on Oxytocin Receptor development 
 
Recent evidence suggests that weaning can influence OTr levels in the ventromedial 
hypothalamus which is likely to be involved in emotional behavioural regulation during early 
postnatal development. Curley et al., (2009) has shown that duration of mother-pup interaction 
during early postnatal development influences the expression of behaviour as well as OTrs in 
mice (Curley et al., 2009). Similarly, Farshim et al., (2016) have shown that weaning rat pups 
from their mothers on PND25 as opposed to the normal age of weaning (PND21) resulted in 
depressive-like behaviour as shown by the forced swim test (FST). Furthermore this study 
demonstrated that weaning influences stress-induced modulation of OTr density in delayed 
weaned rat pups, suggesting that weaning time affects the central oxytocinergic system when 
delayed weaned animals are exposed to stress. These changes in OTr density were observed in 
the basal medial and basal lateral amygdala (Farshim et al., 2016), regions involved in 
emotional processing (LeDoux, 2000). The stress from the forced swim test induced a marked 
down-regulation of OTrs in weaned rats which was absent in non-weaned rats (Farshim et al., 
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2016). There is evidence to suggest that the high degree of plasticity in the OTr system may 
constitute a protective adaptive coping mechanism in response to various insults (e.g. stress) to 
shift brain function and behaviour (Neumann et al., 2012). Therefore given the key role of OT  
in the amygdala in modulating mood, it is possible that changes in the oxytocinergic stress 
responses induced by weaning may represent a homeostatic stress-coping mechanism that is 
found to be absent in animals that are delayed weaned. The mechanism underlying these effects 
remains unclear and could possibly be linked to prolonged exposure to milk caseins.  
1.4.9   The Role of Weaning on other CNS Systems  
 
In both humans and rodents, neurotransmitter systems implicated in modulation of emotive 
behaviours, such as serotonin (5-hydroxytryptamine: 5-HT), dopamine (DA) and corticotropin-
releasing factor (CRF), do not mature fully until early to late adolescences  (Andersen, 2003; 
Vazquez et al., 2006; Lukkes, 2009). Therefore, like the opioid and oxytocinergic systems, it 
is possible that normal development of neurochemical systems involved in regulation of stress 
responses, mood and anxiety states during adulthood are susceptible to disruptions by early life 
factors such as prolonged exposure to milk beyond the normal age of weaning.  Moreover, 
clinical and preclinical studies suggest that perturbations to these neurochemical systems 
during early-life appear to have long-lasting consequences on emotional behaviours in rodents 
and mental health in humans (Gutman et al., 2003; Nemeroff, 2004). 
Indeed studies have shown that weaning age does affect the development of the above 
mentioned neurotransmitter systems. Serotonin, a monoamine neurotransmitter of the 
mesolimbic system mediates its effects through at least 13 distinct G protein-coupled receptors. 
5-HT receptors are separated into seven major classes (5-HT1 – 5-HT7), which were subdivided 
further based on structural and operational features (Hoyer et al., 1994). It was reported that 
mice weaned early on PND14 displayed increased aggression and shown to express reduced 
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levels of 5-HT1B but not 5-HT1A  receptor mRNA  in the hippocampus in comparison to mice 
weaned on PND21 (Nakamura et al., 2008). Furthermore, mice weaned on PND16 reported 
lower brain weights but higher myelin basic protein in brain extracts (Kikusui et al.,  2007) 
compared to mice weaned on PND30. This suggests that early weaning decreases myelin 
formation and increases anxiety like behaviour (Nakamura et al., 2008). 
Like serotonin, dopamine is a monoaminergic neurotransmitter of the mesolimbic system and 
is involved in many reward related behaviours as well as being implicated in number of 
neuropsychiatric and neurodegenerative diseases (Grace, 2016). DA carries out its effects by 
binding to five distinct G-protein coupled receptors including D1A-D-D5. Early studies carried 
out by Sharman et al., (1982) investigated the impact of weaning time on the monoaminergic 
DA system. It was reported that piglets weaned early exhibited stereotyped belly-nosing 
behaviour which was shown to be associated with reductions in the metabolism of DA in the 
regions of the brain receiving DAergic inputs (Sharman et al., 1982; Mann et al., 1983). To 
date no other studies have been published showing a direct link between the DAergic system 
and weaning time.  
Finally, CRF is a neurotransmitter involved in integrating multiple components of stress 
responses via the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a major part of 
the neuroendocrine system and is a set of feedback interactions which occur between the 
hypothalamus, pituitary gland and the adrenal glands (see Hostinar et al.,2014). Systemic 
stressors can act directly on pituitary cells and result in the release of CRF as well as ACTH, 
which then stimulates the release of glucocorticoids with corticosterone being released in 
rodents and cortisol released in humans (see Lightman, 2008) from the adrenal glands. The 
release of glucocorticoids or corticosterone are the final effectors of the HPA axis. They also 
act as the terminators of stress responses via a negative feed-back loop, binding to 
72 
 
glucocorticoid receptors found in the hypothalamus and pituitary gland (Pratt, 1989). 
Variations in weaning patterns have been shown to be associated with altered responses to 
stress as well as modifications of the HPA axis (Cook, 1999). In a study carried out by  Kikusui 
et al (2006) male mice weaned on PND14 showed higher expression of glucocorticoid receptor 
mRNA expression in the hippocampus compared to mice weaned on PND21 (Kikusui et al., 
2006) . They also reported higher levels of corticosterone in male mice weaned on PND14 
compared to animals weaned normally on PND21, with early weaned animals also exhibiting 
increased anxiety-behaviour in the elevated plus maze test, which is shown to be linked to 
higher levels of corticosterone secretion than mice weaned on PND21  (Kikusui et al., 2006). 
Taken together, this evidence indicates that disruptions to the age of weaning can affect the 
development of a number of neurotransmitter systems in the brain and alter behaviour. 
However these studies have not clearly indicated whether the observed changes are due to 
maternal deprivation at different time points or due to nutritional changes which occur with 
weaning. As a result further investigation is required into whether alterations to weaning age 
result in these behavioural changes due to alterations to periods of milk protein exposure in 
early postnatal life.  
1.5 The gut-Brain Axis  
 
One of the proposed mechanisms by which weaning age or period of exposure to milk rich 
diets in early postnatal life influence brain neurochemistry and ultimately behaviour, is via the 
gut-brain axis. Communication between the gut and the brain, which is regarded as the gut-
brain axis is a well-known bidirectional neurohumoral communication system. There is 
growing evidence linking the gut microbiota with brain function and behaviour.  The high co-
morbidity between stress related psychiatric symptoms such as anxiety, with GI disorders 
including irritable bowel syndrome (IBS) and inflammatory bowel disorder (IBD) is strong 
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evidence of a gut-brain axis. The reciprocal impact of the gastrointestinal tract on brain function 
has been recognized since the middle of the 19th century through the pioneering work of Claude 
Bernard and Ivan Pavlov amongst a few others (for a review see Cryan and Dinan, 2012). They 
were amongst the first to emphasize the primacy of brain processing in the modulation of gut 
function. It is now known that the gut-brain axis provides a bidirectional homeostatic route of 
communication that uses neural, hormonal and immunological routes and that dysfunction of 
this axis can have pathophysiological consequences (Grenham et al., 2011; Mayer, 2011). 
There is also growing realization that the bi-directional communication between the digestive 
tract and the brain plays a key role in maintaining brain health and stress responses. An 
increasing number of studies using Germ free (GF) animals or antibiotic or probiotic 
administration have highlighted the involvement of the gut microbiota in the gut-brain axis.  
1.5.1        Gut microbiota 
 
The gut microbiota consists of a complex mixture of microorganisms that inhabit the 
mammalian GI tract, most of which reside in the distal gut. In humans, the distal gut contains 
10 14 – 10 15  bacteria, that is, there are 10-100 times more bacteria in the gut than eukaryotic 
cells in the human body (Gill et al., 2006). Furthermore, it is estimated that the gut microbiome 
has in excess of 1000 species and 7000 strains, at the genomic level, the global human gene 
complement is outnumbered by a factor of at least 100 when compared to the gut microbiome 
(Cryan et al., 2013). The genes in the combined genomes of these bacteria are known 
collectively as the intestinal microbiome.  
Over the past several years, substantial advances have been made in the ability to assess the 
microbiota composition. Recently developed molecular and metagenomic tools combined with 
culture-based approaches have allowed for a better understanding of the structure and function 
of the microbial gut community.  Several bacterial phyla are represented in the gut. The two 
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most prominent phyla in the human microbiota are Firmicutes and Bacteroides, accounting for 
at least 70-75% of the microbiome (Eckburg et al., 2005). Proteobacteria, Actinobacteria, 
Fusobacteria, and Verrucomicrobia are also present but in reduced numbers (Eckburg et al., 
2005). It is becoming clearer how the diversity and distribution of these prominent phyla 
contribute to health and disease. There seems to be a balance that confers health benefits, while 
an alteration in beneficial bacteria can negatively influence the well-being of an individual 
(Grenham et al., 2011). 
The composition of the gut microbiota is highly host-specific and evolves throughout the 
lifetime. The initial colonization of the gut was believed to be a strictly postnatal event. 
However, recent studies characterizing the microbiota of meconium and fecal samples obtained 
from preterm babies during the first three weeks of life, found Firmicutes was the main phylum 
detected in the meconium and Proteobacteria was abundant in the feces (Rodríguez et al., 
2015). Following birth, the human intestine is rapidly colonized by an array of microbes. The 
factors known to influence colonization during this period include, mode of delivery (vaginal 
birth vs. assisted delivery), diet (Breast milk vs. formula milk), sanitation and antibiotic 
treatment (Rodríguez et al., 2015) (see Figure 1.4). The first colonizers after birth, facultative 
anaerobes, create a new environment that promotes the colonization of strict anaerobes such as 
Bacteroides, Clostridium, and Bifidobacterium spp. The intestinal microbiota of a new born is 
characterized by low diversity and a relative dominance of the phyla Proteobacteria and 
Actinobacteria. The third stage of microbial colonization begins once weaning and introduction 
of solid food commences (Mackie et al., 1999), with the microbiota becoming more diverse 
and the emergence and dominance of Firmicutes and Bacteroidetes occurring (Eckburg et al., 
2005; Qin et al., 2010; Bäckhed, 2011). By the end of the first year of life, infants possess an 
individually distinct microbial profile, converging toward the characteristic microbiota of an 
adult. By 2-5 years of age, the microbiota fully resembles that of an adult in terms of 
75 
 
composition and diversity (Koenig et al., 2011; Yatsunenko et al., 2012). Therefore, the first 3 
years of life represent a critical period when the intestinal microbiota, a vital asset for health 
and neurodevelopment (Borre et al., 2014) is established and its alteration during this period has 
the potential to profoundly affect host health and development (Figure 1.4). 
 
 
Microbial colonization in rat pups has been less comprehensively studied compared to the 
ecosystem in human infants; however the principle colonization of intestinal microflora in 
rodents resembles that in humans (Umesaki et al., 2000). As with humans, the neonatal rat 
microbiota is far less diverse compared to the mothers, but continues to become more complex 
as time from birth increases.  Bacterial groups favoured by mother’s milk such as Lactobacilli 
and Bifidobacteria are the first to colonize the neonatal small intestine. After weaning, 
anaerobic bacteria, such as Bacteroidaceae and Lactobacilli, become the dominant microbes. 
Pregnancy Birth Infancy Adult
Maternal Microbiota
Healthy status
Lifestyle Antibiotic 
Geographical location
Family Environment
Breastfeeding vs
Formula  
Diet 
Lifestyle 
Window Of Opportunity for Microbial Modulation
Vaginal vs. C-section Genetics
Complementary food
Duration of lactation
Living environment
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Short and Long Term Health Effects 
Figure 1.4: Factors influencing the infant gut microbiota development, as well as the adult 
microbiota. The first 3 years of life represent the most critical period for modulation of the gut 
microbiota by environmental factors such as diet. Taken and adapted from (Rodríguez et al., 2015). 
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Inoue and Ushida, (2003) investigated the development of the rat intestinal microbiota from 
PND18- 40. The authors showed that the main changes occur at the time of weaning, i.e. 
PND21-22 with significant increase in the number of bacteria belonging to the phyla of 
Firmicutes (Inoue et al., 2003). 
As shown in Figure 1.4, one of the factors influencing the composition of the gut microbiome 
in early postnatal life is diet. Therefore, it is possible that age of weaning and period of exposure 
to milk proteins in infancy may result in changes to the gut microbial signature. Indeed Farshim 
et al., (2016) have shown that delay weaning rat pups on PND25 resulted in significantly lower 
Clostridium histolyticum bacterial groups compared to animals weaned normally on PND21. 
Furthermore PND25 weaned pups exhibited a marked increase in this bacterial group following 
exposure to the FST (Farshim et al., 2016). This study indicates that weaning age does indeed 
influence the composition of the gut microbiota. Moreover, milk caseins have been shown to 
have numerous interactions with bacteria throughout the GI tract. These interactions have been 
shown to be either direct or indirect (Miller et al., 1990). For example the production of β-
lactamase by Enterobactercloacae spp is enhanced by casein. This results in more rapid 
fermentation of carbohydrate to organic acids which then decrease the intraluminal pH of the 
gut. This effect has been proposed as an important component in the initiation of neonatal 
inflammatory bowel disease (Miller et al., 1990). Therefore prolonged exposure to milk caseins 
in early postnatal life could result in changes to the gut microbiota through its effects on luminal 
pH.  
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1.5.2      Gut Microbiota Metabolism 
 
The Gut microbiome is involved in a variety of different essential functions which aid the host 
to remain healthy. It is involved in direct chemical communication through signalling pathways 
which connect many organs and tissues around the body including the brain (Cryan et al., 2011; 
Nicholson et al., 2012). The microbial richness and diversity found in the gut encodes unique 
metabolic functions that are absent from the host providing a metabolic extension to the 
relatively limited host genome (see Ottman et al., 2012). This includes the capacity for the 
metabolism of chemicals derived from endogenous mammalian metabolism, nutrients and 
other xenobiotics. Products of microbial metabolism act as signalling molecules and can in turn 
influence the host’s own metabolism (Tremaroli et al., 2012). These small molecule 
messengers include bile acids, biogenic amines, products of choline degradation and short 
chain fatty acids (SCFAs). 
Signalling molecules are generated by GI bacteria in a number of ways, for example proteins 
from the diet may be catabolized by microbial proteinases and peptidases in cooperation with 
host proteinases (Hollister et al., 2014). The generation of free amino acids by protein 
catabolism in the stomach and small intestine provide substrates for luminal conversion of 
amino acids. These  amino acids can be converted by decarboxylation reactions and catalyzed 
by the GI bacteria to form different signalling molecules (Hollister et al., 2014). As an example, 
L-histidine can be converted to the biogenic amine, histamine, by histidine decarboxylases 
produced by GI bacteria. Histamine can suppress production of inflammatory cytokines by 
signalling through the histamine receptors (Thomas et al., 2012). Other examples of 
microbiome-mediated amino acid decarboxylation include the conversion of glutamate to g-
aminobutyric acid, tyrosine to tyramine, and phenylalanine to b-phenylethylamine (Hollister et 
al., 2014). Bacterial genes also encode glutamate decarboxylases, which can generate the 
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neurotransmitter and potential immunomodulin g-aminobutyric acid in the intestine (De Biase 
et al., 2012). Furthermore, complex carbohydrates such as dietary fibre can be digested and 
subsequently fermented in the colon by gut microorganisms into SCFAs such as n-butyrate, 
acetate and propionate. These metabolites not only act as energy sources for epithelial cells, 
but have been shown to control colonic gene expression and metabolic regulation, for example 
MacFabe et al., (2011) have reported that SCFAs regulate the function of the enzyme, histone 
deacetylase and have neuroactive properties which can stimulate the sympathetic nervous 
system and may modulate rodent social behaviour via these mechanisms (MacFabe et al., 
2011).  
In addition to the generation of small signalling molecules, bacteria can produce antimicrobial 
peptides which confer resilience or resistance to infection by enteric pathogens (Kamada et al., 
2013). The production of antimicrobial compounds by the GI microbiome might therefore 
prevent expansion of enteric pathogens or indigenous pathobionts. The generation of 
antimicrobial peptides, immunomodulatory compounds, and neurotransmitters by the 
microbiome could affect the performance of the mucosal immune system and enteric nervous 
system, and may therefore modulate general health, mood and behaviour of the host via these 
mechanisms.  
Metabolic profiling of biofluids, such as urine, plasma or faecal water, using high-resolution 
spectroscopy methods is an effective tool for measuring metabolites from both microbial and 
mammalian origin (see Section 1.6). When this technique is used in conjunction with animal 
models of varying gut microbial states, this systems biology approach can be used to study the 
metabolic cross-talk between the host and its gut microbiota and provide insight into the 
biochemical influence of the gut microbiome on gut, liver and brain metabolism and 
functioning. 
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1.5.3      Bidirectional Gut-Brain Axis 
 
The idea of a bidirectional communication between the gut and the CNS has long been 
recognized. More recently, this gut-brain axis has been extended to include contents of the 
intestinal lumen and is now referred to as “microbiota-gut-brain axis’, highlighting the 
increasingly appreciated importance of the bacteria in this communication (Luczynski et al., 
2016). 
The microbiota-gut- brain axis consists of a bidirectional communication network that 
monitors and integrates gut functions and links them to cognitive and emotional centres of the 
brain. A number of potential mechanisms have been suggested by which microbiota can affect 
brain function and consequently behaviour. One of the prime proposed mechanisms is via the 
immune system, which has been shown to shape the composition of the gut microbiota, and 
the microbiota in turn shapes the immune system (Dantzer et al., 2008). Some rodent infection 
studies using subclinical doses of pathogenic bacteria have indicated that immune system 
activation is not always necessary in causing changes in brain neurochemistry and behaviour 
(Lyte et al., 2006). While other studies have shown clear evidence of the importance of an 
intact and normally functioning immune system in gut-brain communication (El Aidy et al., 
2015). Another potential communication pathway is via the vagus nerve. The vagus nerve 
regulates several organ functions including gut motility (Cryan et al., 2012). Approximately 
80% of the nerves fibres are sensory, conveying information about the state of the body’s 
organs to the CNS. Numerous studies have shown the effect of gut-microbiota on brain function 
to be dependent on vagal activation (Goehler et al., 2008; Bravo et al., 2011; Bercik et al., 
2011), while others have found evidence of vagal independence, as vagotomy failed to 
influence the effect of antimicrobial (ATM) treatment on brain function (Bercik et al., 2010). 
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The endocrine system too plays an important role in the ability of bacteria to alter brain function 
(Lyte et al., 2006). Many studies have demonstrated changes in endocrine signalling in models 
of intestinal dysbiosis (Sudo et al., 2004; Bercik et al., 2014) and also the ability to alter 
intestinal microbial contents following stress (De Palma et al., 2015; Golubeva et al., 2015). 
For example studies that have used maternal separation models have shown that neonatal stress 
leads to long-term changes in the composition and diversity of the gut microbiota (Cryan et al., 
2011). In addition to altering the gut microbiota composition, chronic stress is known to 
increase the permeability of the intestinal barrier, making it “leaky” and subsequently give 
bacteria the opportunity to translocate the intestinal mucosa and directly access both immune 
and neuronal cells of the enteric nervous system (Gareau et al., 2011). Other possible 
mechanisms of communication include microbial metabolites some of which have neuroactive 
properties (Thomas et al., 2012). Figure 1.5 illustrates the main mechanisms and pathways 
involved in the bidirectional microbiota-gut-brain axis communication. 
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Figure 1.5: Potential pathways involved in the bidirectional communication between the gut 
microbiota and the brain. Taken and adapted from (Cryan and Dinan 2012). 
A number of direct and indirect pathways exist through which the gut microbiota can interact with the 
gut-brain axis. They include endocrine (cortisol), immune (cytokines) and neural (vagus nerve and 
enteric nervous system) pathways. The brain is speculated to use these same pathways to influence the 
composition of the gut microbiome. For example, under stress conditions the hypothalamus-pituitary-
adrenal axis regulates cortisol secretion, in turn cortisol can affect immune cells (including cytokine 
secretion) both act locally in the gut and systemically. Cortisol can also alter both the permeability of 
the gut and barrier function, and change gut microbiota composition. Conversely, the gut microbiota 
and probiotic agents can alter the levels of circulating cytokines, and this can have a significant effect 
on brain function. The vagus nerve is strongly implicated in relaying the influence of the gut microbiota 
to the brain. Moreover, short-chain fatty acids (SCFAs) are neuroactive bacterial metabolites derived 
from dietary fibres that can also modulate brain and behaviour. 
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1.5.4      Gut-Brain Axis and Emotional Behaviour 
 
Alterations in the bidirectional brain-gut microbiota interactions are believed to play a role in 
the pathogenesis of behavioural disorders. There is accumulating evidence from rodent 
behavioural studies to suggest that manipulation of the gut microbiota results in altered 
behavioural responses. Several experimental approaches have been used to alter the gut 
microbiota, including antibiotics, probiotics, faecal microbial transplantation, infection with 
pathogenic bacteria and Germ Free (GF) animal models. Table 1.7 provides a detailed 
summary of the behavioural findings generated by experiments using these approaches to alter 
the gut microbiota.  
When viewed together, the reported evidence in Table 1.7 indicate that rodent behavioural 
responses are impacted when the bacterial status of the gut is manipulated. Depressive-episodes 
are associated with dysregulation of the HPA axis.  As discussed in Section 1.4.9, the HPA 
axis is the principle endocrine pathway, and activation of this system takes place in response 
to a variety of physical and psychological stressors. A direct link between microbiota and HPA 
reactivity is evident from the reported literature. The pioneering work of  Sudo et al., (2004) in 
this field was the first to demonstrate mild stress induced an exaggerated release of 
corticosterone and ACTH  in GF mice when compared to specific pathogen free (SPF) mice 
(Sudo et al., 2004). Recent work has reproduced these findings (Crumeyrolle-Arias et al., 
2014). While several independent laboratories have reported adult GF mice display a reduced 
HPA response to stress (Heijtz et al., 2011; Neufeld et al., 2011; Arseneault-Bréard et al., 2012; 
Clarke et al., 2013). It is important to note that work studying the role of microbiota in 
behaviour has been conducted in several mouse strains including inbred Balb/C, outbred Swiss 
Webster, NMR1 and AKR mice. Genetic differences across strains also have an influence on 
behaviour which may explain these discrepancies. Similarly, the use of antimicrobials to 
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significantly reduce the microbial number and diversity in healthy adult mice has also been 
shown to result in decreased anxiety like behaviour (Verdú et al., 2006). 
Interestingly, it has been demonstrated that reconstitution of microbiota in GF mice in early 
life using microbiota obtained from specific pathogen free (SPF) mice results in 
normalisation/reversal of stress responses (Heijtz et al., 2011; Clarke et al., 2013). By contrast, 
conventionalisation of GF mice in adulthood failed to reverse anxiety like behaviour (Neufeld 
et al., 2011). These data suggest that there is a critical window during development where 
microbiota influence development of the CNS branches related to stress-related behaviours. 
Furthermore, colonisation studies have demonstrated that behavioural phenotypes associated 
with distinct strains of mice can be transferred to another animal via the gut microbiota. For 
example when GF male Swiss Webster mice were colonised with microbiota from SPF Balb/C 
mice, an increased anxiety-like phenotype was observed, reflecting the behavioural phenotype 
that is common in SPF Balb/C mice (Bercik et al., 2011). In the reverse experiment, GF Balb/C 
mice that received microbiota from SPF Swiss Webster mice showed a reduction in anxiety 
like behaviour, similar to that observed in SPF Swiss Webster mice.  
The studies reported in Table 1.7  show an increase in anxiety-like behaviour is observed as a 
result of infection/infestation with pathogens (Heijtz et al., 2011; K. M. Neufeld et al., 2011; 
Clarke et al., 2013). Furthermore, oral administration of probiotics in animals with normal gut 
microbiota was found to have a positive impact on reducing basal or induced anxiety-like 
behaviour (Desbonnet et al., 2008; Bravo et al., 2011; P Bercik et al., 2011) as well as 
depressive like behaviours (Bravo et al., 2011; Arseneault-Bréard et al., 2012).  
In contrast to the emergence of a rich and robust pre-clinical literature on the effects of 
microbiota manipulation on behaviour, limited information is available from human studies. A 
randomized, placebo-controlled study of healthy men and woman reported consumption of 
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probiotics containing lactobacillus and Bifidobacterium improved psychological distress and 
anxiety compared to those taking a matched control product (Messaoudi et al., 2011). Thus 
these findings demonstrate that intestinal bacteria could be used as potential therapeutic targets 
in mood and anxiety disorders due to their well-documented effects on modulation of emotional 
behaviour.  
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Species (Gender)                     Method                                               Neurochemical changes                                 Behavioural outcomes            Reference  
                                                                                                           Germ Free versus SPF mice  
                                                                                                                                                                                                                                                                             
 
 
 
                                                                                                                                                                                                                                                                            
  
 
                                                                                                                                                                                                                                                                               
 
 
                                                                                                                                                                                                                                                                                                                                   
  
 
  
 
 
 
 
Female Swiss-
Webster mice 
Behaviour tested using 
locomotor activity. EPM. 
Serum corticosterone 
levels and gene expression 
levels measured. 
 In GF mice: Increased levels of corticosterone. 
Decreased NMDA subunit NR2B mRNA expression in 
central amygdala. Decreased BDNF expression in dentate 
gyrus layer of hippocampus 
Decreased anxiety-like 
behaviour. No change 
in locomotion  
Male and female 
Swiss-Webster 
mice  
Behaviour tested 
using the LD  
In GF mice: Increased concentrations of 5-hydoxytryptamine 
and 5-hydroxyindoleacetic acid in the hippocampus. Increased 
concentrations of serotonin precursor in males. Decreased 
BDNF levels in hippocampus 
Decreased anxiety-like 
behaviour 
Male NMR1 mice 
Behaviour tested
using OF, LD and 
EPM 
No neurochemical changes reported  Decreased anxiety-like 
behaviour. Increased 
motor activity 
Male Swiss 
Webster mice 
Behaviour tested using OF 
and social interaction. 
BDNF levels in amygdala 
measured 
A significant reduction in the mRNA levels of BDNF 
were found in the amygdala of GF compared to SPF mice 
Decreased anxiety-like 
behaviour and increased 
social interaction 
Female  SPF F344 
rats 
Behaviour tested using 
OF, social interaction. 
Serum corticosterone. 
(CRF) concentrations 
measured 
In GF: Displayed Increased CRF mRNA in 
hypothalamus. Decreased GR mRNA expression in 
hippocampus. Decreased dopaminergic turnover rate in 
hippocampus, frontal cortex and striatum. Increased CRF 
levels after the open field stress test 
Increased anxiety like-
behaviour and reactivity 
to stress and reduced 
social interaction due to 
absence of gut 
microbiota in F344 
Neufeld et al., 2011; 
Clarke et al., 
2013; 
Heijtz et al., 2011; 
Arseneault-
Bréard et al., 
2012; 
Crumeyrolle-
Arias et al., 2014; 
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Species (Gender)                     Method                                          Neurochemical changes                                Behavioural outcomes                 Reference  
 
 
 
n                                                                                                 Re-colonisation of microbiota in GF mice 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
Female Swiss 
Webster mice 
LD. No reported neurochemical changes  
 
No change in anxiety 
like behaviour 
Male NMR1 mice 
GF mice were conventionalised 
in early life using microbiota 
obtained from SPF mice. 
Behaviour tested using OF, LD, 
EPM, locomotor activity and 
compared to SPF and GF mice. 
No reported neurochemical changes  
Conventionalisation of 
GF in early life 
normalised anxiety and 
motor activity 
Male Swiss 
Webster mice 
GF mice were colonised at 3 
weeks of age and allowed to 
grow to adulthood. They were 
then assessed for anxiety using 
LD 
No reported neurochemical changes  
 
Conventionalisation of 
GF mice reversed 
anxiety like behaviour 
Female Swiss 
Webster mice 
 
GF mice were colonised at 10 
weeks of age. Assessed for 
anxiety like behaviour using 
EPM. 
No reported neurochemical changes  
 
Conventionalisation of GF 
mice reversed anxiety like 
behaviour 
Gareau et al., 
2011; 
 
Heijtz et al., 
2011; 
 
Clarke et al., 
2013; 
Neufeld et al., 
2011; 
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Species (Gender)                     Method                                         Neurochemical changes                           Behavioural outcomes                     Reference  
 
 
 
 
n                                                                                                                              Antibiotics 
 
 
 
 
Effect of Infection 
  
 
 
 
 
 
 
 
Male BALB/c 
and Swiss 
Webster 
Gf Swiss Webster BALB/c mice were 
colonized by gavaging fresh cecal 
contents from adult SPF BALB/c or 
Swiss Webster mice. Behaviour tested 
using step-down test. 
Colonisation of GF swiss mice with 
Balb/C microbiota increased anxiety 
like behaviour compared to SPF swiss 
mice. In contrast GF BALB/c mice 
colonized with swiss microbiota 
reduced anxiety like behaviour 
Male BALB/c 
mice  (SPF) 
Balb/c mice received  mixture of  
non-absorbable ATMS (neomycin, 
bacitracin and pimaricin). Behaviour 
tested using step-down and LD. 
BDNF levels measured in 
hippocampus and amygdala 
 BDNF levels were significantly higher in 
the hippocapmus and lower in the 
amydgala in ATM mice compared to 
control mice. 
Decreased anxiety like 
behaviour and Increased 
exploratory behaviour 
Male CF-1 mice 
CF-1 mice were orally treated with 
C.Jejuni  or C. rodentium or saline 
solution for controls. Behaviour tested 
using holeboard. and OF. The protein 
c-Fos was measured as an activation 
marker in the brain. 
c-Fos expression  detected in brain regions 
associated with anxiety like behaviour 
including amygdala. 
Increased anxiety like 
behaviour caused by 
pathogenic bacteria 
No reported neurochemical changes  
 
 Bercik et al., 
2011; 
 
Verdú et al., 
2006; 
 
Lyte et al., 2006; 
Goehler et al., 
2008; 
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Species (Gender)                 Method                                           Neurochemical changes                                 Behavioural outcomes                   Reference  
 
 
 
 
 
n                                                                                                                              
 
 
 
Influence of Probiotics  
 
 
 
 
 
 
 
 
Male Balb/c AKR 
mice 
AKR mice were injected 
with parasite Trichuris 
muris. Behaviour tested 
using LD and step-down 
test. BDNF levels in the 
brain were measured 
Colonisation of GF swiss mice 
with Balb/C microbiota 
increased anxiety like behaviour 
compared to SPF swiss mice. In 
contrast GF BALB/c mice 
colonized with swiss microbiota 
reduced anxiety like behaviour 
Male AKR mice 
Mice with Chronic DSS 
colitis. Treated with 
B.Longum NCC3001 on the 
3rd cycle of DSS. Behaviour 
tested using the Step-down 
and LD. 
Increased anxiety like 
behaviour caused by 
DSS-induced gut 
inflammation 
Male AKR mice Mice with Chronic DSS colitis. 
Treated with B.Longum 
NCC3001 on the 3rd cycle of 
DSS. Behaviour tested using the 
Step-down and LD. brain. 
No reported neurochemical changes  
Increased anxiety like 
behaviour following 
colitis, which was 
normalised by B.longum 
NCC3001 treatment 
Lower levels of BDNF mRNA were found in the 
hippocampus of T muris infected mice compared with 
controls 
No reported neurochemical changes  
Bercik et al., 
2010; 
Bercik et al., 
2011; 
 
Bercik et al., 
2011b; 
 
89 
 
 
Species (Gender)                     Method                                             Neurochemical changes                                  Behavioural outcomes            Reference  
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Male  Balb/c  
AKR  mice 
AKR mice were injected with 
parasite  Trichuris muris, then 
treated with probiotic 
Bifidobacterium Longum. 
Behaviour tested using LD 
and step-down test. BDNF 
levels in the brain were 
measured 
Treatment of T muris–infected mice with B longum: 
normalised BDNF levels 
Increased anxiety like 
behaviour caused by 
parasite infection was 
reversed by B longum 
treatment 
Male  Sprague-
Dawley rats 
Rats underwent MS, followed 
by Administration of 
B.infantis. Behaviour was 
testing using FST. 
Measurement of cytokine 
concentrations in whole blood 
samples, monoamine levels in 
brains and peripheral HPA 
axis indicators 
  
MS rats displayed decreased NA content in the brain, 
increased peripheral IL-6 release, and increased amygdala 
CRF mRNA levels. Treatment with B.infantis resulted in 
normalization of the immune response and restoration of basal 
NA concentrations in the brainstem 
MS mice showed increased 
depressive-like behaviour. 
Treatment with B.infantis 
reversed depressive like 
behaviour. 
Male BALB/c mice Gavage with 
L.rhamnosus (JB-1) 
or without bacteria. 
Anxiety and 
depressive 
behaviour tested 
using SIH. EPM 
and FST 
Treatment with L.rhamnosus (JB-1) increased GABA (B1b) mRNA 
cingulate and prelimbic cortex. Decreased GABA (B1b) mRNA 
expression in hippocampus, amygdala and locus coeruleus 
Increased ABA (Aα2) in hippocampus. Decreased GABA (Aα2) 
mRNA expression in prefrontal cortex and amygdala. 
Decreased anxiety and 
depression like 
behaviour   
Bercik et al., 
2010; 
Desbonnet et 
al., 2008; 
 
Bravo et al., 
2011; 
Table 1.7: Key findings related to the impact of gut microbiota on behaviour. Abbreviations: ATM, antimicrobials; CON: conventionalised; CRF, 
corticotrophin-releasing factor; CR, glucocorticoid receptor; 5-HT1A, 5-hydroxytryptamine 1A;EPM, elevated plus maze; DSS, dextran sodium sulphate; FST, 
forced swim test; GF, germ free; GR, glucocorticoid receptor; LD, light-dark box;  MS, maternal separation; NA, noradrenaline; OF, open field; SIH, stress 
induced hyperthermia; SPF, specific pathogen free 
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1.5.5      Gut-Brain Axis and Neurochemistry  
 
As discussed in Section 1.5.4, recent studies have clearly demonstrated that the gut microbiota 
influences behaviour. The molecular and neurochemical correlates of these effects remain to 
be fully eluded, however the microbiome has been shown to influence neurotransmission, 
neuorotropic factors and formation of the BBB. 
There is ample evidence to show that a number of neurotransmitter systems are influenced via 
the microbiome-gut-brain axis. The neurotransmitter serotonin (5-hydroxytryptamine) 
regulates mood, appetite, sleep and cognition (see section 1.4.9).  Although it is principally 
known for its role in the CNS, approximately 95% of the body’s serotonin is found in the GI 
system, where it mediates pain perception, gut secretion and motility (Ridaura et al., 2015). 
Tryptophan is both an essential amino acid and a precursor for serotonin. GF mice have been 
shown to have elevated levels of plasma tryptophan compared with controls (Clarke et al., 
2013). Increased hippocampal levels of serotonin are also found in male, but not female GF 
mice. Importantly, colonization with bacteria post weaning normalises tryptophan availability 
but not hippocampal serotonin levels  (Clarke et al., 2013). Together these findings indicate 
that the microbiota affects serotonergic signalling in the CNS, perhaps by altering peripheral 
tryptophan availability. Enteric nervous system (ENS) serotonergic levels are also affected by 
microbial metabolites such as SCFAs (Reigstad et al., 2015), since circulating serotonin levels 
are largely derived from GI sources, this agrees with studies showing lower serum levels of 
serotonin in GF animals (Ridaura et al., 2015). 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the CNS and the 
dysfunction of GABAergic signalling has been linked to anxiety and depression (O’Leary et 
al., 2014). It has been shown that Lactobacillus spp. and Bidobacterium spp. are capable of 
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metabolising glutamate to produce GABA in culture (Higuchi et al., 1997; Barrett et al., 2012). 
Moreover, it has also been shown that provision of the probiotic, L. rhamnosus to mice, causes 
reductions in anxiety- and depressive-like phenotypes, as well as inducing region specific 
alterations in GABA (1b) mRNA in the brain, with increases being observed in cortical regions 
(cingulate and prelimbic) and concomitant reductions in the expression in the hippocampus, 
and amygdala, when compared to control fed mice (Bravo et al., 2011). Mice lacking the 
GABA (1b) receptor isoform have been shown to be more resilient to both early-life stress and 
chronic psychosocial stress in adulthood (O’Leary et al., 2014). These observations suggest 
that gut microbes can indeed influence brain neurotransmitter levels.  
Moreover, BDNF promotes the growth and development of new neurones and the survival of 
existing neurones (Park et al., 2012). Altered levels of BDNF in the CNS are well known to be 
associated with mood disorders in humans (Autry et al., 2012). As illustrated in Table 1.7, 
microbiota influences BDNF expression in the CNS, for example in GF mice, BDNF 
expression is lower in the cortex and amygdala compared with controls, these animals also 
displayed increased anxiety-like behaviour (Heijtz et al., 2011). In the hippocampus, the 
changes in BDNF levels documented are inconsistent. Studies report an increase in BDNF 
levels in GF mice which have displayed reduced anxiety-like behaviour (Neufeld et al., 2011), 
while others report a decrease in expression (Sudo et al., 2004; Gareau et al., 2011; Heijtz et 
al., 2011; Clarke et al., 2013).Taken together these studies suggest gut microbes influence brain 
BDNF levels.  
Moreover, recent evidence suggests the gut microbiota may influence the development of the 
BBB. The BBB filters the passage of water-soluble molecules from the blood to the brain. It is 
formed early in foetal life to protect the foetus against harmful toxins and bacteria during the 
sensitive period of brain development (Abbott et al., 2012).  Braniste et al., (2014) examined 
BBB development and function in GF mice. In foetal mice from SPF dams, the BBB prevents 
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the penetration of labelled immunoflobulin, however the BBB of foetal mice from GF dams 
allows the immunoglobulin to diffuse into the brain. As adults, the BBB of GF mice continues 
to be more permeable than that of their SPF counterparts (Braniste et al., 2014). It is proposed 
that these changes in barrier function are due to tight junction abnormalities. Indeed, tight 
junction protein expression is reduced in both foetal and adult GF mice. Moreover, tight 
junctions in the brains of GF mice appear diffused and disorganised. Subsequent colonization 
of adult GF mice with microbiota from SPF mice successfully reduced BBB permeability and 
increased tight junction protein expression (Braniste et al., 2014). The effects of colonization 
on BBB permeability is likely mediated by SCFAs or other metabolites produced by gut 
bacteria. This study highlights the importance of the microbiota in BBB development; 
increased diffusion of molecules into the developing brain could affect brain neurochemistry 
and underlie the behavioural profiles of animals with altered gut microbiome status.  
Altogether these studies highlight the role of the gut microbiota in modulating bodily 
homeostasis and emotional behaviour. An area of growing interests in recent years concerns 
the metabolic capability of the gut microbiota and ways by which their metabolic activity 
influences mammalian metabolic pathways. Some metabolites released by the gut bacteria have 
been implicated in disease states and mood disorders and can be detected using metabolic 
profiling techniques such as metabonomics. 
1.6        Metabonomics 
 
Metabonomics has emerged as a powerful tool which allows for the study of metabolites and 
illuminates the metabolic functionality of the gut microbiome and its interaction with the host. 
The suffix ‘omics’ refers to the study of a set of biological molecules and covers fields such as 
genomics, transcriptomics, proteomics and metabonomics. Metabonomics involves the 
comprehensive characterization of metabolites and metabolism in biological systems in 
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response to drugs, lifestyle, environment, stimuli and genetic modulation with the aim of 
characterizing the beneficial and adverse effects of such interactions (Nicholson et al., 1999). 
In addition, metabolic profiling techniques have been successfully used in the discovery of 
biomarkers of a number of neuropsychiatric and neurodevelopmental disorders such as 
depression (Quinones et al., 2009; Huang et al., 2015), schizophrenia (Yang et al., 2013) and  
autism spectrum disorder (Wang et al., 2016).  
Metabonomic studies are conducted using high resolution analytical techniques such as 1 H 
Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectroscopy (MS). MS requires 
pre-preparation of metabolic samples with the use of Gas Chromotrography (GC), Liquid 
Chromatography (LC) or Ultra High-Pressure LC (UPLC). 1 H NMR-based metabolic profiling 
allows for both the identification and quantification of very large numbers of metabolites, 
giving a good overview of the metabolome, which is a collection of metabolites, of the host. 
NMR analysis produces a spectra containing thousands of peaks that are related structurally to 
metabolites. Analysis of this data is utilises mathematic modelling techniques combined with 
multivariate data analysis.  Metabonomics studies generally use biofluids, cells and tissue 
extracts which are often easily obtained. Urine, plasma and faecal samples can be obtained 
non-invasively and require simple sample preparation (Beckonert et al., 2007). In addition 
there are a variety of other biofluids which may be utilized in metabonomic analysis including 
cerebrospinal fluid, digestive fluids, amniotic fluid and lung aspirates as well as liver and brain 
tissue samples (Lindon et al., 2000).  
1.6.1     Neurodisorders  
 
Mental health disorders such as major depressive disorder, bipolar disorder, schizophrenia and 
addiction effect millions of people. According to WHO, the worldwide problem of 
neuropsychiatric disorders is 13% higher than other major diseases such as cardiovascular 
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diseases and cancer (WHO, 2008).  Current understanding of pathophysiology of these 
disorders remains limited. This is due to the complex nature of these disorders which tend to 
arise from a dynamic and complex dysregulation of gene networks, proteins as well as 
metabolic alterations. In addition, present knowledge is also incomplete in predicting the risk 
of individuals developing CNS disorders. Disease specific molecular finger prints known as 
“biomarkers” can be gained through the study of omics data including metabolomics and can 
aid to map dysregulated systems involved in disease pathogenesis. Furthermore, global 
mapping of uncharacteristic pathways in psychiatric disorders can lead to the identification of 
biomarkers of disease (Quinones et al., 2009; Sethi et al., 2016). Another aspect of 
metabolomics as a tool for discovery of biomarkers is its ability to reflect the relationships and 
interactions between metabolic state of an individual and environmental aspects (diet, lifestyle, 
gut microbial activity, and genetics) under a particular set of conditions (Holmes et al., 2008; 
Quinones and Kaddurah-Daouk, 2009) 
In addition, the gut microbiota is exclusively responsible for several important metabolic 
functions including SCFAs production, amino acid synthesis and bile acid biotransformation 
(see Putignani et al., 2016) (see section 1.5.2). The gut microbiota, through metabolite 
production has been shown to influence the brain, forming the microbiome-gut-brain axis and 
this has been implicated as a critical factor in many physiological and pathophysiological 
processes. For example metabonomics has been used to illustrate changes which occur both in 
mammalian metabolic pathways, as well as those involved in gut microbiota metabolism in the 
pathogenesis of ASD. Metabolomics studies have shown tryptophan metabolism is 
significantly decreased in patients suffering from ASD (Boccuto et al., 2013). Furthermore 
Ming et al., (2012) have reported defective amino acid metabolism, increased oxidative stress 
as well as altered gut microbial metabolism in ASD (Ming et al., 2012). Indeed a high 
comorbidity between gastrointestinal dysfunction and ASD has been reported (see Hsiao, 
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2014),  thus highlighting the role of dietary intake and gut microbial metabolic activity in the 
aetiology of neurodevelopmental disorders.  
Taken together these studies indicate that metabonomics is an instrumental tool in identifying 
metabolic signatures which reflect environmental factors which may influence the 
development of disease state. The use of this technique in this thesis will allow for the 
investigation of early life dietry factors which influence normal brain development and could 
lead to the development of neuropsychiatric disorders.   
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1.7 Thesis Hypothesis and Aims 
 
The evidence provided in this chapter demonstrates that early life represents a period of critical 
development not only for the CNS but also for the gut microbiota. Environmental influences 
during this critical time including diet, play an essential role in modulating the normal 
development of both of these systems.  Milk, either mother's milk or cow’s milk is the main 
source of nutrition in early postnatal life in mammals and is known to contain a range of 
bioactive compounds, however information regarding the influence of these bioactive products 
in milk on brain development during early life is lacking. In recent years there has been an 
increasing awareness regarding the impact of early life environmental influences on the 
development of a range of neuropsychiatric disorders such as autism, schizophrenia and 
depression. This thesis will aim to utilise a multidisciplinary approach to investigate the 
influence of prolonged milk exposure in early postnatal life, in particular, exposure to milk 
caseins which are known to release bioactive peptides, beta casomorphins, on brain 
development and subsequent behaviour. Furthermore, given the growing body of evidence 
suggesting diet can influence host metabolism and the development of the gut microbiome 
which in turn has been linked with brain function and behaviour, the role of the gut-brain axis 
in mediating any neurochemical or behavioural changes will also be investigated.  
This thesis will test the hypothesis that prolonged exposure to milk casein and its bioactive 
breakdown product BCM-7 beyond the normal age of weaning results in depressive-like 
behaviour and induces alterations to neurotransmitter systems in the brain involved in mood 
regulation via a gut-brain axis mediated mechanism. This hypothesis is evaluated using male 
Wistar Albino rats in a number of experiments. It begins with the analysis of behavioural 
development in rats using an animal model of emotional behaviour, the forced swim test, 
following casein exposure from the normal age of weaning, PND21 until PND25 and the effect 
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of this on MOPr DOPr and OTr biding using receptor autoradiographic methods. The effect of 
prolonged casein exposure on the host’s microbial composition will be assessed using 
fluorescence in situ hybridization, and NMR-based metabonomic will be implemented to 
investigate the impact on host metabolism. The role of the gut microbiome in mediating any 
casein induced metabolic and behavioural changes will then be assessed via the use of 
antibiotics to knock-down the gut microbiome before administrating casein for 5 extra days 
beyond the standard age of weaning. Finally the hypothesised exposure to BCM-7 in inducing 
behavioural alterations will be tested by exposing animals to milk containing the A1/A2 variant 
of beta casein which produces BCM-7 against milk containing only the A2 variant, which does 
not produce BCM-7.  
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Chapter 2 
Effect of Prolonged Casein Exposure in 
Early Postnatal Life on Behavioural 
Development and the Gut-Brain Axis  
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2.1 Introduction 
 
Several lines of research suggest that manipulations to the age of weaning in a number of 
species results in both behavioural and neurochemical changes (see Table 1.2). These changes 
are believed to be mediated in part by bioactive components derived from milk proteins. Due 
to health benefits associated with breastfeeding (see Table 1.3), exposure to milk rich diets in 
early life have generally seen an increase in recent years, either in the form of longer 
breastfeeding periods or the use of infant formulas to supplement/extend exposure to milk in 
infancy. However prolonged milk consumption has been linked to a number of negative health 
effects such as gastrointestinal dysfunction and neuropsychiatric disorders (see Bell et al., 
2006). Considering milk is the main source of nutrition in early postnatal life, and its prolonged 
consumption has been linked to negative outcomes, the health risks associated with prolonged 
use of milk rich diets in early postnatal life warrants further investigation. 
The opioid system which consists of MOPr, DOPr and KOPr plays a crucial role in the 
regulation of emotional behaviour with all three receptors playing highly distinct roles in 
mediating emotional responses (see Section 1.4.2). The DOPr system is implicated in 
positively modulating mood states, as genetic deletion of DOPr in mouse models was shown 
to result in both anxiety and depressive-like behaviours (Filliol et al., 2000). Furthermore, 
DOPr agonists have been shown to have mood-enhancing properties (Pradhan et al., 2011). 
Similar to DOPr but less documented, acute pharmacological activation of MOPr was found to 
reduce depressive-like behaviour in rodent models (see Lutz and Kieffer, 2013), while other 
studies have shown MOPr KO mice displayed decreased depressive-like behaviours (Filliol et 
al., 2000), suggesting MOPr play a paradoxical role in regulating emotional responses.  
The opioid system has been shown to have marked differential development in both rodents 
and humans (see Section 1.4.3). In rats, the most marked changes occur from the second 
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through to the fourth postnatal week, with 75% of the total DOPr population developing by the 
standard age of weaning in laboratory rats (21 days of age) (McDowell et al., 1986). As the 
development of the opioid system occurs postnatally, early life environmental factors such as 
diet may influence the development of the opioid system. As such, it has previously been shown 
that weaning rat pups on PND 21, the standard age of weaning for laboratory rats (Cramer et 
al., 1990), compared to those remaining with their mother until PND25, acts as a stimulus for 
the activation of a population of DOPrs (Muhammad et al., 1993). Indeed, significantly higher 
levels of DOPr binding were found predominantly in somatosensory cortical brain regions of 
PND21 weaned rats compared to those weaned on PND25 (Kitchen et al,. 1995). Furthermore, 
this weaning induced development of DOPrs can be delayed by continued housing of rat pups 
with their dam, up to PND40  (Goody and Kitchen 2001; Muhammad and Kitchen 1993). 
Goody and Kitchen (2001) then went on to show that the development of the DOPrs is 
dependent on the loss of dietary caseins from milk, which break down to release casomorphins 
exhibiting opioid activity (see Section 1.2.2) rather than any maternal separation factors. 
Collectively, these studies suggest a potential protective effect of weaning on emotional 
behaviour mediated by the opioid system. In line with this, Farshim et al., (2016) have shown 
that 25 day-old rat pups that are maintained in a non-weaned state display a depressive 
phenotype in comparison to pups weaned on PND21 which further supports this hypothesis. 
Given this evidence, this chapter seeks to build on the preliminary findings of Farshim et al., 
(2016) and investigate the role of milk caseins in mediating the depressive-like phenotype 
caused by delayed weaning. Furthermore autoradiographic binding techniques will be used to 
investigate the effect of prolonged casein exposure on the development of both DOP and MOP 
receptors as the opioid system plays a key role in mood modulation.  
Moreover, recent findings have indicated that the central oxytocinergic system, which has also 
been shown to interact with the opioid system (Gigliucci et al., 2014; Georgiou et al., 2015), 
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as another major player which may affect emotional state of mind. The oxytocinergic system 
is widespread throughout the CNS. In rats, OTR are found in several brain regions including 
the olfactory system, cortex, thalamus, hippocampus, and the amygdala, a region which is well-
known to play a key role in emotional responses (Weiskrantz 1956). Oxytocin also exerts a 
wide range of physiological actions, which include stimulation of sexual and reproductive 
behaviour (Carter, 1992), regulation of the HPA axis in response to stress (Viero et al., 2010), 
social behaviour (Bosch et al., 2012) as well as the modulation of a range of neuropsychiatric 
disorders including depression (Gimpl and Fahrenholz 2001; Neumann 2008; Curley et al., 
2009). 
As described in Section 1.4.7, numerous studies have shown that in general increased OT levels 
produce anxiolytic, antidepressant and pro-social effects (see Bosch and Neumann 2012). 
Furthermore Tribollet et al., (1988) have demonstrated that the distribution and number of OT 
binding sites undergo changes during development. In male and female rats two critical time 
windows during the development period have been recognised: the third postnatal week, which 
precedes weaning and after PND35. Thus like the opioid system, the OT system appears to also 
develop differentially which may be susceptible to insult from environmental stimuli during 
development such as weaning time. Farshim et al., (2016) demonstrated that weaning 
influences stress-induced modulation of OTr density in the amygdala.  They showed that at 
PND25, delayed weaning in rat pups affected stress induced modulation of OTr in the 
amygdala which may reflect a deficient stress coping mechanisms in response to delayed 
weaning. It is hypothesised that environmental factors exert their effects on the OT system 
though epigenetic modifications of the OTr (Carter, 1992; Bales et al., 2011).  Given that 
prolonged exposure to milk caseins may be driving the depressive-like behaviour observed in 
delayed weaned rats, this research chapter will aim to investigate the effect of exposure to milk 
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casein beyond the normal age of weaning on OTr development using autoradiographic binding 
techniques.  
Furthermore, a growing body of literature suggests that the gut microbiota plays a crucial role 
in human health and disease (see Section 1.5). In healthy individuals, the normal dominant 
microbiota is relatively stable and forms a mutually beneficial relationship with its host. 
However, it is becoming clear that diet can dramatically alter this delicate synergetic host-
microbiome relationship and result in negative effects to health and development in both 
rodents and humans (Bercik, 2011; Cryan et al., 2012; Foster et al., 2013; Burokas et al., 2015). 
Recent studies have shown that through interactions within the gut-brain axis, the gut 
microbiota is able to influence brain development, function and behaviour (see Bercik 2011). 
Probiotic bacteria such as Lactobacillus and Bififobacterium have been found to confer health 
benefits such as improving mood states (Desbonnet et al., 2010; Messaoudi et al., 2011) whilst 
infection with gastrointestinal pathogens such as Campylobacter jejuni and Escherichia coli, 
during the perinatal period have been associated with anxiety like behaviour and cognitive 
impairments (Bilbo et al., 2005; Goehler et al., 2008) (see Table 1.7).  Such host-microbiome 
interactions have been shown to be bidirectional in nature, with mood states such as anxiety or 
depression also possessing the ability to affect gut microbial composition (see Section 1.5.3).  
The intestinal microbiota is established in early postnatal life in all mammals. This process of 
bacterial colonization occurs in parallel with a sensitive time in CNS development (Sudo et al., 
2004; Tau et al., 2010). Given that early postnatal life represents a critical time for both gut 
microbiome development and neurodevelopment, it is feasible that the gut microbiota may 
somehow affect and contribute to the process of neurodevelopment. Indeed evidence suggests 
that the initial inoculation and subsequent development of the intestinal microbiota in early 
postnatal life is crucial for healthy neurodevelopment (see Borre et al., 2014). One of the key 
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factors modulating the composition of the developing microbiome is diet, with mode of feeding 
during infancy playing a key role in shaping the infant microbiome (Mackie et al., 1999). 
Human milk is a source of prebiotics and lactic acid bacteria, therefore breastfed infants show 
high levels of Bifidobacterium spp. In contrast, the gut microbiota of formula-fed infants has 
an increased diversity and a high abundance of coliforms, Bacteroides and Clostridium 
(Praveen et al., 2015).   
Moreover, It is also well acknowledged that the process of weaning causes a significant shift 
in gut microbial populations in both humans and other mammals (Hentges 1983; Favier, de 
Vos, and Akkermans 2003; Palmer et al. 2007; Desclee de Maredsous et al. 2016; Mackie et 
al.,  1999). Thus weaning represents a critical and potentially hazardous control point in the 
appropriate development of the gut microflora, which can influence both the developing CNS 
(see Collins and Bercik 2009) and immune system (see Round and Mazmanian 2009).  
A number of studies have been carried out to assess the impact of varying weaning ages on gut 
microbial profiles. For example Franklin et al., (2002), have shown that pigs weaned at 24 days 
of age had significantly higher levels of E.coli populations 3 days post weaning compared to 
piglets weaned at 17 days of age. Furthermore, piglets weaned at 24 days of age had higher 
lactobacillus populations compared to piglets weaned at 17 days of age. Another study by 
Meale et al., (2017) showed that weaning age in calves influences the severity of microbial 
shift caused by switching from a milk based diet to solid food. Calves which were weaned at 6 
weeks old showed a sever shift in gut microbial populations, whereas calves weaned at 8 weeks 
of age showed a more gradual shift in microbial diversity (Meale et al., 2017) 
Other studies have gone on to explore the effect of varying post-weaning diets on microbial 
colonization. For example Merrifield et al., (2013) compared two different protein sources 
(soya and egg) after weaning piglets at 3 weeks of age. It was found that the two different 
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weaning diets caused a shift in urinary metabolic products. Furthermore, even after cessation 
of the original weaning diet, the shifts in urinary metabolic profiles were sustained (Merrifield 
et al., 2013). Similarly, Rist et al., (2014) investigated the effects of soybean vs. casein protein 
sources on intestinal microbiota post-weaning. They showed that piglets fed a casein based diet 
post weaning had significantly higher levels of Enterobacteriaceae and some Clostridium 
species compared to piglets fed soybean protein (Rist et al., 2014). In addition, it has been 
demonstrated in piglets that a decrease in dietary protein intake post weaning results in higher 
levels of Lactobacilli which reflect a healthy gut microbial equilibrium (Wellock et al., 2006). 
Collectively these studies suggest that manipulations to dietary factors around the age of 
weaning can have a significant impact on both the composition and metabolic activity of the 
gut microbiota.  
Given the prolonged exposure of infants in today’s society to milk rich diets, this research 
chapter will investigate the effect of prolonged exposure to milk caseins beyond the normal 
age of weaning on the gut microbiota.  Bacterial populations will be assessed with the use of 
16S rRNA oligonucleotides probes using fluorescence in situ hybridization targeting 
Lactobacilus-Enterococcus, Bifidobacterium spp, and the Clostridium histolyticum bacterial 
groups. 
As discussed in Section 1.5.5, the gut microbiome has been shown to be a metabolically active 
organ with a diverse repertoire of metabolic capabilities (See review by Tremaroli and Bäckhed 
(2012). Gut microbes are capable of producing a vast range of products, which contribute to 
host health and disease (for a detailed review on gut microbial products see Nicholson et al., 
2012). The generation of these microbial products can depend on many factors including diet, 
which has been shown to have a direct influence on host metabolic profiles and hence to disease 
risk (Walsh et al., 2006; Wikoff et al., 2009). 
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As discussed in Section 1.5.3 and 1.5.4 an area of rapidly growing interest has been the ability 
of both host and microbial metabolites to influence brain development and subsequent 
behaviour via the gut-brain axis. Currently exact pathways of how alterations in gut microbiota 
could affect behaviour remain to be fully elucidated. However evidence has shown that  one of 
the ways the gut microbiota can directly communicate with the brain is via the production of 
neuroactive metabolites (Lyte, 2011; Nicholson et al., 2012; Hsiao et al., 2013).   
For example, Hsiao et al., (2013) have provided strong evidence to suggest gut microbes 
regulate metabolites that can alter behaviour in animals. In this study Bacteroides fragilis 
(B.fraglis) was shown to correct gut permeability caused by maternal immune activation which 
then leads to an altered microbial composition and ameliorates defects in anxiety-like, social, 
stereotypic and sensorimotor behaviours in the offspring. Furthermore, these authors showed 
that the offspring display altered serum metabolic profiles and that B.fraglis was able to 
modulate levels of several of these metabolites. Another study showed that rats which were fed 
a diet rich in fermentable carbohydrates revealed a strong correlation between D-lactic acid 
abundance in the caecum and displaying anxiety like-behaviour and impaired memory 
(Hanstock et al., 2010). Moreover, bacterial colonization of germ-free mice with Clostridium 
sporogenes was found to result in a ≥ 2-fold increase in serotonin and its metabolites (owing 
to bacterial metabolism of tryptophan), which in turn influences the brain and behaviour 
(Wikoff et al., 2009). Human studies also suggest a link between microbial fermentation 
products and behaviour. For example high faecal concentrations of propionic acid correlate 
with anxiety in patients with IBS (Tana et al., 2010). In addition, carbohydrate malabsorption 
which results in increased substrate availability for bacterial fermentation has been associated 
with depression in females (Ledochowski et al., 2000). 
As mentioned in Section 1.6, metabonomics has emerged as a powerful and useful tool which 
allows for the characterization of host metabolic profiles in response to external influences 
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such as diet. Metabonomic studies are conducted using high resolution analytical techniques 
such as 1 H Nuclear Magnetic Resonance (NMR) spectroscopy, combined with multivariate 
data analysis. This present chapter will aim to utilise these metabonomic techniques to study 
urinary metabotypes in order to illuminate the metabolic impact of environmental factors, 
namely the diet (milk exposure beyond the normal age of weaning) and the gut microbiota on 
the host.  
Results from this study will provide and important insight into the neuropsychiatric effect of 
prolonged exposure to milk caseins during the critical postnatal developmental period as well 
as the potential mechanism driving this effect.  
Hypothesis:  
 Rats exposed to casein rich milk beyond the normal age of weaning will exhibit 
‘depressive-like’ behaviour due to dysregulation in the development of MOPr, DOPr 
and the oxytocinergic system. Furthermore, variation in the community structure of the 
gut microbiome, specifically an increase in the abundance of enteropathogenic bacteria, 
due to prolonged casein exposure will contribute to this phenotype potentially via gut-
microbial derived metabolites. 
Aims:  
 To investigate the effect of exposing rat pups to milk caseins from PND21 (the standard 
age of weaning) till PND25 on the development of ‘depressive-like’ behaviour, MOP, 
DOP and OT receptor systems, gut microbial profile and host metabolic phenotype.   
 
 
 107 
Objectives:  
 To use casein free or casein rich milk treated rat models in order to investigate the role 
of milk caseins beyond the normal age of weaning on depressive-like behaviour. 
Depression will be assessed using the Forced Swim Test.  
 FISH analysis will be utilized to measure any changes to the gut microbiome induced 
by milk diets.  
 NMR based metabolomics techniques will be used to characterize metabolic changes 
associated with prolonged casein exposure in urine. 
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2.2 Methodology 
 
2.2.1 Animals and Experimental Conditions 
 
Male, Wistar albino rats were purchased from Charles River UK Limited, Kent.  Three groups 
of animals each containing eight male pups plus their cross-fostered mother arrived at the 
Experimental Animal Unit (EBU) at the University of Surrey on PND7, where day of birth is 
PND0. These animals were maintained in litters of 8 pups with their mothers at all times. Pups 
were left to acclimatise to their new environment for 7 days (up until PND14), after which 
point they were handled and weighed daily by the experimenter. The standard day of weaning 
in laboratory rats is on PND21, a process where the mother is simply removed from the cage 
(Cramer et al., 1990).  All groups were weaned on PND21. The animals were placed in a 12 
hour light-dark cycle (lights on 6AM - 6PM) with free access to a standard rat chow diet 
(purchased from B & K Universal Ltd.) and tap water and kept at a constant temperature of 
22°C ± 1 °C, humidity of 45-55%.. All experimental procedures were conducted in accordance 
with the U.K Animal Scientific Procedures Act (1986).  
2.2.2    Casein Free and Casein Rich Milk Diets 
 
Three experimental groups were generated, with each group containing 8 pups caged together. 
Group one were weaned by having their mothers removed at 10.00am on PND21. This group 
acted as the control and were provided with free access to rat chow and water until the 
completion of behavioural testing on PND26. Group two were weaned on PND21 and provided 
with casein free milk formula as well as having free access to standard rat chow and water from 
PND21 through till PND26. Group three were weaned on PND21 and provided with casein 
rich milk formula as well as free access to standard rat chow and water from PND21 through 
till PND26.  
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The groups provided with either casein free or casein rich milk formulas, had milk freshly made 
up twice a day, once between 9:00-10:00 AM and then again between 5-6 PM. Casein rich milk 
formula, (Welpi: Petlife International Ltd, Bury St. Edmunds UK) was made up as 1 part 
formula to 2 parts boiling water. When cooled to approx. 40°C, the milk was poured into bottles 
with ball bearing nozzles and placed in the appropriate cages to be consumed ad libitum. The 
casein free milk formula (Special Diet Services, Cambridge UK) was custom manufactured to 
provide the closest dietary match of the casein rich milk formula, however casein protein was 
removed and replaced with overall 20% w/w soya protein (approximating to the level of casein 
contained in the casein rich milk formula) (see Table 2.1). The casein free milk formula was 
also made up as 1 part formula to 2 parts hot water then cooled before provision to pups. 
 
Casein Rich Milk formula  
Parameter  analysed  Units  Results Fresh Weight 
Moisture % 3.37 
Crude Fat % 18.9 
Crude Protein % 26.5 
Crude Fibre % 0.9 
Ash raw % 6.2 
NFE (Nitrogen Free extract)  % 44.13 
Ingredients  
 
Spray dried skimmed Milk, vegetable oils 
and fats mix, spray dried milk albumin, 
spray dried whey products  
Casein Free Milk Formula  
Parameter  analysed  Units  Results Fresh Weight 
Moisture % 5.64 
Crude Fat % 18.9 
Crude Protein % 26.6 
Crude Fibre % 1.3 
Ash raw % 8.78 
NFE  % 38.01 
Ingredients  
 
Whey powder, soya protein concentrate, 
maze oil, soya oil, vitamin and mineral 
mix 
Table 2.1: Formulations of casein rich and casein free milk diets. 
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2.2.3 Body Weights and Milk Consumption 
 
Animals belonging to all three treatment groups were weighed daily from PND14 until the day 
of sacrifice on PND27. Milk consumption was also recorded on a daily basis from PND21 until 
PND26.  
2.2.4 Behavioural tests 
 
2.2.4.1 Forced Swim Test  
 
Behavioural testing was performed between 10am and 2pm when animals reached PND25. The 
FST was used to assess depressive-like behaviours and was carried out as originally described 
by Porsolt (Porsolt et al., 1977). On the day of behavioural testing the rats were allowed to 
acclimatise to the testing laboratory for one hour prior to the start of experiments. The 
experimental laboratory was window-less, air controlled and was kept under the same 
conditions as the home-cage room. The testing room was maintained at a minimal noise level. 
The rats tested on PND25 were placed in a 5-litre glass beaker (Fisher Scientific, UK) with the 
dimensions of 170 mm diameter and 270 mm height. The beakers were filled to a depth of 165 
mm with tap water (23°C ± 1°C). This depth was chosen as at this level the rats were unable to 
escape with their hind limbs or tails unable to reach the bottom of the beakers.  Four beakers 
were set up for each trail and the beakers were separated using white sheets of paper to prevent 
visual contact between the test subjects (see Figure 2.1). A black cloth was placed behind the 
four beakers to assure a high contrast between the dark background and white rats. The 
apparatus was kept clean by changing the water following each set of tests and cleaned with 
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odour-free detergent then dried. This process was carried out in a separate room to minimise 
noise disturbance to other animals. 
The forced swim test is run over two consecutive days. One the first day (PND 25 the rats were 
exposed to a ‘pre-test’ swimming session lasting 15 minutes followed 24 hours later by a ‘test’ 
session lasting 6 minutes. During the first day, the swim session consisted of 15 minutes, when 
the rats would have experienced “helplessness or behavioural despair” in the beakers. On the 
second day, consisting of 6 minutes, following an initial period of struggling, the rats exhibited 
a floating movement pattern (known as ‘immobility’). The immobility time is believed to 
demonstrate “learned helplessness” or depressive-like behaviour. Antidepressants reduce the 
duration of immobility (or floating time) and the latency to the first period of immobility are 
both key predictors of antidepressant activity. 
Both the test and pre-test sessions were conducted under low illumination levels adjusted from 
normal lighting (~350 lux) to a dimmer setting of ~40 lux. This level of lighting was selected 
as light has been shown to be an important factor influencing behaviour in the FST. It has been 
shown that standard illumination caused hyperlocomotion in the FST (Bogdanova et al., 2013), 
therefor dim lighting is used as rats prefer a dimmer environment, thereby eliminating a factor 
which could induce extra stress and influence behaviour. Following either pre-test or test 
sessions, rats were dried with towels and placed in a warm (30°C ± 2°C), fanned recovery 
chamber for 15 minutes or until adequately dried before being returned to their home cages. At 
the end of all 6-minute swim sessions, the rats were individually housed in metabolic cages to 
allow for the collection of faecal and urine samples for metabolic analysis (see Section 2.2.6).  
Both pre-test and test swim sessions were recorded using a Sony Handycam HDR-CX250. The 
real time video recordings of each session were used for behavioural analysis. The total 
immobility time, latency to the first immobility, total time spent swimming and total time spent 
 112 
climbing were quantified from the recordings. The minimal duration of an episode of 
immobility was set at 2 seconds. A rat was judged immobile when it stopped all active attempts 
to escape from the beaker such as struggling, swimming, climbing, diving and remained a float, 
making only the movements necessary to keep its head above the water. Swimming was 
recorded when smooth movements were made around the beaker with all four paws immersed 
in the water. Climbing was scored when strong up-ward movements with the four paws were 
made whereby the water surface was vigorously broken. These behaviours from the ‘test’ day 
on PND26 were scored by one independent observer who was blind to the identity of animals.  
The FST was chosen as the most appropriate model to assess for depressive like behaviour in 
this study for a number of reasons. Firstly, it is the most commonly used test for depression as 
it involves the exposure of animals to stress, which was shown to have a role in the tendency 
for major depression (Anderson, 2006). It has also been shown to share some of the factors that 
are altered by depression in humans, including changes in food consumption and sleep 
abnormalities (Yankelevitch-Yahav et al., 2015), making it a reliable model to use. Moreover, 
it is easy to perform and the results are easily analysed making it a favourable model to use for 
the current study. Secondly, the FST provides a ‘read out’ of depressive-like behaviour, i.e. it 
does not induce depression unlike some of the other models available such as social defeat, but 
instead provides a way of assessing already existing depressive-like behaviour which is what 
is required in this current study. Finally, the FST is run over two days which is a relatively 
short time window in comparison to other depression models. As the current study is looking 
at the effect of casein exposure over only 5 days, the behavioural test selected needed to be one 
which could be performed in the space of this limited time frame. The sucrose preference test 
is another depression model which is reliable, relatively simple and quick to perform, however 
this model was not selected for this study as it involves the consumption of sucrose which 
would have been a confounding nutritional factor. 
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2.2.5     Data Analysis 
 
Body weight differences between control, casein free and casein rich treated animals were 
analysed using a one-way ANOVA .The behavioural data for the FST were also analysed 
using a one-way ANOVA. Where ANOVA revealed a significant difference an LSD post-hoc 
analysis was carried out. All data were expressed as means ± SEM, n = 8 per group. A p 
value of less than 0.05 was accepted as significantly different. All statistical analyses were 
performed on GraphPad Prism 7. 
Postnatal Day
7 14 21 25 26 27
Appropriate 
groups 
provided with 
no milk, casein 
free or casein 
rich milk
Mothers 
removed from 
all groups
Forced 
Swim Test 
Animals go 
into metabolic 
cages for 24 
hours 
Animals 
sacrificed, 
samples 
collected 
Animals 
weighed daily 
Animals 
arrive in EBU
Figure 2.1: Experimental timeline showing key points in the casein free vs. casein rich study. 
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2.2.6    Metabolomics 
 
Following the completion of behavioural testing on PND25 and PND26, animals were placed 
into individual metabolic cages for 24 hours. On PND27 urine was collected from the cages 
using plastic pipettes into 2ml Eppendorf tubes and stored in -80°C for metabolic analysis. 
2.2.6.1 Sample Preparation  
 
2.2.6.1.1     Urine 1H NMR Protocol  
 
The urine samples were defrosted from -80°C and vortex mixed. The samples were prepared 
by mixing 400 µl of urine with 200 µl of phosphate buffer (pH 7.4) containing 10% D2O and 
1 mM 3-trimethylsilyl-1 [2,2,3,3-2H4] propionate (TSP). Eppendorfs were centrifuged at 
13,000 rpm at 4°C for 10 minutes and 550 µl of the resulting supernatant was transferred to a 
5 mm internal diameter Norell® NMR tubes and stored at 4°C until 1H NMR spectroscopy. 
2.2.6.2         Data Acquisition  
 
For each sample the 1H NMR spectra were acquired as described by Beckonert et al., (2007) 
using a Bruker Avance 700 MHz spectrometer (Bruker Biospin, Rheinstetten, Germany) with 
a 14 T magnet, equipped with a 5 mm cryogenically cooled inverse probe. Standard one-
dimensional (1D) NMR spectroscopy has been used throughout this experiment and consisted 
mainly of two steps, pulse and acquire. Briefly, one radiofrequency pulse generates a response, 
the free induction decay (FID), which can then be acquired. This sequence can be repeated 
numerous times to allow improvement of signal to noise ratio, thus reducing background noise. 
Between consecutive pulses a delay time was used to allow complete relaxation to occur. For 
each urine sample a standard 1D-Nuclear Overhauser Effect Spectroscopy (NOESY)-presat 
pulse sequence (recycle delay (RD)-90°-t1-90°-Tm-90°-acquire-FID) was used with water 
suppression. Spectra were acquired after 8 dummy scans followed by 128 scans and collected 
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into 64K data points using a spectral width of 12 ppm (parts per million). This involved an 
acquisition time per scan of 3.79 seconds and a mixing time (tm) of 100 milliseconds.  
2.2.6.3      Data Processing  
 
The spectra were processed in TOPSPIN 3.0 (Bruker Biospin, Rheinstetten, Germany). 
Following Fourier transformation, the spectra were manually phased, baseline-corrected and 
calibrated to the TSP resonance at 0 ppm (δ 0.00). Spectra were then digitised using MATLAB 
(Version R2012a, MathWorks Inc; Natwick, MA) scripts provided by Korrigan Sciences. In 
order to carry out pattern recognition, the data were digitised into a data matrix, consisting of 
n observations (samples) and k variables (chemical shifts or metabolites). Peak alignment was 
applied to adjust peak shifts due to pH differences.  
The spectral regions that possessed no real diagnostic information or disrupted other spectral 
data were removed. The region 4.5-6.0 ppm was removed as this included the resonances of 
water and urea. Once the unrequired spectral regions were removed, each observation was 
normalised. Urine samples were normalised using the probalistic quotient method  (Dieterle et 
al., 2006). Normalisation is a mathematical correction method that is applied to the 
experimental data to adjust variation (bias) that could potentially influence the data and hence 
allows the data to more realistically reflect biological differences occurring within the data. 
2.2.6.4        Multivariate data analysis  
 
All multivariate analyses were performed using the MATLAB scripts provided by Korrigan 
Sciences and using SIMCA-P+ 11 (Umetrics AB, Umeå Sweden) software. All figures were 
generated using Adobe Illustrator CS5 (Adobe systems, Ireland). Metabolic data obtained from 
1H NMR spectroscopy typically contain thousands of variables from each sample that are 
highly correlated. The multi-dimensional nature of the data generated is difficult to visualise 
and understand and thus requires statistical techniques that can be used to extract the necessary 
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information. Here, chemometrics methods were used due to their ability to decompose complex 
multivariate data into simpler and potentially interpretable structures (Wold et al., 1984). 
Depending on the aim of the study under analysis supervised or unsupervised methods can be 
applied and can assist in obtaining an overview of the data, in variable selection and in-group 
classification. The chemometric methods applied in this Chapter are described below. 
2.2.6.5   Principal Component Analysis  
 
The unsupervised multivariate technique used here was Principal Component Analysis (PCA), 
as described by  (Wold et al., 1984). PCA can be described as a method that reveals the internal 
structure of a data set in a way that best explains the variance in the data. PCA offers a reduced 
dimensional model that summarises the major variation in the data into a few axes, and in this 
way, systemic variation is captured in a model that can be used to visualise which samples in 
the data are similar or different from each other. 
From this, it will be possible to determine if the treatment related variation has been detected 
by the given PCA model with possible spectral loadings that then depict any `treatment' related 
separation along the respective principal component(s). 
In the present study, PCA was used as an initial explorative method to investigate to which 
extent different treatments (casein free vs. casein rich milk) could be discriminated by the 
urinary metabolite profiles. The most variance in the data is explained by the first principal 
component (PC) and each PC thereafter explains less of the total variance existing in the data 
than the previous component(s).  
The PCA model provides a scores matrix that summarises the original variables and discovers 
the direction of the data swarm that illustrates the maximum degree of variation (PC1) and 
exposes information regarding relationships between the objects (e.g. groupings). Principal 
component loadings plots provide information on which variable(s) contribute to the patterns 
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observed in the scores plots for a given component. When the PCA is applied to digitised NMR 
spectra, the loadings correspond to spectral frequencies with each shift relating to specific 
metabolites. From this point on changes in metabolites could be further observed and their 
interaction with other metabolites assessed and this forms the basis of metabonomics. 
The total amount of variance explained by the model is given by R2 and is a quantitative 
measure of the goodness of fit that shows the degree of variation within the data set that can be 
explained by the model. The R2 values have been expressed on each PCA scores plot as the 
sum of the percentages of variance explained by each PC. 
2.2.6.6       Orthogonal Projection to Latent Structures-Disciminant Analysis 
 
The supervised method used in this study was Orthogonal Projection to Latent Structures-
Discriminant Analysis (OPLS-DA) as described by Trygg & Wold (2002). This method is an 
extension of the widely used supervised method, Partial Least Squares-DA (PLS-DA) (Haque 
et al., 2009).  PLS regression is a robust and powerful algorithm that is used to relate a data 
matrix containing independent variables from samples, such as spectral values (X matrix), to a 
matrix containing dependent variables (e.g. treatments or responses) for those samples (Y 
matrix) and thus find the relationship between the two matrices. Whilst PCA models the major 
variation in the data itself, PLS derives a model that describes the correlation between X 
variables and then a feature (Y variable) of interest. For this analysis a `class' vector is 
constructed, with one variable of each class having a value of 1, if the sample belongs to a 
particular class and 0 if not. By regression against this class vector, latent variables can be 
derived which enable separation of classes from one another. In order to avoid over fitting and 
ensure model reliability, cross validation methods were used. 
In the present study, a PCA model was built using MATLAB. Where clear variability (i.e. 
separation) was found between treatment groups, an OPLSDA model was constructed to 
 118 
further define metabolic variation between the groups. The contribution of each variable 
(metabolite) to the model was visualised by generating correlation coefficient plots. These are 
colour-coded according to the significance of correlation (r2) to the \class" (e.g. casein free or 
casein rich). Red indicates a highly significant metabolite whilst blue indicates low 
significance. The direction of the peaks relate to the covariance of the variable multiplied by 
its standard deviation (back-scaling). This generates a plot that closely resembles a 1H NMR 
spectrum to aid model interpretation. The predictive performance (Q2Y) of each model was 
also obtained using a 7-fold cross validation approach. This indicates how well data in the X 
matrix (metabolites) can predict information in the Y matrix (e.g. whether the animal received 
casein-rich or casein-free milk). The validity of these models (based on their Q2Y values) was 
confirmed using permutation testing (10,000 permutations).  
 
2.2.6.7       Metabolite Identification  
 
There are two methods available for the identification of metabolites, targeted or explorative.  
Which method is used depends largely on the scope of the study.  The explorative metabolite 
identification method was used in this study and resulted in the identification of metabolites 
that related to the effect of diet. Metabolites were assigned according to their peak shifts and 
multiplicity using Chenomx NMR Suite software version 7.5 (Chenomx Inc. Edmonton, 
Canada) and via existing databases such as the Biological Magnetic Resonance Data Bank 
(BMRB: http://www.bmrb.wisc.edu), and the Human Metabolome Database (HMDB) 
Metabolomics Toolbox (http://www.hmdb.ca) as well as comparison with chemical shifts 
provided in existing data in the literature.  
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 2.2.6.8        Biological Interpretation  
 
After metabolites have been identified, a relevant biological interpretation should be drawn 
related to the study. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
database (http://www.genome.jp/kegg/pathway) is an example of a freely available online 
database that provides information about numerous pathways and the metabolites that interact 
in corresponding pathways. Furthermore, the HMDB provides metabolite information in the 
‘MetaboCard’ and contains clinical, biochemical and chemical data. In addition to the use of 
such online databases, the literature was searched to put the identified metabolites into 
biological context.  
2.2.7      Tissue Dissection 
 
Following on from the metabolic caged on PND27, animals were then killed by cervical 
dislocation on PND27 after acute exposure to CO2. Approximately 2ml of trunk blood was 
collected into plastic lithium-heparin coated anticoagulant tubes. The samples were then 
shaken by inversing and placed on ice during the collection procedure. All samples were 
centrifuged using a Beckman Coulter Allegra X-15R centrifuge at 1600 g for 30 minutes for 
collection of plasma (Beckonert et al. 2007). The supernatant was then transferred into 2 ml 
Eppendorf tubes, labelled and secured using Parafilm and stored at -80°C until use in future 
metabonomics studies. 
Intact brains were dissected and rapidly frozen in isopentane at -20°C for 30 seconds and then 
stored at -80°C for quantitative receptor autoradiographic experiments (see Section 2.2.8). The 
carcasses were transferred into a fume hood and six regions of the intestine (stomach, 
duodenum, jejunum,ileum, ceacum and colon) were dissected. Contents from these regions 
were weighed (30-200 mg) into sterile 2 ml Eppendorf tubes and kept over ice and then stored 
in -80°C for use with fluorescence in situ hybridization experiments (see Section 2.2.9).  
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2.2.8       Quantitative Receptor Autoradiography  
 
2.2.8.1 Brain collection 
 
Rat pups were killed by decapitation, intact brains removed as described in Section 2.2.7, and 
brain sections prepared as detailed below. 
2.2.8.2 Tissue Sectioning  
 
2.2.8.2.1 Cleaning and Gelatin-Coating of Microscope Slides 
 
Microscope slides (74 mm x 26 mm) (Marieneld, Germany) were loaded onto metal slide 
holder racks in a washing tray and soaked in Decon detergent and warm water solution 
overnight. The following day, all slides were rinsed under hot running water for 15 minutes 
followed by a further rinse with cold distilled water. A 90:10, ethanol:hydrochloric solution 
(v/v), was used to soak slides for 15-20 minutes before rinsing in distilled water for 15 minutes. 
Slides were then coated by immersing into a 1% w/v gelatin/chrom-alum solution for 2 minutes 
and left to dry in a dust-free environment before use. 
2.2.8.2.2 Sectioning of Brain Tissue  
 
Brains were removed from a -80°C freezer and placed into a cryostat apparatus (Zeiss Microm 
505E, Hertfordshire, UK) set at -21°C and coronally aligned by fixing the cerebellum onto a 
mounting stage using plastic embedding solution (O.C.T compound, BDH Chemicals, Dorset, 
UK). Adjacent 20 μm thickness coronal sections were cut at 400 μm intervals and thaw-
mounted onto gelatine-coated ice-cold microscope slides to define receptor binding levels from 
fore- to hind-brain regions. Brain slides were stored at -20°C in airtight containers containing 
a layer of anhydrous calcium sulphate (Dreirite-BDH Chemicals, Dorset, U.K.) for a minimum 
of 1 week before use. 
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2.2.8.3 Autoradiographic binding of Oxytocin Receptors  
 
Quantitative OTr autoradiography was performed on brain sections from control, casein free 
and casein rich treated animals tested for depression using the FST on PND 25 and PND26. 
Sections were rinsed twice for 10 minutes in a pre-incubation buffer solution (50 mM Tris-HCl 
pH 7.4) at room temperature to remove endogenous OT. Total binding was determined by 
incubating the sections with 50 pM [125I]-Ornithine vasotocin analog 
[d(CH2)5[Tyr(Me)
2,Thr4,Orn8,[125I]Tyr9-NH2]-vasotocin] ([
125I]-OVTA) (Perkin Elmer, 
Boston, MA) in an incubation buffer medium (50 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 
0.1% w/v bovine serum albumin, 0.05% w/v bacitracin; Sigma-Aldrich, Poole, UK, pH 7.4 at 
room temperature). Adjacent sections were incubated with [125I]- OVTA (50 pM) for 60 
minutes in the presence of 50 μm of OT ligand, (Thr4, Gly7)-oxytocin (Bachem, Germany), to 
determine non-specific binding (NSB). Following the radioligand binding period, slides were 
rinsed 3 times for 5 minutes in ice-cold rinse buffer solution (50 mM Tris-HCl, 10 mM MgCl2, 
pH 7.4) followed by a 30 minute wash in the ice-cold rinse buffer, and a subsequent 2 second 
wash in ice-cold distilled water. Slides were then dried under a stream of cool air for 2 hours 
and stored in sealed containers with anhydrous calcium sulphate (Drierite) for 2 days. 
2.2.8.3.1 Film Apposition  
 
Slides were mounted onto card and secured into place using tape. Sections were apposed to 
Kodak MR-1 films (Sigma-Aldrich, U.K.) in Hypercassettes with autoradiographic [14C] 
microscales of known radioactive concentration (GE Healthcare Life Sciences, Amersham, 
U.K.) for 3 days. Sections for all treatment groups were processed in parallel and apposed to 
the same film at the same time to avoid inter-experimental variation. 
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2.2.8.3.2 Film development  
 
Film development was conducted in a dark room using red-filter light. The films were 
developed by immersing them individually one at a time into a tray containing 50% Kodak 
D19 developer (Sigma-Aldrich, Poole, UK) for 3 minutes. The films were then immersed in a 
second tray containing distilled water and three drops of glacial acetic acid solution for 30 
seconds to stop the development reaction. This was followed by a 5-minute fixation step by 
immersing the films into a third tray containing Kodak rapid fix solution (Sigma-Aldrich, 
Poole, UK). Finally, the films were rinsed under cold running water for 20 minutes and left to 
dry on hanging clips in a fume hood. 
2.2.8.3.3    Image Analysis of Autoradiograms  
 
Quantitative analysis of autoradiographic films were carried out using video-based, 
computerised densitometry using an MCID image analyser (Imaging Research, Canada) as 
previously described by Kitchen and co-workers (Kitchen et al. 1997). Optical density values 
were quantified from the [14C]-microscale standards of known radioactive concentration and 
cross- calibrated with [125I] (GE Healthcare, UK) and were entered into a calibration table on 
MCID. The relationship between radioactivity and optical density was determined using the 
MCID system. Specific binding was calculated by subtraction of NSB from total binding and 
expressed as fmol/mg tissue equivalents. The analyses of brain structures were carried out by 
reference to the rat brain atlas of Paxinos and Watson (Paxinos & Watson, 2006). Measures 
were taken from both the right and left hemispheres for most structures, thus representing a 
duplicate determination for each region. Central brain regions such as the hypothalamus and 
thalamus were singularly taken using the free-hand drawing tool to outline the structures. The 
following structures were analysed by sampling 5-8 times with a box-sampling tool (box size 
in pixels shown in parantheses): cortex (8 × 8 mm), olfactory tubercle (6 × 6 mm) and 
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hippocampus regions (5 × 5 mm). For each film analysed, regions were always quantified at 
the same level of the brain by reference to Bregma co-ordinates given in the Paxinos and 
Watson rat brain atlas and as shown in Table 2.2. 
2.2.8.4            Autoradiographic binding of Delta Opioid Receptors 
 
Quantitative DOPr autoradiography was performed on brain sections from control, casein free 
and casein rich treated animals tested for depression using the FST on PND25 and PND26. 
Sections were rinsed twice for 20 minutes in a pre-incubation buffer solution (50 mM Tris-HCl 
pH 7.4) at room temperature to remove endogenous opioids. Total binding was determined by 
incubating the sections with [3H] deltorphin -1 (7nM) in an incubation buffer medium (50 mM 
Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1% w/v bovine serum albumin, 0.05% w/v 
bacitracin; Sigma-Aldrich, Poole, UK, pH 7.4 at room temperature) for 60 minutes. Adjacent 
sections were incubated with 1µM naloxone for 60 minutes to determine non-specific binding 
(NSB). Following the radioligand binding period, slides were rinsed 3 times for 5 minutes in 
ice-cold rinse buffer solution (50 mM Tris-HCl, 10 mM MgCl2, pH 7.4) followed by a 30 
minute wash in the ice-cold rinse buffer, and a subsequent 2 second wash in ice-cold distilled 
water. Slides were then dried under a stream of cool air for 2 hours and stored in sealed 
containers with anhydrous calcium sulphate (Drierite) for 2 days. 
2.2.8.4.1      Film Apposition  
 
Slides were mounted onto card and secured into place using tape. Sections were apposed to 
Kodak MR-1 films (Sigma-Aldrich, U.K.) in Hypercassettes with autoradiographic [3H] 
microscales of known radioactive concentration (GE Healthcare Life Sciences, Amersham, 
U.K.) for 10 weeks. Sections for all treatment groups were processed in parallel and apposed 
to the same film at the same time to avoid inter-experimental variation. 
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2.2.8.4.2       Film development 
 
As described in Section 2.2.8.3.2 
 
2.2.8.4.3        Image Analysis of Autoradiograms  
 
As described in Section 2.2.8.3.3 but using [3H] microscale instead of [14C]. Regions analysed 
for the Delta opioid binding are shown in Table 2.2.  
2.2.8.5         Autoradiographic binding of Mu Opioid Receptors  
 
Quantitative MOPr autoradiography was performed on brain sections from control, casein free 
and casein rich treated animals tested for depression using the FST on PND25 and PND26. 
Sections were rinsed twice for 20 minutes in a pre-incubation buffer solution (50 mM Tris-HCl 
pH 7.4) at room temperature to remove endogenous opioids. Total binding was determined by 
incubating the sections with [3H] DAMGO (4nM)  in an incubation buffer medium (50 mM 
Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1% w/v bovine serum albumin, 0.05% w/v 
bacitracin; Sigma-Aldrich, Poole, UK, pH 7.4 at room temperature) for 60 minutes. Adjacent 
sections were incubated with 1µM naloxone for 60 minutes to determine non-specific binding 
(NSB). Following the radioligand binding period, slides were rinsed 3 times for 5 minutes in 
ice-cold rinse buffer solution (50 mM Tris-HCl, 10 mM MgCl2, pH 7.4) followed by a 30 
minute wash in the ice-cold rinse buffer, and a subsequent 2 second wash in ice-cold distilled 
water. Slides were then dried under a stream of cool air for 2 hours and stored in sealed 
containers with anhydrous calcium sulphate (Drierite) for 2 days. 
2.2.8.5.1      Film Apposition  
 
As described in Section 2.2.8.4.1 
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2.2.8.5.2       Film development 
 
As described in Section 2.2.8.3.2 
 
2.2.8.5.3        Image Analysis of Autoradiograms  
 
As described in Section 2.2.8.3.3 but using [3H] microscale instead of [14C]. Regions analysed 
for the Delta opioid binding are shown in Table 2.2. 
2.2.8.6       Data Analysis for Quantitative Receptor Autoradiography  
 
The mean (and standard error of the mean, SEM), n=8 per group specific radioligand binding 
was determined for all brain structures analysed from each treatment group for OTR DOPr and 
MOPr. Comparisons of OTR, DOPr and MOPr binding levels were made using a one-way 
ANOVA on individual brain regions followed by LSD post-hoc analysis where applicable.  A 
p value of less than 0.05 was accepted as statistically significant. All statistical analyses were 
performed using GraphPad Prism 7. All the values were expressed as mean ± SEM.
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 [125I]-OVTA receptor 
                                           Brain Region                                                                                                                         Bregma Coordinate (mm) 
 
 
 
 
 
 
[3H] Deltorphin -1 
 
 
 
 
 
 
 
Olfactory bulb - external and lateral, dorsal, medial, ventral 
Cingulate cortex 
Nucleus accumbens shell and core 
Olfactory tubercle 
Piriform cortex 
Medial septum 
Vertical limb of the diagonal band of Broca 
Lateral septum 
Hippocampus 
Thalamus 
Hypothalamus 
Amygdaloid nuclei {central, basolateral and basomedial} 
 
4.20 
0.7 
0.7 
0.7 
0.7 
0.7 
0.7 
0.7 
0.20 
-4.80 
-4.80 
-4.80 
 
 
Olfactory bulb - external and lateral, dorsal, medial, ventral 
Caudate putamen 
Cingulate cortex 
Nucleus accumbens shell and core 
Olfactory tubercle 
Motor Cortex (Deep, superficial layers) 
Somatosensory cortex (Deep, superficial layers) 
Piriform cortex 
Motor Cortex (Deep, superficial layers) 
Somatosensory cortex (Deep, superficial layers) 
Hippocampus 
Thalamus 
Hypothalamus 
Amygdaloid nuclei { central, basolateral and basomedial} 
 
4.20 
1.20 
1.20 
1.20 
1.20 
1.20 
1.20 
1.20 
2.30 
2.30 
2.30 
2.30 
2.30 
2.30                                     
2.30 
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[3H] DAMGO 
 
 
 
 
 
 
 
 
 
 
4.20 
1.20 
1.20 
1.20 
1.20 
1.20 
1.20 
2.30 
2.30 
2.30 
2.30 
2.30 
2.30                                     
 
Olfactory bulb - external and lateral, dorsal, medial, ventral 
Caudate putamen 
Cingulate cortex 
Nucleus accumbens shell and core 
Olfactory tubercle 
Motor Cortex (Deep, superficial layers) 
Somatosensory cortex (Deep, superficial layers) 
Motor Cortex (Deep, superficial layers) 
Somatosensory cortex (Deep, superficial layers) 
Hippocampus 
Thalamus 
Hypothalamus 
Amygdaloid nuclei {central, basolateral and basomedial} 
 
Table 2.2: Bregma coordinates used for brain regions analysed by [125I] OVTA receptor, [3H] Deltorphin-1 and [3H] DAMGO respectively.  
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2.2.9       Fluorescence in situ Hybridization (FISH) 
 
2.2.9.1     Intestinal Dissection and Contents Collection  
 
Intestinal contents and tissue specimens from five various intestinal regions were collected 
from casein free and casein rich treated animals behaviourally tested on PND25 & PND26 and 
sacrificed on PND27. The five gut regions included: stomach, caecum, jejunum, Ileum and 
colon. The University of Surrey Guide to the Autopsy Procedure for Rats was utilised to obtain 
each sample. Prior to the sample collection process, sterile 2ml Eppendorf tubes were labelled 
and placed in the fume hood over ice. All surgical equipment were sprayed with ethanol prior 
to the autopsy procedure. An incision was made through the abdominal skin and muscle wall 
of test subjects and the intestines were unravelled onto a dissection board. To start, the stomach 
was cut around its greater curvature and the contents were collected using sterile forceps and 
weighed into the corresponding Eppendorf tubes. Following the stomach, samples of intestine 
of around 2-3 cm in length were taken and contents transferred to tubes from predetermined 
sites, in the following way: duodenum: 1-2 cm down from the stomach; jejunum: 10 cm down 
from stomach; ileum: 10 cm up from caecum and, colon: 3-4 cm from caecum. The caecum 
was punctured open and the contents weighed and transferred into the corresponding tubes. 
Approximately 20- 2000 mg of intestinal content from each region was collected. The 
remaining carcasses and tissue remnants were placed in polythene bags for containment and 
disposal by incineration. The cells were then vortexed using paraformaldehyde as described 
below. 
2.2.9.2     Sample Fixing  
 
In order to avoid high amounts of fibre within the samples, around 0.15 g of intestinal contents 
was suspended in 600 μl of phosphate buffer saline (PBS) solution; an extra 600 μl was added 
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to samples from the colon and caecum due to the higher fibre content in these regions. Samples 
were then mixed thoroughly by vortexing for 1 minute, then aspirating with a 1 ml pipette tip. 
The samples were then centrifuged at 1000 rpm for 2 minutes and the supernatant were 
collected into separate 2 ml Eppendorf tube and the pellet was re-suspended in 400 μl of PBS 
solution and centrifuged again for 2 minutes at 1000 rpm. This procedure was repeated once 
more and each supernatant was added to the 2 ml tube with the pellet from the last spin being 
discarded. The resulting supernatant was then centrifuged for 5 minutes at 13000 g. Following 
this, the supernatant was discarded and the pellet was re-suspended in 750 μl of PBS solution. 
Half (375 µl) of the produced solution was then added to 1125µl of 4% paraformaldehyde 
(PFA, Sigma UK) solution, vortex mixed and promptly stored in the 4°C fridge for 4-8 hours.  
The 4% PFA solution was prepared by transferring 2 g of PFA powder into a 50 ml Duran 
bottle and adding 30 ml of sterile distilled water and 100 μl of 1 M NaOH solution, and 
dissolved in a 50°C waterbath. Once the PFA powder dissolved, 100 μl of 1 M HCl solution 
and 16.6 ml of 3 × PBS solution was added and made up to 50 ml with sterile distilled water. 
The PFA solution was then filter-sterilised through a Millex® 0.22 μm Millipore syringe filter 
into a sterile container.  
The samples were removed from the refrigerator and centrifuged at 13000 rpm for 5 minutes. 
The supernatant was then carefully discarded, and the pellet re-suspended in 1mL of 1 × PBS.  
Next the samples were centrifuged twice at 1300rpm for 5 minutes. All the resulting 
supernatants from the tubes were carefully removed using a 1ml pipette tip to ensure as much 
supernatant is removed as possible from the tubes. The final pellet was then re-suspended in a 
solution that is determined by the original weight of that sample. The equation was as follows 
[(Original weight of sample / 150mg) x (150 µl)] of PBS solution and [(Original weight of 
sample / 150mg) x (150 µl)] of Ethanol. Fixed samples were then stored in a -20°C freezer. 
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2.2.9.3      Reagents  
 
The methods described for FISH in this chapter originated from (Daims et al., 2005). The 
following reagents were prepared prior to the commencement of experimental procedures: 
Reagent Concentration  Storage Temperature  
Tris-HCl (pH 8.0) 1M RT 
NaCl 5M RT 
Ethanol 50,80,96% (v/v) RT 
EDTA 0.5M RT 
SDS 10% RT 
PBS/SDS (pH 7.2) 10% SDS RT 
Lysozyme 1mg/ml  -20°C 
Table 2.3:  List of reagents required for FISH. RT: Room Temperature  
 
Table 2.4 lists the hybridization conditions for the oligonucleotide probes used in this 
experiment. Details for the bacteria targeted by individual probes used can be found in the 
relevant publications listed and further sequence databases can be found via ProbeBase (http: 
//www.microbial-ecology.net/probebase/). 
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Probe 
Name 
Microorganism 
Specificity 
Sequence  ( 5’ to 3’) Hybridization 
pre-treatment 
Hybridization 
Temp (°C) 
Washing 
Temp (°C) 
Reference 
Bif164 Bifidobacterium spp. CATCCGGCATTACCACCC Lysozyme 50 50 (Langendijk et al., 
1995) 
Chis 150 Clostridium histolyticum 
group ( clusters I and II) 
TTATGCGGTATTAATCTYC
CTTT 
None 
 
50 50 (Franks et al., 1998) 
Lab158 Lactobacillus-
Enterococcus 
GGTATTAGCAYCTGTTTCC
A 
Lysozyme 50 50 (Harmsen et al., 1999) 
EUB338 I* Most bacteria GCTGCCTCCCGTAGGAGT None 46 48 (Daims et al. 2003) 
EUB338 II* Most bacteria GCAGCCACCCGTAGGTGT None 46 48 (Daims et al. 2003) 
EUB338 III* Most bacteria GCTGCCACCGTAGGTGT None 46 48 (Daims et al. 2003) 
 
Table 2.8: Hybridization conditions for oligonucleotide probes used in FISH. The dyes are mono-labelled with the indocarbocyanine dye Cy3 (MWG 
Biotech, Milton Keynes, U.K). * These eubacterial probes were applied simultaneously and used in equimolar concentrations (all at 50 ng µl -1) to assess total 
bacterial counts ( from here on referred to as EUBMIX). 
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2.2.9.4      Dehydration and Fixing of Samples to Slides 
 
On the day of the experiment, the fixed samples stored in ethanol/PBS were removed from the 
-20°C freezer and placed on ice. Samples were then dispersed by vortexing thoroughly. Next 
the samples were diluted according to the probe and region (see table 5.2) with sterile PBS/SDS 
diluent and vortex mixed. Diluted samples (20 µl) were carefully applied to each well of 
Teflon- and poly-L-lysine-coated, 6-well, 10-,diameter slides ( Tekdon Inc. Myakka City, FL, 
USA) with the appropriate samples. The slides were then dried for approx. 15 minutes at 46-
50°C on a desktop plate incubator. The cells requiring lysozyme treatment (See Table 2.5) 
were treated at this stage and the reaction left to incubate on the bench top for 15 minutes.  To 
ensure sufficient permeabilisation of the cell wall to allow probes to enter the cells efficiently, 
some gram-positive bacteria require enzymatic treatments prior to the hybridisation step for 
example LAB158 and Bif164. Lysozyme treatment hydrolyses (1                 4) linkages between 
N- acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan. Gram-positive 
cells are susceptible to this hydrolysis as their wall has a high proportion of peptidoglycan 
compared with Gram-negative bacteria which possesses a thinner peptidoglycan membrane. 
Prior to treating these cells with lysozyme, an aliquot of the prepared lysozyme was defrosted 
and 20 µl of lysozyme was added to each well and incubated on a desktop plate incubator for 
15 minutes. After this, the slides were briefly dipped into distilled water to remove the 
lysozyme. 
All the slides were then immersed fully into 50, 80 and 96% (v/v) ethanol for 3 minutes each. 
The dehydrating effect of the ethanol concentration gradient disintegrates cytoplasmic 
membranes, which then become permeable to oligonucleotide probes. Following this, the slides 
were dried for 2 minutes at 46-50°C on a desktop plate incubator.  
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Probe                Region(s)                                                                Animal Group                                 Dilution  
BIF164          IIeum, Jejunum, duodenum, stomach              Casein free and casein rich                     1:10 
                      Colon and caecum                                              Casein free and casein rich                     1:30 
 
Lab158         All six regions                                                       Casein free and casein rich                    1:30 
 
Chis150        All six regions                                                       Casein free and casein rich                    1:10    
 
EUB MIX      All six regions                                                       Casein free and casein rich                   1:300 
 
2.2.9.5      Hybridization of Probes to Samples  
 
20 minutes prior to starting the hybridization step, the Boekel InSlide OutTM Slide hybridisation 
oven (Progen Scientific, U.K) was turned on and set at the appropriate temperature for each 
probe (see Table 4.2). A piece of absorbent paper towel was soaked with approximately 50 ml 
of distilled water and placed in the bottom of the hybridisation tray, ensuring it was flat.   
2.2.9.6     Preparation of Hybridisation Buffer   
 
Table 2.6 below shows the components needed for the hybridization buffer. EUB338 (MIX) 
probes was the only one requiring formamide (35%). This was done to achieve the correct 
hybridisation stringency ensuring probe specificity. The volume required for all slides were 
calculated accordingly.  
 
 
 
 
 
Table 2.9: Sample dilutions used for FISH analysis  
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                                                                                                                            Volume (µl)  
Component                                                                          0% Formamide           35% Formamide  
5 M NaCl 
1 M Tris/HCL (ph 8.0)  
Formamide  
Double distilled H2O 
10% sodium dodecyl sulfate  
 
 
The Oligonucleotide probes were thawed in the dark and 5 µl of probe was added to 50 µl of 
hybridization buffer and mixed by inversing three times. A master mix containing sufficient 
probe/hybridization buffer was prepared by calculating the amount needed to cover all slides. 
From this mix, 50 µl of probe mixture was applied onto each well containing the dehydrated 
sample. The slides were placed onto the slide holders with the samples facing upwards. The lid 
of the slide tray was then sealed tightly ensuring it was airtight, this is to ensure no evaporation 
of the probe/hybridization mixture occurs. The trays were then placed in the oven and left to 
incubate for 4 hours.  
2.2.9.7  Washing, Drying and Storage  
 
2.2.9.7.1     Preparation of Wash Buffer  
 
After placing the slide trays in the incubator, a sufficient amount of wash buffer was prepared 
as shown below (Table 2.7) in 50 ml centrifuge tubes. EUBMIX required 35% formamide and 
so EDTA was added to capture trace amounts of divalent cations, which frequently occur and 
reduce the stringency of the washing step because they stabilise the DNA-RNA hydrides. The 
180 
20 
0 
799 
1 
 
180 
20 
350 
499 
1 
Table 2.10: Composition of hybridisation buffers used to achieve different hybridization 
stringencies for FISH analysis. Volumes given are required for 2 slides. The SDS solution was 
added last to inhibit precipitation.  
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wash buffers were then placed in the corresponding temperature in a water bath (see Table 
2.4).   
                                                                                                                     Volume (µl)  
Component                                                                          0% Formamide            35% Formamide  
5 M NaCl 
1 M Tris/HCL (ph 8.0)  
Formamide  
Double distilled H2O 
10% sodium dodecyl sulfate  
 
 
Immediately prior to the removal of the slides from the incubation oven, a centrifuge tube 
containing 50 of distilled water was placed over ice. At this point 20 µl of 4’6-diamidino-2-
phenylindole dihydrochloride (DAPI;50 NG µl -1 ) was added to the wash buffer tubes. DAPI 
was then added to the wash buffer to allow cells to be found easily on the microscope slide. 
This reagent binds to the minor groove (at A-T BONDS) of double-stranded DNA, staining 
the DNA molecule of the bacteria (Kapuscinski, 1995). 
Once the incubation is complete, the hybridization tubes were removed from the oven and the 
slides rapidly transferred into the wash buffers in the water baths. This step was carried out 
quickly to reduce cooling of the hybridization buffer on the slide that may cause a reduction 
in the stringency and non-specific binding of probes to non-targeted organisms. Two slides 
were placed back to back into the 50 ml centrifuge tube for 10-15 minutes. Using tweezers, 
the slides were then taken out the wash buffers and immersed rapidly into the ice cold 
distilled water for 2-3 minutes. This step ensured all residual washing buffer was removed 
9.0 
1 
0 
40 
1 
0.70 
1 
0.5 
47.8 
1 
Table 2.11: Composition of wash buffer for FISH analysis. Volumes given are for 2 slides only 
and prepared in 50 ml centrifuge tubes.  
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which might not otherwise cause crystal formation on the slides thus hampering microscopic 
visualisation of fluorescing cells. The low ionic strength of distilled water destabilises nucleic 
acid duplexes, and the cold minimises dislocation of probes from the ribosomes of their target 
organisms (Daims et al., 2003). 
The slides were the placed on paper towels and dried using a stream of compressed air. 
Antifade (5 µl) was then added to each well and a cover slide was applied by gently pressing 
over the samples to carefully remove any bubbles being formed by the antifade. Slides were 
transferred to slide boxes and placed int eh fridge overnight before microscopy. 
2.2.9.8      Microscopic Visualisation  
 
The stained sections were inspected in a dark room using EPI-fluorescence Eclipse E400 
Nikon microscope (Nikon, U.K., Kingston-upon-Thames, and U.K) equipped with a 100 x 
Plan Apochromat oil objective lens and a HBO 100-W vapor lamp. Cy3-stained cells were 
viewed with immersion oil under 100 × magnification with the use of a green excitation filter 
(510 nm 560 nm) and the DAPI-stained cells were examined under ultraviolet (UV) light 
(330nm 380nm). Bacterial cells from fifteen random microscopic fields of view were counted 
per sample and used for the calculation of the number of cells in each sample ( g intestinal 
sample) -1  using this formula: 
Log10 (bacteria / ml of sample) = 0.8  ×  A  ×   6732.42  ×  50  ×  B 
 
Where A is the average number of cells counted per field of view, B is the dilution factor 
(e.g. 20 if 1 in 20 dilutions used) and 6732.42 is the magnification constant of the 
microscope. 0.8 is the dilution factor which was initially used (i.e. 375 µl if sample into 150 
µl PBS and 150 µl ethanol 300/375) and 50 µl was used in the calculations as 20 µl of sample 
was applied to the slide and so bring the total to 1 ml. 
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2.2.9.9     Data Analysis 
 
The log10 of bacterial counts were analysed for differences for each individual probes. The raw 
data counts were tabulated and collected in Microsoft Excel, here they were adjusted to show 
the true counts and averages of all 15 repetitions were determined. The final data set was then 
transferred to GraphPad Prism 7 for graphing. Statistical analysis was conducted using a two-
way ANOVA followed by Bonferroni post-hoc analysis where applicable. No statistical 
analysis was conducted for the Duodenum as there was no casein-rich to compare to the casein-
free samples.  
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2.3 Results 
 
2.3.1 Body Weight and Milk Consumption  
 
Rats provided with casein rich milk consumed significantly more milk from PND22 to PND26 
compared to rats provided with casein free milk. Furthermore, rats fed casein rich milk gained 
significantly more bodyweight over time compared to control and casein free treated animals 
(p ˂  0.001 Figure 2.2 A and p ˂ 0.01 Figure 2.2 B respectively).  
2.3.2 Behaviour 
 
The FST was used to assess depressive-like behaviour in rats provided with no milk (control), 
casein free or casein rich milk from PND21 until PND26. The total immobility time and total 
time spent climbing were scored from the ‘test’ session on PND26 (Figure 2.3 A and B 
respectively).  The quantification from the ‘test’ times were used in the assessment of 
depressive-like behaviour as described by (Cryan et al., 2005). 
Quantification of the results from the ‘test’ swim test session on PND26 showed that rats fed a 
casein rich diet displayed depressive-like phenotypes as shown by a marked increase in 
immobility time compared to both the control (p < 0.001) and casein free treated animals (p <  
0.01). In addition casein rich treated rats spent significantly less time climbing compared to 
both control (p < 0.01) and casein free animals (p < 0.005). 
Taken together these results show that casein rich treated animals exhibit marked ‘depressive-
like’ behaviour when compared to control animals and animals fed casein free milk.  
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Figure 2.2:  Effects of casein free and casein rich diets on milk consumption and body weight.  
(A) Milk consumption for casein free and casein rich groups. Animals provided with casein rich milk 
consumed significantly more milk compared to their casein free counter parts from PND22-PND26 (B) 
Weight change in grams for control, casein free and casein rich groups from PND14 to PND27. Data are 
expressed as mean ± SEM (n=8 per group). Casein rich animals showed the greatest weight change 
compared to control and casein free animals (**p<0.01, ***p<0.001 one way ANOVA followed by 
LSD  post-hoc test) 
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Figure 2.3: Increase in depressive-like behaviour following prolonged exposure to milk caseins 
beyond the normal age of weaning in rats (pnd21). 
 Male Wistar Albino rats were provided with no milk, casein free or casein rich milk from PND21 
through to PND26 then subjected to behavioural testing using the FST on PND25 & 26 (A) Immobility 
time during the 6 minute test session ran on PND26 (B) Total time spent climbing during the 6 minute 
test session ran on PND26. Casein rich milk caused an increase in immobility time and a decrease in 
total time spent climbing compared to both control and casein free treatment. Data are expressed as 
mean scores (± SEM) (n=8) obtained from manual video analysis by two independent observers.  One-
way ANOVA followed by LSD post-hoc test was used and a p value of less than 0.05 was accepted as 
significantly different. *p=0.05, **p<0.01, ***p<0.001 
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2.3.3          Neurochemical Analysis 
 
2.3.3.1      Quantitative Oxytocin Receptor Autoradiography 
 
Quantitative OTr autoradiographic binding using [125I]-OVTA was performed on rat brain 
sections cut at the level of the olfactory nuclei, caudate and thalamus from control, casein free 
and casein rich treated animals. Figure 2.4 (A) shows reduced OTR binding in the olfactory 
nuclei of casein free and casein rich treated animals compared to control (first row). The second 
row of Figure 2.4 (A) shows a lower density of OTr binding in the thalamus of casein rich 
treated animals compared to control group. 
In order to assess the impact of casein rich vs. casein free milk on OT receptor levels, a One-
Way ANOVA for the factor ‘treatment’ was employed and revealed a significant general milk 
effect in the AOV and Th of casein rich and casein free treated animals compared to control (p 
< 0.05).  In the Hip and CE a decrease of OTr binding was observed only in casein rich treated 
animals compared to control (p < 0.05) indicating a casein effect. Furthermore, a decrease in 
OTr binding was also observed in the BLA, and BMA of casein rich treated animals compared 
to both control and casein free (p < 0.01 and p < 0.05 respectively) again highlighting a casein 
effect on OTr binding in these regions (Figure 2.4 B).  No effect of treatment was found in the 
remainder of the regions analysed shown in Table 2.2. 
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Figure 2.4: Region-specific alterations of [125I]-OVTA binding in rats provided with casein free or 
casein rich milk from PND21-PND26.   
Male Wistar Albino rats were provided with either no milk, casein free or casein rich milk from PND21 
through to PND26 (A) Computer-enhanced representative autoradiograms of adjacent coronal brain 
sections from control, casein free and casein rich treated rats at the levels of olfactory nuclei (Bregma 
4.20mm, first row) and thalamus (Bregma -2.80mm, second row). OTRs were labelled with [125I]-OVTA 
(50 pm). The colour bar illustrates a pseudo-colour interpretation of black and white film images in 
fmol/mg tissue equivalent. Representative images for the non-specific (50pm [125I]-OVTA in the presence 
of 50 µM unlabelled oxytocin) are shown for all the treatment groups. (B) Quantitative oxytocin receptor 
autoradiographic binding from control, casein free and casein rich treated animals. Data are expressed as 
mean ± S.E.M (n=8 per group) specific [125I]-OVTA binding (fmol/mg tissue equivalent). * p<0.05; 
**p<0.01 (one-way ANOVA followed by LSD post-hoc test). Abbreviations: Acb, nucleus accumbens; 
Amy, amygdala; AOL, anterior olfactory nucleus-lateral; AOM, anterior olfactory nucleus-medial; AOV, 
anterior olfactory nucleus-ventral; BLA, basal lateral amygdala; BMA, basal medial amygdala; CE, 
Central Nucleus of Amygdala; CgCx, cingulate cortex; CPu, caudate-putamen; Hip, hippocampus; Hyp, 
hypothalamus; LS, lateral septum; MS, medial septum;  Pir, piriform cortex; Th, thalamus; Tu, olfactory 
tubercle; VDB, vertical limb of the diagonal band of Broca. 
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2.3.3.2          Quantitative Mu Opioid Receptor Autoradiography 
 
Quantitative MOPr autoradiographic binding using [3 H] DAMGO was performed on rat brain 
sections cut at the level of the frontal cortex, striatum and thalamus from control, casein Free 
and casein Rich treated animals. Figure 2.5 (A) shows a low density of MOP receptor binding 
in the frontal cortex of casein rich treated animals compared to both control and casein free 
animals (first row) followed by decreased MOPr binding in the striatum of casein free animals 
compared to both control and casein rich groups (second row). The last row of Figure 2.5 (A) 
shows reduced MOPr binding in the thalamus of casein rich treated animals compared to both 
control and casein free treatment groups.   
 In order to assess the impact of casein free vs casein rich milk diets beyond the normal age of 
weaning, a One-Way ANOVA was employed and revealed a significant general milk effect in 
the CgCx, (p< 0.05), AcbC whole (casein free p< 0.05, casein rich p< 0.01 ), AcbC shell  (p< 
0.01) and the CPu ( casein free p< 0.01, casein rich p< 0.001) in both casein free and casein 
rich treated animals compared to controls.  
Casein rich milk alone caused a decrease in MOPr binding in M2 (p< 0.05), PrL (p< 0.05), 
M1/M2 superficial (p< 0.05), M1/M2 deep (p< 0.05), Amy (p< 0.01) and Hyp (p< 0.01) 
compared to control treated animals. Furthermore casein rich milk induced decreased binding 
in S1/S2 deep compared to both control and casein free treatment groups (p< 0.05) indicating 
a casein effect Figure 2.5 (B). No effect of treatment was found in the remainder of the regions 
analysed shown in Table 2.2. 
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Figure 2.5: Region specific alterations of [3H] DAMGO specific binding in rats provided with 
casein free or casein rich milk from PND21-PND25.   
Male Wistar Albino rats were provided with either no milk, casein free or casein rich milk from 
PND21 through to PND26 (A) Computer-enhanced representative autoradiograms of adjacent coronal 
brain sections from control, casein free and casein rich treated rats at the levels of the frontal cortex 
(Bregma 4.20, first row), striatum (Bregma 1.20, second row) and thalamus (Bregma -2.30, third row). 
MOPrs were labelled with [3H] DAMGO (4nM).  The colour bar illustrates a pseudo-colour 
interpretation of black and white film images in fmol/mg tissue equivalent. (B) Quantitative oxytocin 
receptor autoradiographic binding from control, casein free and casein rich treated animals. Data are 
expressed as mean ± S.E.M (n=8 per group) specific [3H] DAMGO binding (fmol/mg tissue 
equivalent). * p<0.05  **p<0.01 (one-way ANOVA followed by LSD post-hoc test). Abbreviations: 
Acb, nucleus accumbens; Amy, amygdala; AOM, anterior olfactory nucleus-medial; CgCx, cingulate 
cortex; CPu, caudate-putamen; Hip, hippocampus; Hyp, hypothalamus; M1/M2 motor coretex; PrL, 
prelimpic cortex; S1/S2 somatosensory cortex; Th, thalamus; Tu, olfactory tubercle;  
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2.3.3.3           Quantitative Delta Opioid Receptor Autoradiography 
 
Quantitative DOPr autoradiographic binding using [3H] Deltorphin -1 was performed on rat brain 
sections cut at the level of the thalamus from no milk control, casein free and casein rich treated animals. 
Figure 2.6 (A) shows a low density of DOPr in the somatosensory cortex of casein free treated animals 
compared to both control and casein rich. 
 In order to assess the impact of casein free vs. casein rich milk diets beyond the normal age of weaning, 
a One-Way ANOVA was employed and showed casein free milk induced decreased binding in S1/S2 
deep (p< 0.05) compared to both control and casein rich treatment groups. Indicating a soy protein 
effect Figure 2.6 (B). No effect of treatment was found in the remainder of the regions analysed shown 
in Table 2.2 
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Figure 2.6: Down-regulation of [3H] Deltorphin -1 specific binding in the deep layer of the somatosensory 
cortex of rats fed casein free milk beyond the normal age of weaning (PND21). 
Male Wistar Albino rats were provided with either no milk, casein free or casein rich milk from PND21 through 
to PND25 (A) Computer-enhanced representative autoradiograms of adjacent coronal brain sections from 
control, casein free and casein rich treated rats at the levels of  Thalamus (Bregma -2.30). DOPrs were labelled 
with [3H] deltorphin -1 (7nM).  The colour bar illustrates a pseudo-colour interpretation of black and white 
film images in fmol/mg tissue equivalent. (B) Quantitative oxytocin receptor autoradiographic binding from 
control, casein free and casein rich treated animals. Data are expressed as mean ± S.E.M (n=8 per group) 
specific [3H] deltorphin -1 binding (fmol/mg tissue equivalent). * p<0.05 (one-way ANOVA followed by LSD 
post-hoc test). Abbreviations: Acb, nucleus accumbens; Amy, amygdala; AOM, anterior olfactory nucleus-
medial; CgCx, cingulate cortex; CPu, caudate-putamen; Hip, hippocampus; Hyp, hypothalamus; M1/M2 motor 
coretex; Pir, piriform cortex; PrL, prelimpic cortex S1/S2 somatosensory cortex; Th, thalamus; Tu, olfactory 
tubercle. 
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2.3.4       Analysis of Urine Samples (Metabolomics) 
 
2.3.4.1      PCA of Urine Samples 
 
PCA was first used as an unsupervised multivariate statistical analysis method to give an 
insight into how urine samples from control, casein free and casein rich treatment groups 
differed from one another.  The percentage of variance explained by each PC (R2) is shown for 
each axis. In order to aid visualisation of any trends associated with casein free or casein rich 
test groups, the two different groups are shown colour coded according to their group, with 
green circles representing casein free animals and blue circles representing casein rich animals.  
Following initial PCA modelling of the urine data, clear separation along PC1 can be seen 
between casein free and casein rich treated animals Figure 2.6 (A). This indicates that casein 
exposure from PND21 until PND26 is responsible for the largest source of variation in the 
metabolic data.  
2.3.4.2     1H-NMR Spectroscopy of Urine Samples  
 
OPLS-DA was used to further investigate the effect of exposure to casein free or casein rich 
milk on animal metabolic profiles. This supervised method allows for the examination of the 
data in question with reference to only one source of variation as opposed to all possible 
variations as was the case with the PCA approaches Figure 2.6 (B).  The model had a strong 
predictive ability (Q2Y = 0.27) that was found to be significant after permutation testing (p = 
0.0; 10,000 permutations). From the correlation coefficients plot extracted from the OPLS-DA 
model, casein rich rats were found to excrete higher amounts of hippurate and betaine than the 
casein free rats and lower amounts of benzoate, glycine, acetate and alanine.  
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Figure 2.7: Multivariate analysis of urinary 1H NMR spectral profiles showing the influence of casein free diet and 
casein rich diet on urinary metabolites. 
Male Wistar Albino rats were provided with either no milk, casein free or casein rich milk from PND21-PND26 (n= 8 per 
group) after which they were placed into individual metabolic cages to allow for the collection of urine. (A) PCA scores 
plot of normalised NMR data showing separation along PC1 between casein free and casein rich groups (B) OPLS-DA 
coefficient plot showing all metabolite responsible for driving the separation between the groups. Labelled peaks are the 
metabolites which are increased in the respective groups (Q2Y =0.27). 
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Metabolite                                            Chemical Shift (Multiplicity)                                 Sample   
Acetate                                                                 1.92 (s)                                                         
Alanine                                                            3.77 (q), 1.8 (d)                                                 
Betaine                                                            3.27 (s), 3.91 (s)                                                
Benzoate                                                         7.49 (t), 7.56 9t)                                                 
Glycine                                                                  3.57 (s)                                                       
Hippurate                                                  3.97 (d), 7.64 (t), 7.84 (d)                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Casein-free 
Casein-free 
Casein-rich 
Casein-free 
Casein-free 
Casein-rich 
Table 2.12: Full 1H- NMR chemical shifts for metabolites identified in Urine samples. Key: s, 
singlet; d, doublet; t, triplet; q, quadruplet 
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2.3.5.        Assessment of Intestinal Microbiota (FISH) 
 
 2.3.5.1     Assessment of Total Bacteria  
 
Two-way ANOVA for factors ‘diet’ and ‘gut region’ showed no significant effect of either 
factor in EUB338 probe counts between casein free and casein rich groups in all of the gut 
regions analysed therefore no post hoc analysis was carried out (Figure 2.8). 
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Figure 2.8: Effect of casein free vs. casein rich milk diets from PND21-PND26 on the composition 
of total bacteria within different gut regions.  
Male Wistar Albino rats were provided with either casein free or casein rich milk from PND21 through 
to PND26. A mixture of EUB 338 I,II & III  probe were used for the enumeration of total bacteria in 
contents obtained from five different regions of the intestine from the study animals. All data expressed 
as mean log10 cells (g wet weight of intestinal content)-1 , ± S.E.M  (n=8 per group). Two-way ANOVA 
was carried out and no significant differences were observed between the two groups, therefore no post hoc 
analysis was carried out.  
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2.3.5.2         Assessment of Clostridium Histolyticum Groups  
 
Two-way ANOVA for factors ‘diet’ and ‘gut region’ of Chis150 probe counts showed a 
significant ‘diet’ [ F (1,60) =  21.56; p  <0.001 ] and ‘gut region’ [ F (4,60) =  64:64; p  <0.001 ] 
and ‘diet’ x ‘gut-region’ interaction [ F (4,60) =  3.763; p  <0.0085 ]. Post-hoc analysis revealed 
casein rich animals harboured increased total numbers in the caecum (p= 0.01) and colon (p= 
0.001) compared to casein free treated animals (Figure 2.9). 
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Figure 2.9:  Effect of casein free vs. casein rich milk diets from PND21-PND26 on clostridium 
histolyticum bacterial groups within different gut regions.  
Male Wistar Albino rats were provided with either casein free or casein rich milk from PND21 through 
to PND26. The Chis150 probe was used for the enumeration of C.histolyticum spp. In contents obtained 
from five different regions of the intestine from the study animals. All data expressed as mean log10 
cells (g wet weight of intestinal content)-1 , ± S.E.M  (n=8 per group). Animals provided with casein 
rich milk had significantly higher levels of C.histolyticum in the caecum and colon compared to their 
casein free counter parts (**p<0.01, ***p<0.001 two way ANOVA followed by Bonferroni post-hoc test). 
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2.3.5.3   Assessment of Bifidobacterium Groups  
 
Two-way ANOVA for factors ‘diet’ and ‘gut region’ showed no significant effect of either 
factor in Bif164 probe counts between casein free and casein rich groups in all of the gut 
regions analysed, therefore no post-hoc analysis was carried out (Figure 2.10). 
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Figure 2.9: Effect of casein free vs. casein rich milk diets from PND21-PND26 on Bifidobacterium 
bacterial groups within different gut regions.  
Male Wistar Albino rats were provided with either casein free or casein rich milk from PND21 through 
to PND26. The Bif164 probe was used for the enumeration of Bifidobacterium spp. In contents obtained 
from five different regions of the intestine from the study animals. All data expressed as mean log10 
cells (g wet weight of intestinal content)-1, ± S.E.M (n=8 per group). Two-way ANOVA was carried out 
and no significant differences were observed between the two groups, therefore no post hoc analysis was 
carried out. 
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2.3.5.4         Assessment of Lactobacillus-Enterococcus Groups 
 
Two-way ANOVA for factors ‘diet’ and ‘gut region’ showed no significant effect of either 
factor in Lab158  probe counts between casein free and casein rich groups in all of the gut 
regions analysed, therefore no post-hoc analysis was carried out (Figure 2.11). 
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Figure 2.10: Effect of casein free vs. casein rich milk diets from PND21-PND26 on Lactobacillus-
Enterococcus bacterial groups within different gut regions.  
Male Wistar Albino rats were provided with either casein free or casein rich milk from PND21 through 
to PND26. The Lab158 probe was used for the enumeration of Lactobacillus-Enterococcus spp. In 
contents obtained from five different regions of the intestine from the study animals. All data expressed 
as mean log10 cells (g wet weight of intestinal content)-1 , ± S.E.M  (n=8 per group). Two-way ANOVA 
was carried out and no significant differences were observed between the two groups, therefore no post hoc 
analysis was carried out. 
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2.4       Discussion  
 
The aim of this study was to investigate whether exposure to milk caseins beyond the normal 
age of weaning (PND21) would result in the development of a depressive-like phenotype in 
male Wistar Albino rats. Moreover, we investigated the effects of prolonged casein exposure 
in early postnatal life on the development of the opioid system, namely MOPr and DOPr as 
well as OTr. Finally we investigated the effect of 5 extra days of casein exposure beyond the 
normal age of weaning on gut microbial populations as well as urinary metabolites. The results 
revealed rats fed casein rich milk beyond the normal age of weaning displayed a depressive-
like phenotype which was concomitant with a down regulation of OTr in the amygdala, as well 
as a down regulation of MOPr in a number of brain regions associated with mood. Furthermore, 
these rats also displayed higher levels of Clostridium Histolyticum (C.Histolyticum) species in 
the gut compared to their casein free counter parts as well as an increase in microbial urinary 
metabolites. Interestingly, we also observed a general milk effect with rats fed both casein free 
and casein rich milk beyond the normal age of weaning  displaying a down regulation of both 
MOPr and OTr in a number of brain regions indicating a casein independent effect on brain 
neurochemistry. Moreover, animals fed casein free milk but not casein rich milk displayed a 
down regulation of DOPr in the deep layer of the somatosensory cortex, however these animals 
did not display a depressive phenotype, suggesting that soy protein exposure in early postnatal 
life also influences normal brain development but not necessarily depressive-like behaviour.  
A rat model mimicking delayed weaning or weaning onto cow’s milk based formula was 
established by providing rat pups with a casein rich milk formula (containing approx. 20% w/w 
casein) from PND21 (the standard age of weaning) till PND26. Another group was provided 
with a casein free milk formula, custom manufactured to match the nutritional composition of 
the casein rich milk except casein protein was removed and replaced with approx. 20% w/w 
 155 
soya protein), again from PND21 until PND26. The control group, which mimicked normal 
weaning practices, where no milk is provided past weaning, had their mothers removed on 
PND21 and were provided with no milk post-weaning.  
Animals provided with casein rich milk consumed significantly more milk from PND22 till 
PND26 compared to animals provided with casein free milk (see Figure 2.2 A). This is in line 
with findings by Goody and Kitchen (2001) who provided casein free or casein rich milk 
formula to 21 day old rat pups and reported that the casein rich group consumed significantly 
greater amounts than their casein free counterparts. These observed differences in voluntary 
milk consumption could be attributed the characteristic taste and smell of soya making the 
casein free milk less palatable. Another potential mechanism which could be driving the 
differences in milk consumption between the casein free and casein rich treated animals could 
be linked to the direct effects of the milk proteins on the gut. The casein free milk contained 
soy protein which is a mixture of different proteins classified into 4 categories, with β-
conglycinin and glycinin making up more than 80% of the soy protein content (Saio et al. 
1969). The β-conglycinin protein is made up of three subunits, namely α, α1 and β (Tierney et 
al., 1987). It has been shown that the β-subunit contains the same sequence as bovine and 
human β-casomorphins (YPFV). Peptides which have a Tyr-Pro-aromatic amino acid sequence 
are selective for the MOPr (Brantl et al., 1982) (see Section 1.3 ). Indeed it has been shown 
that the peptides derived from the β-subunit of β-conglycinin also possess opioid activity and 
were therefore named soymorphins (Ohinata et al,. 2007). A study by Kaneko et al., (2010)  
found that oral administration of soymorphins in fasted rats resulted in a suppression of food 
intake and small intestinal transit time. This effect was found to be inhibited by naloxone, hence 
indicating that this was MOPr mediated effect. In general it has been well documented that 
MOPr agonists such as those derived from milk caseins enhance food intake, while MOPr 
antagonists supress food intake (see review by Yeomans et al., 2002). Soymorphins are the 
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first MOPr agonist peptides that were found to suppress food intake (Kaneko et al., 2010). 
Although we did not measure food intake in this current study, it is feasible that soymorphins 
found in the casein free milk could be responsible for the reduced amount of milk consumption 
observed in this group, while BCM-7 derived from casein rich milk could be stimulating gut 
MOPr to result in higher milk consumption.   
Furthermore, the preference for casein rich milk over the casein free formula was very evident 
in this study and indicates that the difference in consumption between casein free and casein 
rich milk may represent reward properties of casein and its breakdown products found only in 
the casein rich milk. Although previous studies on the reward (reinforcing)  potential of milk 
derived β-casomorphins did not demonstrate conditioned place preference following systemic 
administration, while morphine administration did induce place preference in the same 
experiments (Reid et al., 1994), it is still possible that casein rich milk was more rewarding 
than its casein free variant leading to higher consumption.  
Moreover, casein rich animals gained significantly more weight compared to control and casein 
free treated animals (see Figure 2.2 B). The significant difference in weight gain between 
casein rich and control animals indicates that, not surprisingly the absence of milk formula 
results in lower body weights by 26 days of age which is more than likely due to the absence 
of this significant nutritional source from the diet of control vs. casein rich animals. Casein rich 
treated animals also gained significantly more weight compared to the casein free group. This 
result can be explained by the fact that casein free animals consumed significantly less milk 
then their casein rich counterparts and therefore gained less weight.  
Furthermore, the nutritional composition of soy protein vs casein protein could also be driving 
the difference observed in weight gain between the two groups. This is in line with a study by 
Silva et al., (2015) who provided 21 day old mice with either soy-based infant formula or cow’s 
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milk-based infant formula for a period of 10 days. They measured milk consumption and 
weight gain throughout the duration of the study and found that mice provided with soy-based 
infant formula gained significantly less weight compared to mice who consumed the cow’s 
milk based infant formula. This result was in part attributed to the differences in amino acid 
composition between soy protein and casein. For example soya protein has lower levels of 
methionine, lysine and proline. Moreover, it has previously been shown that soya based 
formula contains anti-nutritional factors which prevent the absorption of nutrients such as 
phytic acid (Lönnerdal, 1994). 
It was hypothesised that consumption of milk caseins beyond the normal age of weaning would 
result in depressive–like behaviour due to impairments to both the opioid system and the 
oxytinergic system. Indeed, the results obtained in this chapter demonstrate that animals 
provided with casein rich milk from PND 21 until PND 26 exhibited ‘depressive-like’ 
behaviour as evidenced by a significant increase in the total time spent immobile and a decrease 
in time spent climbing in the FST compared to both control and casein free treated animals (see 
Figure 2.3). These results extend previous findings from our laboratory conducted by Farshim 
et al., (2016) which showed that rat pups which are maintained in a non-weaned state exhibit 
depressive-like behaviour compared to rat pups weaned  at the normal age of 21 days old. 
Taken together, these results suggest that it is the prolonged exposure to maternal milk caseins 
in the non-weaned rats that maybe responsible for the depressive phenotype observed.  
It is possible to argue that the difference in weight gain between the three treatment groups 
discussed above could have influenced the immobility times in the FST, especially as evidence 
shows weight is indeed a factor which can influence immobility in the FST (Bogdanova et al., 
2013). However in order to address this, the total immobility time for each test animal (in 
seconds) was divided by the individual body weights of animals on the day of testing ( animal 
weight in grams on PND26) and these results were plotted and statistically analysed using a 
 158 
one-way ANOVA followed by LSD post-hoc analysis. The results revealed that the significant 
increase in immobility observed in the casein-rich treated animals was still present in 
comparison to both casein free and control animals even after taking body weight into account. 
This analysis provides assurance that the difference in weight between the three test groups did 
not affect depressive-like behaviour. Indeed various methods of statistical analysis have 
previously been carried out by other groups to account for variation in weight of animals used 
in the FST (Brenes et al., 2008). 
Previous investigations from our laboratory conducted by Kitchen et al., (1995) have 
demonstrated weaning rat pups on PND21  activates a population of DOPrs which mediate 
swim SIA whereas maintaining pups in a non-weaned state until PND 25 resulted in a lack of 
development of these DOPrs. Moreover, it was shown that casein exposure was responsible for 
mediating this effect as the removal of casein from the neonatal rat diet at the time of weaning 
acted as developmental trigger for the transition of MOPr to DOPr in the mediation of swim 
SIA (Goody and Kitchen 2001). This transition can be delayed up to PND40 by continued 
dietary provision of casein rich milk formula. This set of experiments were able to exclude the 
possibility of psychological (maternal presence) or physiological (suckling) influence upon this 
transition and showed that this was driven by nutritional factors with potential candidates being 
casein derived BCM7 or similar compounds. The results obtained in this chapter show that 
casein consumption beyond the normal age of weaning results in a depressive phenotype. As 
DOPrs are known to modulate depressive-like behaviour (Filliol et al., 2000) it is possible that 
a dysfunction of DOPrs caused by casein exposure could be responsible for the depressive 
phenotype observed in animals provided with casein rich milk till PND26. 
In order to investigate this, receptor binding autoradiography on DOPrs was performed in rats 
treated with no milk (control), casein free milk or casein rich milk from PND 21-PND 26. 
Interestingly, a significant down regulation of DOPrs was observed in the deep layer of the 
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somatosensory cortex of animals treated with casein free milk compared to both control and 
casein rich treated animals which is in apparent contradiction with the original hypothesis (see 
Figure 2.6). Based on the DOPr KO model created by Filliol et al., (2000) the depressive 
phenotype observed in casein rich treated rats was predicted to be mediated by a down-
regulation of DOPrs in the brain caused by casein and its bioactive breakdown product BCM-
7. However the results obtained revealed that casein rich treated animals displayed a depressive 
phenotype which was not accompanied with a reduced DOPr density in the somatosensory 
cortex, but it is instead casein free treated rats which displayed no signs of depressive-like 
behaviour, who had a significant reduction of DOPrs in the somatosensory cortex. This data 
suggests that DOP receptors may play a differential role in mediating depressive-like 
behaviour. Consistent with this theory, a recent study by Chu Sin Chung et al., (2015) who 
created a conditional knockout mouse line that lacks DOPrs in specific brain regions, showed 
a low-anxiety phenotype in these mice. Indicating that DOPrs exert both anxiolytic and 
anxiogenic activities at distinct levels of neural circuits. As decreased DOPr density in the 
somatosensory cortex was not associated with emotional impairment in our study, it is unlikely 
that the depressive phenotype observed in casein rich rats was due to DOPr dysregulation 
induced by casein. Nonetheless, the dysregulation of DOPr in the casein free rats may be 
responsible for the modulation of other behaviours which may be affected by casein free milk. 
Indeed, as described earlier, casein free milk contains soymorphins which may affect DOP 
regulation and as a result DOPr mediated behaviours (e.g. social reward, pain). This set of 
results warrants further investigation in order to determine the implications of these findings.  
Next, MOP receptor binding levels in animals treated with no milk, casein free or casein rich 
milk from PND21-PND26 were investigated. It can be seen that both casein free and casein 
rich milk appear to have caused a down-regulation of MOPr in the cingulate cortex and the 
shell of the nucleus accumbens indicating a general milk effect independent of casein or soya 
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on brain neurochemistry (see Figure 2.5). Continued or intermittent agonist stimulation of a 
receptor results in loss of receptor activity termed desensitization (Lefkowitz et al., 1983).  This 
is believed to be a homeostatic mechanism and is triggered in response to continued agonist 
stimulation of a receptor.  A large body of literature shows that one of the ways the MOP 
receptor is regulated following long-term opioid exposure is via desensitization and/or  
internalization (see Williams et al., 2013). A number of studies have shown peptide opioid 
ligands such as DAMGO can cause desensitization or internalization of the receptor (Yu et al., 
1997; Whistler et al., 1998; Koch et al., 2001; Bailey et al., 2009). Whereas non peptide ligands 
such as morphine cause desensitization of the receptor (Levitt et al,. 2012). In this present 
study, it is likely that bioactive components liberated from both casein free and casein rich milk 
with an affinity for MOPr have resulted in desensitization and subsequent down-regulation of 
the receptor.  Upon proteolytic cleavage in the gut, beta-caseins found in the casein rich milk 
release BCM-7. BCM-7 has previously been detected in the plasma of infants suffering from 
ASD, indicating BCM-7 can cross over from the luminal side of the gut into the blood (Kost et 
al., 2009b). Evidence also suggests that BCM-7 may possess the ability to cross the BBB and 
elicit effects directly on the brain. A study by Ermisch et al. (1983) measured the accumulation 
of radioactivity in different brain regions following an intracarotid injection of [3H] BCM-5 in 
rats. The results showed a low but measurable brain uptake of the peptide. Although BCM-7 
differs slightly in structure to BCM-5 it is feasible that it also possesses the ability to cross the 
BBB especially in early postnatal life when the BBB is not yet fully formed.  It is thus 
conceivable that the milk induced down regulation of MOPr may be due to reported 
desensitization and internalization of the receptor by an excess of soymorphin and 
casomorphins in the brain from PND21 until PND26. 
Indeed, as discussed earlier, soya protein has been shown to liberate soymorphins. These 
soymorphins have been shown to have a similar affinity to MOPr as bovine BCM-7. For 
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example the IC50 of soymorphin-5 is 6.0 µm (Ohinata et al., 2007) compared to 5.14 µm for 
bovine BCM-7 (Koch et al., 1985). It is therefore feasible that soymorphins derived from soy 
protein acted directly on MOPr found in the brain to cause desensitization or internalization of 
the receptor. 
Another proposed mechanism by which BCM-7 or soymorphins may be causing a reduction in 
MOPr density is via epigenetic regulation.  Evidence shows that BCM-7 and other 7aa-proline 
containing food derived opioid peptides can inhibit cysteine uptake in cultured human neuronal 
and GI epithelial cells. The decrease in cysteine uptake was  accompanied by a decrease in 
levels of the antioxidant glutathione (GSH) whose synthesis is limited by cysteine availability 
(Trivedi et al., 2014). This may explain the downregulation of the MOPr observed in the CgCx, 
CPu, This also indicates that BCM-7 can affect oxidative stress levels. Furthermore it was 
shown that food derived opioid peptides increased genome wide DNA methylation in the 
transcription start site region with a potency order similar to their inhibition of cysteine uptake. 
Altered expression of genes involved in redox and methylation homeostasis was also observed 
(Trivedi et al., 2014). DNA methylation of genes is well known to be associated with decreased 
gene expression (Moore et al., 2013), it is therefore tempting to speculate that a potential 
mechanism by which BCM-7 or soymorphin exposure causes a downregulation of MOPr DOPr 
and OTr may be related to changes in DNA methylation and/or regulation. Taken together, 
these findings illustrate the potential of BCM-7 and other food derived opioid peptides to exert 
epigenetic changes, which may ultimately result in reduced levels of opioid and oxytocin 
receptors observed in this current study. 
Unlike casein rich fed rats, casein free treated animals showed no depressive phenotype in the 
FST despite the neurochemical changes discussed.  In support of this, it has been shown that 
intraperitoneal administration of soymorphin-5, 6, and 7 at doses of 3-10 mg/kg resulted in 
anxiolytic behaviour as demonstrated by increased time spent in the open arms of the elevated 
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plus maze (Fukuda et al., 2011). Given the high co-morbidity between anxiety and depression, 
this could explain why casein free treated animals showed no signs of depressive-like 
behaviour unlike their casein rich counter parts despite eliciting similar neurochemical changes 
to the MOPr receptor in the CgCx and Acb of casein rich fed rats.  
Lastly, MOP receptor binding results revealed a significant casein only effect in the deep layer 
of the somatosensory cortex compared to control animals (see Figure 2.5).  Interestingly, this 
downregulation is concomitant with the depressive like phenotype observed in rats exposed to 
casein rich milk. Although it is impossible to prove any causality between MOPr 
downregulation and the emergence of depressive like behaviour based on this study alone, the 
possibility is intriguing. Indeed MOPr have been show to play a differential role in regulating 
emotional responses. MOPr KO mice have been shown to exhibit decreased anxiety and 
depressive like behaviour (Filliol et al., 2000), whilst acute pharmacological activation of 
MOPr was shown to reduce depressive-like behaviour in rodent models (Zhang et al., 2006).  
Moreover, a recent study has shown that MOPr play differential roles in mediating mood and 
behaviour depending on their location in the brain (Charbogne et al., 2017). Although a 
downregulation of MOPr was present in brain regions linked to emotionality, such as the 
hypothalamus and amygdala compared to control animals, no difference in MOPr density was 
observed in these regions compared to casein free animals. Thus, the possibility that the 
changes in these specific regions are driving the depressive phenotype seen in casein rich 
animals is unlikely. However, the deep layer of the somatosensory cortex showed a significant 
downregulation of MOPr in casein rich animals compared to both control and casein free. 
Altogether we can conclude that exposure to either casein rich or casein free (soya rich) milk 
during the sensitive early developmental period effects the endogenous opioid system in the 
brain. These results suggest that casein and its break down products (most likely BCM7) 
supress the development of MOPr in the deep layer of the somatosensory cortex, whereas soya 
 163 
(most likely its breakdown products soymorphins) supress the development of DOPr also in 
the deep layer of the somatosensory cortex. Interestingly this is the same region in which 
(Kitchen et al.,1995) observed a down regulation of DOPr in rats which were delayed weaned 
on PND25, indicating the somatosensory cortex is the main site of action of food derived opioid 
peptides. The behavioural consequences of these alterations should be the focus of future 
investigations.  Nonetheless, as the reduction of MOPr density in the deep layer of the 
somatosensory cortex of casein rich animals is concomitant with the depressive phenotype seen 
in this group, we can postulate that there may be a link between MOP receptor alterations and 
behaviour.  
Given the impact of experiences during early postnatal development, on shaping the central 
OTr system, including weaning time,  combined with the key role of oxytocin in emotional 
regulation, we hypothesised that dysregulation of the oxytocinergic system may be involved in 
the observed expression of depressive-like behaviour in animals provided with casein rich milk 
beyond the normal age of weaning. Indeed, the results obtained in this chapter revealed a 
significant down-regulation of OTr receptor density in the Basalmedial Amygdala (BMA) of 
casein rich treated animals compared to both casein free and control groups (see Figure 2.4). 
These results extend the findings by Farshim et al., (2016) who demonstrated that delayed 
weaning influences the stress-induced modulation of OTr density in the BLA amygdala. The 
current results go beyond that to demonstrate that it is a nutritional component, milk caseins, 
which are likely to be responsible for the alterations to OTr density in the amygdala observed 
in delayed weaned rat pups reported by Farshim et al., (2016). 
The amygdala is strongly implicated in the modulation of behavioural and neuroendocrine 
stress responses (see LeDoux 2000) in particular with respect to the OT system (Bale et al., 
2001; Neumann et al., 2000). Evidence shows that OT release in the amygdala can cause 
inhibition of the activity of neuronal populations that project to the hypothalamic and brainstem 
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areas regulating peripheral stress and fear responses respectively (Huber et al., 2005; Viviani 
et al., 2011). Furthermore a number of studies have shown that exposure to the FST which is a 
stressor (Abel, 1994), triggers OT release into the brain as shown by increased concentrations 
of OT in a number of brain regions known to be involved in the modulation of stress 
mechanisms such as the PVS, SON and the amygdala (Landgraf and Neumann 2004). Increases 
in OT release in the amygdala attenuates fear responses to stressful stimuli (which is believed 
to shift stress coping)  via a number of different mechanisms including regulation of the HPA 
axis activity (Neumann et al., 2000). Indeed studies have reported corticosterone levels to 
increase during and after the Forced swim test (Wotjak et al., 1998). Therefore OT release in 
the amygdala regulates active and passive stress-coping strategies under stressful paradigms 
(Ebner et al., 2005). 
Indeed, the antidepressive-like effects of oxytocin have been well documented. Arletti and 
Bertolini (1987) demonstrated that intra-peritoneal administration of OT both acutely and 
chronically decreased immobility time in the FST in mice. Furthermore, subcutaneous OT was 
found to decrease the number of escape failures in the learned helplessness test (Nowakowska 
et al., 2002) which is indicative of an antidepressant-like effect (Cryan et al., 2002). Moreover, 
activation of the oxytocinergic system have also been reported amongst depressed patients 
possibly as a homeostatic coping mechanism to counteract the depressive state (Purba et al., 
1996). It is therefore clear that oxytocinergic system is highly implicated in depressive like 
responses. However, it is unclear whether such alteration in the oxytocinergic system represent 
cause or consequence of depression.  
In this current study there are two likely possibilities for the down-regulation of OT receptors 
observed in the BLA of casein rich treated animals compared to both control and casein free 
groups. Firstly, casein rich milk is somehow causing these animals to become depressed and 
highly stressed, and therefore release higher levels of endogenous OT in the amygdala during 
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the FST as a coping mechanism that subsequently causes a significant down-regulation of OTr 
in the casein rich animals. In line with this, there is evidence to suggest that the high degree of 
plasticity in the OTr system may constitute a protective adaptive coping mechanism in response 
to stress resulting in a shift of brain function and behaviour (Neumann et al., 2012). Hence, 
these results indicate that casein rich animals were significantly more stressed compared to 
casein free and control as evidenced by the down-regulation of OTr in the BLA. Secondly, 
casein rich milk could be causing the depressive phenotype observed by dysregulating the OTr 
system and hence resulting in an absence of homeostatic stress coping mechanisms compared 
to casein free and control animals. Although it is not possible to prove any causal effect 
between the emergence of depressive like behaviour and hampered development of the OTr in 
casein rich treated rats. 
Exactly how casein rich milk is dysregulating the OT system remains unclear. However, the 
opioid system has been shown to interact with the oxytocinergic system in a number of studies 
(see Georgiou et al., 2015). In particular, acute morphine administration was shown to decrease 
hypothalamic OT release in female rodents (Haldaret al. 1978; Clarke et al. 1979). While 
Kovács et al., (1987) observed increased OT immunoreactivity in some regions including the 
amygdala of male mice, suggesting differential effects of acute opioid administration on OT 
neurotransmission in different areas of the brain. In this current study, it is feasible that opioid 
peptides derived from casein such as BCM-7 could be eliciting similar effects on the OT system 
resulting in a down regulation of OTr in the basal lateral amygdala. Furthermore, recent 
evidence linking the gut microbiota to the oxytocinergic system (Erdman et al., 2016) may 
implicate the gut microbiota as a key mechanism underlying the effect of prolonged casein 
consumption on the oxytocinergic system and behaviour.  As casein rich milk exposure results 
in alterations to the gut microbiome (see below), it maybe conceivable that milk caseins induce 
the depressive phenotype by a mechanism implicating the oxytocin-gut-brain axis.   
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In order to investigate the role of the gut-brain axis in mediating the neurochemical and 
depressive phenotype observed in casein rich treated animals, we sought to investigate the 
effects of casein rich vs. casein free milk diets from PND 21-PND 26 on the composition of 
several representative groups of intestinal microorganisms that have previously been 
implicated in modulating neurobehavioral development. The results obtained from the FISH 
analysis revealed negligible variation between casein free and casein rich treatment on total 
Bacteria (Figure 2.8) Bifidobacterium (Figure 2.10) and Lactobacillus (Figure 2.11) 
indicating that an additional 5 extra days of milk exposure was insufficient to increase the 
abundance of these bacterial genera. In contrast, the population of bacteria belonging to the 
C.histolyticum group were significantly increased in casein rich treated animals compared to 
casein free (see Figure 2.9). Coupled with the increase in depressive-like behaviour observed 
in these animals, it is feasible to suggest that casein exposure beyond the normal age of weaning 
could be acting via the gut-brain axis to result in a depressive phenotype.  
In line with this finding, Farshim et al., (2016) have previously shown that rat pups which were 
delayed weaned on PND25 harboured significantly higher numbers of C.histolyticum 
compared to animals weaned normally on PND21 after being exposed to the FST. These 
delayed weaned animals also showed a significant increase in depressive like behaviour 
(Farshim et al., 2016). Combined with the results from this current study, it is feasible to 
suggest that the increase in C.histolyticum seen in non-weaned animals was caused by 
prolonged exposure to milk caseins in particular rather than a general milk effect post weaning, 
as animals provided with casein free milk from PND21-PND25 did not display a similar 
increase in C.histolyticum. 
Clostridia are recognised as a group of toxin-producing bacteria and their metabolic products 
have been shown to exert systemic effects (Voth et al., 2005). Specifically they are known to 
produce five toxins including alpha, beta, delta, gamma and epsilon (Hatheway, 1990). It is 
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feasible that casein exposure resulted in an increase of C.histolyticum bacterial groups in the 
gut and subsequently an increase in the expression of toxic products in the bloodstream exerting 
effects on the developing brain. As such, it has been shown that the faecal microbiota of patients 
suffering from ASD were found to contain a higher number of C.histolyticum groups compared 
to healthy children (Parracho et al., 2005) indicating an association between clostridia and 
neurodevelopmental disorders. Moreover, an increase in clostridium species has previously 
been shown to increase with stress, together with increased levels of circulating cytokines 
(Bailey et al,. 2011). Indeed, one of the hallmarks of depression is increased levels of 
circulating pro-inflammatory cytokines (Dantzer et al., 2008). To this end, the effect of the gut 
microbiota on host immune system and in regulating behaviour via the gut brain axis has been 
well documented (see Bercik et al., 2012). Furthermore, it was also shown that stress induced 
increases in clostridia together with increasing levels of cytokines was shown to result in 
translocation of bacteria and/or their products (Janeczko et al., 2008). Indeed bacterial 
recolonization has previously been shown to be linked to mood disorders such as depression 
(Bailey et al., 2011; Maes 2008; Collins et al., 2009). Hence, providing a possible mechanism 
by which the increase in clostridia observed in casein rich treated animals could be causing the 
depressive phenotype observed in this group. 
Exactly how milk caseins result in increased levels of C.histolyticum bacterial groups remains 
unclear. However, a number of studies have indicated that protein casein levels do indeed effect 
microbial composition in the gut (Zhu et al., 2015; An et al. 2014; Rist et al., 2012). 
Furthermore Farshim et al., (2016) also found that  C.histolyticum groups were significantly 
higher in animals which were delayed weaned on PND25 following exposure to the FST 
compared to animals weaned normally on PND21. Combined with the findings from this 
current study, it is feasible to suggest that the increase of clostridia seen in non-weaned animals 
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was caused by exposure to milk caseins rather than a general milk effect beyond the normal 
age of weaning. 
The alterations observed in the gastrointestinal microbiota may also be a consequence of 
changes in gut motility caused by casein and its break down products (see Section 1.3). It has 
been previously shown that rats fed casein rich suspensions took longer in gastric emptying 
and gastrointestinal transit time then rats given a whey protein suspension (Daniel et al.,1990), 
these effects were found to be mediated by casomorphins including BCM-7 by acting on MOPr 
found in the luminal side of the gut (Daniel et al., 1990). In addition BCM-7 has also been 
shown to induce a strong release of gastrointestinal mucin secretion, again via MOPr mediated 
pathway (Zoghbi et al., 2006). These gastrointestinal effects of casein and its breakdown 
products could be altering gut conditions in casein rich treated animals to create favourable 
conditions, which promote growth of C.histolyticum bacterial populations. 
In order to investigate the metabolic impact of casein rich vs. casein free diets and the gut 
microbiota on the host, we studied urinary metabotypes from these two treatment groups. Urine 
is the preferred biofluid for the study of environmental impacts on host metabolism as it 
provides a measure of the environmental inputs that are absorbed from the gut environment, 
which can in turn interact with the host system and subsequently be excreted. From the 
metabolic phenotyping analysis, casein rich rats were observed to excrete greater amounts of 
betaine compared to casein free rats. Betaine is an endogenous metabolite of choline (Zeisel, 
1981a). Increased excretion of betaine in the urine of casein rich animals indicates increased 
choline metabolism induced by prolonged casein consumption. Choline is a micronutrient 
found in food which is involved in methyl metabolism, transmembrane signalling and is needed 
for the biosynthesis of the neurotransmitter acetylcholine which in turn plays an important role 
in normal brain development (Wessler et al., 2008).  Casein rich treated animals also excreted 
higher amounts of hippurate, a mammalian-microbial co-metabolite originating from bacterial 
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action upon plant phenols to produce benzoate, which then becomes conjugated with glycine 
in the liver to produce hippurate. Thus an increase in hippurate excretion as well as a decrease 
in the excretion of glycine in casein rich urine indicates increased gut microbial activity. 
Indeed, this is in line with the FISH analysis results, which showed an increase in bacteria 
belonging to C.histolyticum genera in the gut of casein rich treated rats. Together these findings 
indicate that consumption of milk caseins beyond the normal age of weaning may be acting via 
the gut brain axis to induce the depressive phenotype observed.  
In conclusion this study is the first to demonstrate that casein exposure beyond the normal age 
of weaning results in depressive-like behaviour in rats. Based on previous work from our lab, 
we hypothesised that this depressive phenotype would be driven by changes to the opioid 
system as well as alterations to the oxytocinergic system. Whilst autoradiographic binding 
revealed a significant down regulation of OTr in the amygdala of casein rich treated animals 
which may correlate to the depressive phenotype observed, MOPr and DOPr data was less clear 
cut. We observed region specific alteration to both MOPr and DOPr in both casein free and 
casein rich treated rats. Indicating a general milk effect independent of casein on modulation 
of the opioid system. However the deep layer of the somatosensory cortex appears to be a key 
region in which milk protein break down products (casomorphins or soymorphins) exerts its 
effects on the opioid system. These results further support the theory that early life 
environmental factors can influence the normal development of the brain. Furthermore, the 
findings in this chapter indicate that casein exposure alters the gut microbial and metabolic 
profiles of the host and thus provides evidence that casein may be acting via the Gut-brain axis 
to elicit its behavioural effects  
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Chapter 3 
Role of the Gut Microbiota in Mediating 
the Depressive Phenotype Induced by 
Prolonged Casein Exposure  
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3.1 Introduction 
 
Results obtained in Chapter 2 demonstrated that exposure to milk caseins beyond the normal 
age of weaning resulted in a depressive-like effect on offspring behaviour and also resulted in 
a shift in gut microbial composition, functionality and metabolic exchange with the host. These 
findings suggest a key influence of milk casein exposure in early postnatal life on behaviour 
and raise the potential for the gut microbiota to be involved in mediating this effect. With 
increasing evidence for a bi-directional interplay between the gut microbiota and the host brain, 
termed the gut-brain axis (Cryan and O’Mahony 2011), the role of the gut-microbiota in 
mediating the depressive-like phenotype caused by prolonged casein exposure was explored. 
Literature described in Chapter 1 Sections 1.5.3 to 1.5.5 provide strong evidence of a 
bidirectional communication system enabling gut microbes to communicate with the CNS and 
the CNS with the gut through direct and indirect pathways. These involve the endocrine (HPA 
axis), immune system, autonomic nervous system and enteric nervous system forming the gut-
brain axis. Alterations in these gut-brain interactions are believed to be involved in the 
pathogenesis of well-known brain-gut disorders such as IBS (see Kennedy et al., 2014) as well 
as a possible mechanism in the pathogenesis of mood disorders such as depression (see Dinan 
and Cryan, 2013; Naseribafrouei et al., 2014).  Multiple lines of approach have been used to 
interrogate the gut brain axis in animal models, including the use of GF animal models and 
antibiotics (AB) to determine the effects of dysregulating the axis (see Table 1.7). 
A study by Heijtz et al., 2011 showed that in comparison to conventional mice who were 
growing in a SPF environment, GF mice under the same experimental conditions displayed 
decreased anxiety like behaviour and increased 5-HT synthesis in the thalamus, confirming 
that gut microbiota play a role in normal brain function and behaviour. However, GF animals 
represent an extreme ‘microbial knock-out ‘model that lack morphological and physiological 
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characteristics associated with having an intact intestinal microbiota (see Luczynski et al., 
2016; Lundberg et al., 2016). Therefore, it is feasible to suggest this model does not provide a 
meaningful comparison with ‘conventional’ animals. An alternative model to investigate the 
role of the gut microbiota in health and disease is the use of antibiotics to inhibit gut flora 
activity. Dosing conventionally-raised animals with antibiotics allows the gut microbial 
populations and their activities to be temporarily suppressed whilst the conventional phenotype 
is preserved. This animal model is morphologically, physiologically and immunologically 
consistent with that of a conventional animal.  
Suppression of the microbiota through oral administration of antibiotics was first described by 
Van der Waaij  et al., (1968). Since then a number of studies have used a combination of 
antibiotics to deplete the gut microbiota and assess behaviour. For example a recent study by 
Desbonnet et al., (2015) used a combination of antibiotics to treat mice from weaning age 
onwards and assessed effects on behaviour. The results showed that antibiotic treatment not 
only resulted in depletion of the gut microbiota but also caused a reduction in anxiety-like 
behaviour as assessed by the light/dark box. These findings are in line with several other 
studies, which have demonstrated antibiotic treatment results in reduced anxiety in rodent 
models (Verdú et al., 2006; Bercik et al., 2011).  
In this study, a combination of antibiotics was used to investigate the role of the gut microbiota 
in mediating the effect of prolonged milk casein exposure on depressive-like behaviour. A 
variety of antibiotics, including bacitracin, kanamycin, neomycin, streptomycin and penicillin 
have been used in the past, either alone or in combination to effectively decontaminate the 
digestive tract (Verdú et al., 2006). Although the exact microbial composition of antibiotic 
(AB) treated animals cannot be controlled, different antibiotic dosing regiments can be used to 
selectively target different groups of microbiota. Here, penicillin and streptomycin sulfate were 
chosen due to their complementary bacteriocidal qualities. Penicillin G, is most effective 
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against Gram-positive bacteria (Rammelkamp et al.,1943), while streptomycin is effective 
against Gram-negative bacteria (Adcock et al., 1946). Both antibiotics are also poorly absorbed 
and so should not have a direct impact on host biochemistry. 
This research chapter will determine the microbial and metabolic impact of antibiotic treatment 
and casein rich or casein free milk exposure in rats. Results from this study will provide an 
insight into the role of the gut microbiota in mediating behavioural changes induced by changes 
in diet in early postnatal life.  
Hypothesis:   
 The depressive phenotype observed in animals exposed to casein rich milk beyond the 
standard age of weaning is mediated by the gut microbiota. As such, suppression of the 
gut microbiota through antibiotic treatment will inhibit the depressive phenotype 
observed after prolonged exposure to casein rich milk. 
Aim:  
 Investigate the role of the gut microbiome in mediating the depressive phenotype 
induced by prolonged casein exposure. 
Objectives:  
 Use the streptomycin/penicillin treated rat model to explore the role of gut bacteria in 
mediating the depressive phenotype induced by prolonged casein exposure.  
 Assess depression using the forced swim test.  
 Use fluorescence in-situ hybridisation (FISH) analysis to enumerate the intestinal 
bacterial populations of study animals following AB treatment. 
 Characterise the urinary metabolic profiles of the study animals using 1H nuclear 
magnetic resonance (NMR) spectroscopy to identify biochemical modulations induced 
by bacterial attenuation, casein consumption and combinations of the two. 
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3.2   Methodology  
 
3.2.1 Animals and Experimental Conditions  
 
Male, Wistar Albino rats were purchased from Charles River UK Limited, Kent. Six groups of 
animals each containing eight male pups plus their cross-fostered mother arrived at the 
Behavioural Research Facility (BRF) in St. Georges University of London on PND7, where 
day of birth is PND0. These animals were maintained in litters of 8 pups with their mothers at 
all times. Pups were left to acclimatize to their new environment for eleven days, after which 
point they were handled and weighed daily by the experimenter. The standard day of weaning 
in laboratory rats is on PND21, a process where the mother is simply removed from the cage 
(Cramer et al., 1990). Antibiotic-treated and control groups were all weaned on PND21. All 
rats were placed in a 12 hour light-dark cycle (lights on 6 AM -6 PM) with free access to a 
standard rat chow diet (purchased from SDS, Kent U.K) and tap water and kept at a constant 
temperature of 22°C ± 1 °C, humidity of 45-55%. All experimental procedures were conducted 
in accordance with the U.K Animal Scientific Procedures Act (1986).  
3.2.2   Antibiotic Treatment 
 
3.2.2.1   Control Animals 
 
Three experimental groups were generated, with each group containing 8 pups caged together. 
All three groups were provided with free access to rat chow and water throughout the duration 
of the study. The control group was weaned by having their mothers removed at 10:00 am on 
PND21.  The casein free group were also weaned on PND21 and subsequently provided with 
casein free milk formula from PND21 until the end of behavioural testing on PND26. The 
casein rich group were weaned on PND21 and provided with casein rich milk formula from 
PND21 until PND26. 
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3.2.2.2.      Antibiotic Treated Animals  
 
Three experimental groups were generated with each group containing 8 pups caged together. 
All three groups were provided with free access to rat chow and water throughout the duration 
of the study, and were all weaned by having their mothers removed at 10.00am on PND21.  On 
PND17 4mg/ml Streptomycin and 2mg/ml Penicillin G (Purchased from Sigma Aldrich) were 
added to 250ml of drinking water and provided to all three groups daily until PND21. On 
PND21, the control antibiotic (control AB) group continued to be provided with bottled water 
containing the antibiotic solution daily until the end of behavioural testing on PND26. The 
casein free antibiotic group (casein free AB) were provided with casein free milk formula 
mixed with the AB solution daily from PND21 until the end of behavioural testing on PND26. 
Similarly, the casein rich antibiotic group (casein rich AB) were provided with casein rich milk 
formula from PND21 until PND26, which was treated with antibiotic solution. As the AB 
solution was now being provided in the milk diets for both casein rich AB and casein free AB, 
both these groups were provided with normal tap water free of AB solution from PND21 
onwards. The antibiotic treatment was therefore effectively switched from the drinking water 
to the milk diets as pups provided with milk diets show a preference for milk over drinking 
water. Thus the switch would ensure the animals continued to receive their dose of antibiotics. 
 
 
 
 
AB free 
n= 8 each group  
Control AB  
Casein free AB 
Casein rich AB 
 
Control  
Casein free  
Casein rich  
 
AB treated 
n= 8 each group  
 
Figure 3.11: Diagram showing experimental groups in the antibiotic study. Antibiotic treated 
animals were dosed with 4mg/ml Streptomycin and 2mg/ml Penicillin G drinking water/milk for a total 
of 10 days.  
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3.2.3 Milk Diets  
 
The groups provided with casein free or casein rich milk with or without AB solution had milk 
freshly made up twice a day, once between 09:00-10:00 and again at 17:00-18:00. Milk diets 
were made as described in Section 2.2.2, for the formulations of casein free and casein rich 
milk diets please see Table 1.2.  
3.2.4 Body Weights, Milk and Water Consumption  
 
To monitor the general health of the animals, body weights were recorded daily from PND14 
until the end of behavioural testing on PND26 and also on the day of sacrifice. To monitor 
antibiotic treatment, water consumption was measured daily from PND17 until PND26. 
Similarly, milk consumption was measured daily from PND21 until PND26.  
3.2.5 Behavioural Testing- Forced Swim Test  
 
Behavioural testing was performed between 10am and 2pm when animals reached PND25 
using the forced swim test, which is run over two consecutive days (PND25 & PND26). The 
FST was run as described in Section 2.2.3. 
3.2.6 Collection of Urine  
 
Following the completion of behavioural testing on PND25 and PND26, animals were placed 
into individual metabolic cages for 24 hours with access to standard rat chow and water. On 
PND27 urine was collected from the cages for metabolic analysis (see Section 3.2.7). 
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3.2.7 Tissue Dissection  
 
Animals were killed by cervical dislocation on PND27 after acute exposure to CO2. Intact 
brains were dissected and rapidly frozen in isopentane at -20°C for 30 seconds and then stored 
at -80°C for quantitative receptor autoradiographic experiments. The carcasses were then 
transferred into a fume hood content from the caecum was collected and weighed (30-200 mg) 
into sterile 2 ml Eppendorf tubes and kept over ice and then stored in -80°C for use with 
fluorescence in situ hybridization experiments (see Section 3.2.9).  
3.2.8   Metabolomics of Urine Samples 
 
As described in Section 2.2.6 
 
3.2.8.1    Multivariate Data Analysis      
 
As described in Section 2.2.6.4  
 
3.2.8.2   Principal Component Analysis  
 
As described in Section 2.2.6.5  
 
3.2.9   Fluorescence in situ Hybridization (FISH) 
 
FISH analysis was carried out on caecal content collected from control, casein free, casein rich, 
control antibiotic, casein free antibiotic and casein rich antibiotic groups behaviourally tested 
on PND25 & PND26 and sacrificed on PND27, for the enumeration of total bacteria as 
described in Section 2.2.6. Prior to the dehydration stage (Section 2.2.9.4), EUB MIX probes 
were added and samples collected from non- antibiotic treated animals were diluted 1:300 using 
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sterile PBS/SDS diluent. However samples collected from antibiotic treated groups were 
diluted 1:20 due to a low number of bacteria.  
3.2.10    Data Analysis  
 
The weight change, water consumption, milk consumption and behavioural data for the FST 
were analysed using two-way ANOVA for factors “diet” and “AB treatment’ in GraphPad 
Prism 7. Where ANOVA revealed a significant difference an LSD post-hoc analysis was 
carried out. All data were expressed as means ± SEM, n = 8 per group. A p value of less than 
0.05 was accepted as significantly different. All statistical analyses were performed on 
GraphPad Prism 7. 
 
 
 
 
Postnatal Day
7 14 17 21 25 26 27
Antibiotic 
treatment 
begins in 
drinking water 
Mothers 
removed, 
casein free or 
casein rich milk 
provided 
Antibiotic 
treatment 
switched to 
milk 
Forced 
swim test 
Animals go 
into metabolic 
cages for 24 
hours 
Animals 
sacrificed, 
samples 
collected 
Animals 
weighed daily 
Figure 3.12: Experimental timeline showing key points in the methodology for antibiotic 
dosing study. 
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3.3     Results 
 
3.3.1 Water Consumption 
 
 
Male Wistar Albino rats were provided with free access to bottled water treated with or without 
antibiotics from PND17 until the end of behavioural testing on PND26. Water consumption 
was measured daily for this duration for all treatment groups. Two-way ANOVA for factors 
‘diet’ and ‘AB treatment‘ showed a significant ‘diet’ only effect on water consumption  [F (2,48) 
= 3.63; p < 0.05]. Post-hoc analysis showed animals provided with casein rich milk drank 
significantly less water than control treatment group (p < 0.05), furthermore animals provided 
with casein rich milk treated with AB drank significantly less water than both control AB and 
casein free AB treatment groups (p <  0.05) (Figure 3.3). 
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Figure 13.3:  Water consumption in rats provided with free access to bottled water treated with 
or without penicillin/streptomycin from PND17 until PND26. 
Mean daily water consumption in grams for control, casein free, casein rich, control antibiotic, casein 
free antibiotic and casein rich antibiotic groups from PND17 until PND26. Data are expressed as mean 
± SEM (n=9 readings). Animals provided with casein rich milk drank significantly less water 
than control treatment group, animals provided with casein rich milk treated with AB drank 
significantly less water than both control AB and casein free AB treatment groups (*p<0.05 
two-way ANOVA followed by LSD post-hoc test). 
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3.3.2 Milk Consumption  
 
 
Male Wistar Albino rats were provided with casein rich or casein free milk treated with or 
without antibiotics from PND21 until the end of behavioural testing on PND26 as well as being 
provided with free access to bottled tap water. Milk consumption was measured daily for this 
duration.  Two-way ANOVA for factors ‘diet’ and AB treatment showed a significant effect 
of both ‘diet’ [F (1,16) = 16.03; p < 0.001] and ‘AB treatment’ [F (1,16) = 4.742; p< 0.01] on 
milk consumption. Post-hoc analysis revealed animals provided with casein free AB milk drank 
significantly less milk than animals provided with casein free milk  (p < 0.05), and animals 
provided with casein rich AB milk (p < 0.001) (Figure 3.4). 
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Figure 3.14: Milk consumption in rats provided with casein free or casein rich milk treated with 
or without penicillin/streptomycin from PND21 until PND26. 
Mean daily milk consumption in grams for control, casein free, casein rich, control antibiotic, casein 
free antibiotic and casein rich antibiotic treated groups from PND21 until PND26. Data are expressed 
as mean ± SEM (n=4 readings). Animals provided with casein free AB milk drank significantly 
less milk than animals provided with casein free milk and animals provided with casein rich 
AB milk (*p<0.05 , ***p<0.001.  Two-way ANOVA followed by LSD post-hoc test) 
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3.3.3 Weight Change 
 
 
Male Wistar Albino rats were weighed daily from PND14 until the end of behavioural testing on 
PND26. Antibiotic treated groups (see Figure 1.3) were provided with water containing 
penicillin/streptomycin from PND17 until PND21. On PND21 appropriate groups were provided with 
casein free or casein rich milk treated with or without penicillin/streptomycin while control groups 
continued with or without antibiotic treatment in bottled water. Two-way ANOVA revealed no 
significant effect of diet or AB treatment on weight gain (Figure 3.5). 
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Figure 3.15: Effects of casein free and casein rich diets with or without penicillin/streptomycin 
treatment on body weight change from PND14 until PND26. 
Male Wistar albino rats were weighed daily from PND14 until the end of behavioural testing on PND26. 
Graph shows weight change in grams for control, casein free, casein rich, control AB , casein free AB 
and casein rich AB treatment groups. Data are expressed as mean ± SEM (n=8 per group). No difference 
in weight change was observed between all treatment groups (two-way ANOVA followed by LSD post-
hoc analysis). 
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3.3.4 Behaviour  
 
 
The FST was used to assess depressive-like behaviour on PND25 and PND26 in all the study 
animals. The total immobility time was scored from the ‘test’ session on PND26. The 
quantification from the ‘test’ times were then used in the assessment of depressive-like 
behaviour as described by Cryan et al., (2005). 
Two-way ANOVA for factors ‘diet’ and ‘AB treatment’ showed a significant interaction 
between both factors [F (2,29) = 14.76; p < 0.001], a significant ‘diet’ effect [F (2,29) = 4.395; p 
< 0.05] and a significant ‘AB treatment’ effect [F (1,29) = 23.27; p < 0.001]. Post-hoc analysis 
showed rats fed a casein rich diet displayed an increase in depressive-like behaviour as 
indicated by an increase in immobility time compared to casein free treated animals (p = 0.05). 
AB treatment caused a significant decrease in immobility times in both casein rich AB 
compared to conventional casein rich animals (p < 0.001) and control AB compared to 
conventional control animals (p = 0.01) but not in the casein free AB treatment group. 
Immobility exhibited by the casein free AB animals was significantly higher than both casein 
rich AB and control AB (p < 0.001) (Figure 3.6). 
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Figure 3.16: Immobility times exhibited by rats fed no milk, casein free or casein rich milk 
treated with or without streptomycin/penicillin from PND17 until PND 26 in the forced swim 
test. 
Male Wistar albino rats belonging to control, casein free, casein rich, control antibiotic, casein free 
antibiotic and casein rich antibiotic treated groups were subjected to behavioural testing using the FST 
on PND25 &26. Figure shows immobility time during the 6-minute test session on PND26. Data are 
expressed as mean scores (± SEM) (n=8) obtained from manual video analysis by one independent 
observer. Casein rich milk caused an increase in immobility time compared to casein free milk. AB 
treatment caused a significant decrease in immobility times in both casein rich AB and control AB but 
not casein free AB animals compared to conventional casein rich animals and conventional control 
animals. Immobility exhibited by the casein free AB animals was significantly higher than both casein 
rich AB and control AB. Two-way ANOVA followed by LSD post-hoc test was used and a p value equal 
to or less than 0.05 was accepted as significantly different. *p =0.05, ** p ˂ 0.01, *** p ˂ 0.001. 
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3.3.5 Assessment of Intestinal Microbiota (FISH)  
3.3.5.1 Assessment of Total Bacteria  
 
Male Wistar albino rats were provided with no milk, casein free or casein rich milk from 
PND21 until PND26. Antibiotic treated animals were provided with water containing 4mg/mL 
streptomycin and 2mg/ml Penicillin from PND17 until PND21, after which AB treatment was 
switched into their milk diets. Two-way ANOVA for the factors ‘diet’ and ‘AB treatment’ on 
the Log10 of total bacteria counts showed a significant ‘AB treatment’ effect only following 10 
days of AB treatment on total bacteria  [F (1, 38) = 21317;  p < 0.001]. Post-hoc analysis showed 
antibiotic treatment significantly reduced the average number of total bacteria (determined by 
EBU mix probes) contained within the caecal content in all AB treated groups compared to 
non AB treated animals (p < 0.001 ) (Figure 3.7). 
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Figure 3.7: Effect of 10 days of streptomycin/penicillin treatment from PND17 on the composition 
of total bacteria within the caecum of control, casein free and casein rich treated animals. 
Male Wistar albino rats were provided with no milk, casein free milk or casein rich milk from PND21 
until PND26. Antibiotic treated animals were provided with water containing 4mg/mL streptomycin 
and 2mg/ml Penicillin G from PND17 until PND21. On PND21 the control AB group continued to be 
provided with antibiotic solution in the drinking water until PND26 whereas casein free AB and casein 
rich AB groups were provided with antibiotic solution in the milk rather than in drinking water until 
PND26. All groups were subjected to behavioral testing on PND25 & PND26.  A mixture of EUB 338 
I, II and III probe were used for the enumeration of total bacteria in the caecum of study animals. All 
data expressed as mean log10   cells (g weight of intestinal content) -1 , S.E.M (n=8).. Two-way ANOVA 
followed by Bonferroni post--hoc test, a p value of less than 0.05 was accepted as significantly different, 
*** p˂0.001. 
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3.3.6 Metabonomic Analysis of Urine Samples 
 
3.3.6.1   PCA of Urine Samples: All data 
 
To gain an overview of how 10 days of AB treatment modulated the biochemical status of the 
animal, PCA analysis was used to identify metabolic variation in urinary profiles. The 
percentage of variance described by each PC (R2 ) is shown for each axis. Individual animals 
are color-coded in the scores plot to indicate their class membership. Figure 3.8 A shows two 
groups separating along the first PC. Animals receiving AB separated in the positive direction 
of PC1 (with the exception of a casein-rich AB animal) and AB-free treated animals separated 
in the negative direction of PC1 (with the exception of a control animal). To identify the 
metabolites driving this separation, the loadings for PC1 were investigated. Figure 3.8 B shows 
that AB treatment caused an increase in the excretion of energy metabolites citrate and glucose, 
choline metabolism metabolites betaine and TMAO and the amino acid ascorbate, while 
reducing the excretion of gut microbial metabolites hippurate and 4-HPPA, the amino acid 
taurine, choline metabolism metabolite DMA, and also reduced the excretion of acetate.  
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Figure 3.8: Effect of antibiotic treatment from PND17 until PND26 on host urinary metabolic 
profile. 
PCA model (R2 = 30.1%.) constructed on the urinary metabolic profiles of all study animals measured 
by 1H NMR spectroscopy. A) PCA scores plot showing separation along PC1 between AB-treated and 
AB-free groups. B) Corresponding loadings plot showing the metabolic features contributing to the 
separation observed in the PC1 scores plot. n= 3-4 per group Abbreviations: DMA: dimethylamine. 
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3.3.6.2  PCA of Urine Samples: Metabolic impact of casein exposure  
 
 
In order to examine the effect of casein exposure on metabolic profiles, pairwise comparisons 
were made between control, casein rich and casein free groups. Variation between urinary 
metabolic profiles from casein free and casein rich animals was observed along PC1 (Figure 
3.9 A). The corresponding loading plots shows that the excretion of  citrate, succinate and 
DMA was higher in the rats receiving casein free milk compared to those consuming casein-
rich milk (Figure 3.9 B) while excretion of creatinine, taurine, alanine and hippurate were 
lower compared to casein rich treated animals, with citrate being the main driving factor.  
PCA modelling of control versus casein rich treated animals shows clear separation along PC3 
(Figure 3.10 A). The corresponding loading plots identified that the excretion of betaine, 
TMAO taurine, and citrate was higher in control animals compared to rats consuming casein-
rich milk (Figure 3.10 B). 
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Figure 3.9: Effect of casein rich or casein free milk diets from PND21 until PND26 on host urinary 
metabolic profile. 
PCA model (R2 = 71.6%) constructed on the urinary metabolic profiles casein rich and casein free 
animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along PC3 
between casein rich and casein free groups. B) Corresponding loadings plot showing the metabolic 
features contributing to the separation observed in the PC3 scores plot. P shows the loadings vector 
values. n =3-4 per group.  Abbreviations: DMA; dimethylamine; TMAO: trimethylamine-N-oxide 
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Figure 3.17: Effect of casein rich milk or control diets from PND21 until PND26 on host urinary 
metabolic profile. 
PCA model (R2 = 84.5%) constructed on the urinary metabolic profiles of casein rich and control 
animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along PC3 
between casein rich and control groups B) Corresponding loadings plot showing the metabolic features 
contributing to the separation observed in the PC3 scores plot. P shows the loadings vector values. n=3-
4 per group Abbreviations: DMA; dimethylamine; TMAO: trimethylamine-N-oxide 
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3.3.6.3    PCA of Urine Samples: Metabolic impact of microbial suppression  
 
To assess the metabolic impact of AB treatment, the urinary metabolic profiles of control rats 
were compared with control rats that received AB using PCA analysis (Figure 3.11 A). 
Separation between the two groups was observed along PC3 and the corresponding loadings 
plot for PC3 identified citrate, ascorbate, betaine, alanine and taurine to be reduced with 
antibiotics while DMA and 2-oxoglutarate were increased (Figure 3.11 B) with taurine and 
citrate being the main driving factors.  
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Figure 3.18: Effect of microbial suppression from PND17 until PND26 on urinary metabolic 
profiles of control and control AB treated rats.  
PCA model (R2 = 93.7%) constructed on the urinary metabolic profiles of control and control with 
antibiotic animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along 
PC3 between control and control with antibiotic treatment groups. B) Corresponding PC3 loadings plot 
showing the metabolic features contributing to the separation observed in the PC3 scores. n=3 per group 
Abbreviations:  AB: antibiotic; DMA: dimethylamine.  
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3.3.6.4     PCA of Urine Samples: Metabolic Impact of Microbial 
Suppression in Casein Rich Treated Animals  
 
 
AB treatment was found to ameliorate the behavioural alterations induced by casein rich milk 
exposure.To assess whether AB treatment modified the metabolic changes associated with 
casein-rich milk intake, the urinary metabolic profiles of the rats receiving casein rich milk 
were compared with those receiving casein rich milk plus AB (Figure 3.12 A). Differences 
were observed between the two groups with the profiles separating along PC1. Casein rich milk 
plus antibiotics cause an increase in taurine, betaine, alanine, ascorbate, citrate and succinate 
while causing a decrease in DMA excretion as well as acetate compared to casein rich animals. 
(Figure 3.12 B) 
 To assess the metabolic impact of both casein and AB treatment combined, the urinary 
metabolic profiles of rats consuming casein rich milk with AB were compared with control rats 
using PCA analysis (Figure 3.13 A).  Differences were observed between the two groups with 
the profiles separating along PC3 with taurine and citrate excretion increasing as a result of 
casein and AB treatment, while hippurate, alanine, ascorbate, DMA, arginine, 2-OG and 
acetate are decreased (Figure 3.13 B). 
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Figure 3.19: Effect of microbial suppression from PND17 until PND26 on urinary metabolic 
profiles of in casein rich and casein rich AB treated rats. 
PCA model (R2 = 73%) constructed on the urinary metabolic profiles of casein rich and casein rich with 
antibiotic animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along 
PC1 between casein rich and casein rich AB treatment groups. B) Corresponding PC1 loadings plot 
showing the metabolic features contributing to the separation observed in the PC1 scores. P shows the 
loadings vector values. n=3-4 per group Abbreviations:  AB: antibiotic; DMA: dimethylamine.  
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Figure 3.20: Effect of microbial suppression from PND17 until PND26 on urinary metabolic 
profiles of control and casein rich AB treated rats. 
PCA model (R2 = 93.9%) constructed on the urinary metabolic profiles of casein rich with AB and 
control animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along PC4 
between casein rich with AB and control treatment groups. B) Corresponding PC4 loadings plot 
showing the metabolic features contributing to the separation observed in the PC4 scores. P shows the 
loadings vector values. Abbreviations:  AB: antibiotic; DMA: dimethylamine; 2-OG; 2-oxoglutarate 
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3.3.6.5     PCA of Urine Samples: Metabolic Changes in Casein Free 
Animals Following Microbial Suppression  
 
 
The metabolic impact of AB treatment in animals provided with casein free milk was assessed 
through a pair-wise PCA model comparing urinary profiles from casein free rats and casein 
free AB treated rats. Figure 3.14 A shows the two groups separate along PC1. Excretion of 
glucose, DMA, DMG, TMAO and taurine were increased in casein free AB animals, while 
citrate, succinate, acetate, Hippurate and 3-HPPA were reduced (Figure 3.14 B).  
To assess the metabolic impact of both casein free milk and AB treatment combined the urinary 
metabolic profiles of rats consuming casein free milk with AB were compared with control rats 
using PCA analysis (Figure 3.15 A).  Differences were observed between the two groups with 
the profiles separating along PC3. Unlike AB treatment in casein rich animals, AB treatment 
in casein free animals increased the excretion of TMAO, leucine and ascorbate, while causing 
a decrease in the excretion of creatine. Consistent with AB treatment in casein rich animals, 
AB treatment in casein free animals caused an increase in the excretion of taurine while DMA 
excretion was reduced (Figure 3.15 B). 
Table 3.1 provides a summary of 1H-NMR chemical shifts for the metabolites identified in 
urine samples from all six-treatment groups.  
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Figure 3.21: Metabolic impact of microbial suppression from PND17 until PND26 on urinary 
metabolic profiles of animals provided with casein free and casein free AB milk. 
PCA model (R2 = 60.2%) constructed on the urinary metabolic profiles of casein free and casein free  
with AB animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along 
PC1 between casein rich with AB and control treatment groups. B) Corresponding PC1 loadings plot 
showing the metabolic features contributing to the separation observed in the PC1 scores. P shows the 
loadings vector values. n= 2-3 per group Abbreviations:  AB: antibiotic; 3-HPPA: 3-
hydrophenylpropionate; DMA: dimethylamine; DMG: dimethylglycine; TMAO: trimethylamine-N-
oxide 
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Figure 3.22: Metabolic impact of microbial suppression from PND17 until PND26 on urinary 
metabolic profiles of animals provided with casein free AB milk and control treatment group. 
PCA model (R2 = 100%) constructed on the urinary metabolic profiles of casein free with AB and 
control animals measured by 1H NMR spectroscopy. A) PCA scores plot showing separation along PC3 
between casein free with AB and control treatment groups. B) Corresponding PC3 loadings plot 
showing the metabolic features contributing to the separation observed in the PC3 scores. P shows the 
loadings vector values. n= 2-3 per group Abbreviations:  AB: antibiotic; DMA: dimethylamine; TMAO: 
trimethylamine-N-oxide 
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Table 3.13: Summary of  1H-NMR chemical shifts for metabolites associated with alterations following antibiotic treatment and casein free or casein 
rich milk treatment. (+) indicates higher excretion (positive correlation)  in the treatment group (identified according to the corresponding colour); ( - ) , lower 
excretion ( negative correlation) in the relevant control groups (identified in black colour) and  ‘-‘ represents absent peak or no significant difference found 
between the corresponding groups. Metabolites were assigned using the literature and available databases. The metabolites identified have been separated 
according to metabolic pathways they are mainly involved in.  Abbreviations: 3-HPPA:  3-hydrophenylpropionate; TMAO: trimethylamine-N-oxide  DMA; 
dimethylamine; DMG: dimethylglycine; AB: antibiotic; CR: casein rich; CF: casein free; CTRL: control.
Metabolite  
Chemical Shift  AB CR CTRL CTRLAB CRAB CRAB CFAB CFAB 
(Multiplicity) vs  
No AB 
vs  
CF 
vs  
CR 
vs  
CTRL 
vs  
CR 
vs 
CTRL 
vs  
CF 
vs 
CTRL 
Microbial Derived  
3-HPPA 2.44 (t), 3.02(t) ( - )  − − − − −  ( - )  − 
Acetate 1.93 (s) ( - )  − − − ( - )   ( - )  − − 
Hippurate 7.8 (d), 7.6 (t), 7.5 (d)  ( - )  ( + ) − − −  ( - )   ( - )  − 
Choline Metabolism 
Betaine 3.91 (s) 3.27 (s) ( + )  − ( + ) ( - )  ( + ) − ( - )  − 
TMAO 3.2 (s) ( + )  − ( + ) − − − ( + )  ( + ) 
DMA 2.7 (s) ( - )  ( - ) ( - )  ( + ) ( - )   ( - )  ( + )  ( - )  
DMG 2.9 (s) − − − − −  ( - )  ( + ) − 
Energy Metabolism  
2-oxoglutarate 2.44 (t) − − −  ( + ) −  ( - )  − − 
Citrate 2.71 (d), 2.56 (d) ( + )  ( - ) ( + )  ( - )  ( + ) ( + )  ( - )   ( + ) 
Glucose 5.2 (d) ( + )  − − − − −  ( + ) − 
Succinate 2.41 (s) − ( - ) − − ( + ) −  ( - )   ( - )  
Other 
Alanine 3.77 (q) − ( + )  ( - )  ( - )  ( + )   ( - )  − − 
Arginine  3.2 (t) − − − − −   ( - )  − − 
Creatinine  3.0 (s) − ( + ) − ( - )  − − −  ( - )  
Ascorbate 4.5 (d) ( + )  − − ( - )  ( + )  ( - )   ( - )   ( + ) 
Leuicine  3.72 (m) − − − − − − −  ( + ) 
Taurine 3.43 (t) 3.28 (t) ( - )  ( + ) ( + ) ( - )  ( + ) ( + ) ( + )  ( + ) 
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3.4 Discussion  
 
The aim of this study was to investigate if the gut microbiota plays a role in mediating the 
depressive-like phenotype observed in animals provided with casein rich milk beyond the normal 
age of weaning. To achieve this, the abundance and activity of the gut microbiota was temporarily 
suppressed for 10 days from PND17 through the administration of penicillin and streptomycin in 
the drinking water/ milk diets. To assess the diet-microbiota-biochemical host cascade and its 
impact on behavioural development, the bacterial load was measured in the intestinal contents 
using FISH analysis, biochemical alterations associated with antibiotic and casein exposure was 
characterized by 1H NMR spectroscopic analysis of urine samples, and finally depressive-like 
behaviour was determined using the FST. The effect of antibiotic treatment alone, independent of 
casein was also investigated.  
Following 10 days of antibiotic treatment the total number of bacteria present in the gut was 
markedly reduced with accompanying changes in the excretion of numerous metabolites including 
those derived from gut microbial metabolism. We also observed a profound antibiotic effect on 
behaviour in both control and casein rich treated rats but not in casein free. These results provide 
evidence for a role of the gut microbiota in mediating depressive-like behaviour.  
A rat model representing a gut free of bacteria was established by dosing rat pups belonging to the 
AB treatment groups (see Figure 3.1) with penicillin and streptomycin for a total of 10 days 
starting on PND17.  Animals belonging to the AB treatment groups were all weaned on PND21 
after which point one group received no milk (control AB), casein rich milk (casein rich AB) or 
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casein free milk (casein free AB). Matched controls were established by having the same exact 
three treatment groups but with no AB administered.  
Water consumption data showed a significant effect of diet but not AB treatment on water 
consumption. Rats provided with casein rich milk with or without antibiotics consumed 
significantly less water compared to control, control AB as well as casein free AB treatment groups 
(see Figure 3.3), indicating that rats preferred to drink casein rich milk over water, whether it 
contained antibiotics or not. Animals provided with casein free milk treated with AB drank 
significantly more water than animals provided with casein rich AB milk, indicating these animals 
preferred to drink water for hydration rather than the casein free milk treated with antibiotics. 
Indeed casein free AB animals consumed similar levels of water as the control group who only 
had access to bottled water. Milk consumption data confirms these findings and shows a significant 
AB and diet effect on milk consumption in that casein free AB animals consumed significantly 
less milk compared to all other groups provided with milk diets (see Figure 3.4). Furthermore, 
milk consumption data shows that animals provided with casein free milk consumed less milk than 
the casein rich group although this was not statistically significant; it indicates that in general, 
animals showed less of a preference towards casein free milk with or without AB. These results 
are in line with findings from the previous results chapter  (see Section 2.3.1) as well as findings 
from Goody & Kitchen, (2001) which both  showed rat pups provided with casein rich milk 
consumed significantly greater amounts compared to animals provided with casein free milk.  
Interestingly, unlike the significant differences in weight gain observed in results Chapter 2 
following casein rich milk treatment in comparison to casein free treated animals, no significant 
weight differences were observed between all 6-treatment groups in the current study, indicating 
that the varying milk diets with or without antibiotics had no effect on weight gain (see Figure 
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3.5). It should be noted however that the casein free AB free treatment group displayed lower body 
weights compared to all other treatment groups but this was not significantly different. Similarly, 
in results Chapter 2 it was the casein free treatment group which had the lowest weight gain, 
further indicating a soy protein effect on milk consumption and subsequent weight gain as 
discussed in detail in Section 2.4. 
The results obtained from FISH analysis showed that following 10 days of AB administration the 
average number of total bacteria contained within the caecum was reduced from 10.1 log10 cells.g 
in AB-free rats, to 6.7 log10 cell/g in AB treated groups. This is in line with findings from Swann 
et al., (2011) who dosed 10 week old male rats for 8 days with the same daily dose of 
penicillin/streptomycin and found the average total number of bacterial cells contained within 
intestinal contents was reduced from 10.7 log10 cells/g in control animals to 8.4 log10 cells/g in AB 
treated animals. These findings show that AB regime used in this study is capable of successfully 
suppressing the gut microbial profile of rat pups.  
The results obtained from the FST showed a significant diet and AB effect on immobility and more 
importantly a significant diet and AB interaction effect. Animals provided with casein rich milk 
without AB treatment, exhibited depressive-like behaviour as evidenced by a significant increase 
in immobility time in the FST compared to animals provided with casein free milk (no AB) (see 
Figure 3.6). This confirms findings from the previous results chapter (see Section 2.3.2) and 
further confirm that casein exposure beyond the age of weaning results in a depressive phenotype 
in rats. Interestingly, we observed a profound reduction in immobility time in AB treated control 
and AB treated casein rich animals demonstrating an ‘antidepressive-like’ effect of AB treatment 
at least in these two groups of animals. This is in line with behavioural data from a number of 
studies including Bercik et al., (2011) who show that following 7 days of AB treatment, mice 
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exhibited more exploratory and less apprehensive like behaviour than controls in the light/dark 
box indicating an anxiolytic-like effect of AB treatment. They also showed that AB treated mice 
had increased levels of hippocampal BDNF levels (Bercik et al., 2011). An increase in BDNF 
levels in the hippocampus has been shown to be associated with anxiolytic and antidepressant 
behaviour (Deltheil et al., 2008) further supporting the anti-depressant like effect caused by AB 
treatment in control and casein rich animals. Furthermore, Desbonnet et al., (2015) showed that 
mice who were treated with a combination of AB from weaning age onwards  had a depleted gut 
microbiome and displayed reduced anxiety further supporting the finding that AB treatment in 
early postnatal life results in alterations to behaviour. Thus, the antidepressive-like effect of AB 
treatment reported in our study is not likely to be mediated by any other mechanism aside from its 
effect as an antimicrobial agent, as similar anxiolytic changes are reported in GF mice in which 
bacteria are absent from birth (Heijtz et al., 2011; Neufeld et al., 2011). Taken together, these 
findings further support the link between gut microbial suppression using antibiotics with 
alterations to mood.  
In support of the antibiotic induced antidepressive-like behaviour reported here, the antibiotic 
minocyline has been show to illicit antidepressive-like effects via the immune system. Pro-
inflammatory agents such as Interleukin-1 beta (IL-1β) and Tumour Necrosis Factor alpha (TNF-
α) are believed to be amongst the most important players in the pathogenesis of depression and 
anxiety related behaviours (see Singhal et al., 2017). Indeed Majidi et al., (2016) showed that 
following neonatal injection with Eschichia coli, mice went on to develop anxiety and depression 
like behaviour in adulthood accompanied by increased expression of glial cell markers, IL-1β and 
TNF-α in the hippocampus. Treatment with minocycline was able to attenuate Eschichia coli 
induced expression of pro-inflammatory cytokines and reverse depressive-like behaviour by 
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reducing immobility time in the FST.  These findings were replicated in a similar study by Zheng 
et al., (2015) who also showed minocycline treatment resulted in attenuation of LPS-induced 
increase of pro-inflammatory cytokines and depressive-like behaviour.  In line with this, it has also 
been shown that minocycline attenuates LPS-induced neuroinflammation, sickness behaviour and 
anhedonia in adult mice through reduced microglial activation and decreased mRNA levels of IL-
1β in the hippocampus (Henry et al., 2008). Collectively, these studies suggest antibiotics may be 
acting directly via the immune system to elicit their anti-depressive like effects. Indeed in this 
present study, 10 days of AB treatment was shown to result in a reduction in total bacteria 
accompanied with a reduction in gut microbial metabolites as shown by metabolomic analysis, 
which could indicate a reduction in immune system activation and in turn explain the protective 
effect AB treatment displayed against the development of depressive like phenotype observed in 
casein rich treated animals. In future it would be useful to measure inflammatory markers in control 
and casein rich treated animals with or without AB to determine whether or not the gut microbiota 
is interacting with the immune system in mediating the behavioural changes observed. 
As the results from the FST showed that immobility time was decreased in the control rats treated 
with AB compared to control rats that did not receive AB, it suggests the antibiotic treatment, 
independent of casein, reduced immobility time in the FST. It should also be noted that in general 
AB treated animals were a lot more active and harder to handle than control animals and as a 
personal observation from the experimenter, even displaying signs of aggression. These 
observations are in line with Leclercq et al., (2017) who reported decreased anxiety like behaviour 
and increased aggression as well as persistent alterations to the gut microbiota in mice following 
penicillin treatment during the perinatal period. 
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One of the limitations of this study is the lack of measurement of locomotor activity in the groups 
of animals exposed to the FST to exclude the possibility that the changes in immobility observed 
between the groups merely represent changes in locomotion rather than mood. Nonetheless, this 
is unlikely to be the case as Leclercq et al., (2017) measured locomotion using the open field test 
following early life penicillin treatment in mice and reported no difference in locomotion. This is 
also in line with findings from Molina-Hernández et al., (2008) who also showed minocycline 
treatment did not induce hyperlocomtion and in some cases even decreased motor activity. These 
findings support the hypothesis that the effects of AB treatment on the FST results are unlikely to 
be driven by increased motor activity.  
Interestingly, animals provided with casein free milk treated with AB did not display the same 
drastic decrease in immobility time in the FST as the control and casein rich AB treated animals. 
To the contrary, they displayed immobility times in the same range as AB-free animals. This 
indicates that AB treatment had no effect on behaviour in casein free treated animals. It is possible 
the casein free AB group did not receive the same dose of AB as control and casein rich AB 
treatment groups as milk consumption data shows casein free AB treated animals consumed 
significantly less milk than all the other groups provided with milk diets. As AB treatment was 
switched into the milk diets from PND17, this could indeed suggest these animals received a lower 
dose of AB and therefore did not display the same ‘anti-depressive’ like behaviour observed 
following AB treatment. In line with this hypothesis, the study by Bercik et al., (2011) discussed 
above showed that smaller doses of AB treatment failed to influence anxiety like behaviour in 
mice suggesting that the changes in bacterial composition caused by AB treatment, are responsible 
for the changes in anxiolytic behaviour observed in their study. Although FISH analysis data 
showed that the gut microbiota of casein free AB animals was indeed suppressed to the same extent 
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as the other AB treatment groups, it could be argued that a lower dose of AB in these animals 
resulted in a different compositional makeup of the gut microbiome. Indeed Swann et al., (2011) 
used FISH analysis for the enumeration of several key bacterial groups following 8 days of 
antibiotic treatment. They observed that the relative proportions of bacteria belonging to the 
Bacteroidetes phylum were reduced, while bacteria belonging to the Firmicutes and 
Actinobacteria phyla were increased, suggesting not only does antibiotic treatment suppresses the 
total bacteria in the gut, but also results in shifts to the compositional makeup of the gut 
microbiome. Furthermore, Leclercq et al., (2017) also reported an increase in Proteabacteria due 
to increased penicillin resistance Enterobacteria family following penicillin treatment in early 
postnatal life in mice, this bacterial group is a potential source of lipopolysaccharides, which are 
endotoxins and can elicit a strong immune response in the host. This increase in Enterobacteria 
following penicillin treatment has been reported in other studies alongside decreased anxiety like 
behaviour (Candon et al., 2015; Desbonnet et al., 2015). Given this evidence it may be possible to 
suggest that casein free AB animals did not receive the same dose of penicillin and thus did not 
harbor the same increase in Enterobacteria thus displaying a similar behavioural profile to AB-
free treated animals. In future it would be of use to characterize the faecal microbiota of casein 
free AB study animals versus control and casein rich AB groups to determine any compositional 
differences in the microbiome of these animals which could in turn be linked to the discrepancies 
in behaviour.  
Another explanation for the lack of antidepressive-like effect of AB treatment in casein free 
exposed rats may be due to soy protein exposure, which was used as the protein substitute for 
casein in casein free milk.  As discussed in the previous results chapter (see Section 2.4), exposure 
to soy rich/casein free milk induces a number of region specific neurochemical changes to MOPr 
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in the brain as well as a down regulation of DOPr in the deep layer of the somatosensory cortex 
compared to control and casein rich treatment via an unknown mechanism. As it has been shown 
that peptides derived from soy protein named soymorphins possess opioid receptor activity 
(Kaneko et al., 2010; Ohinata et al., 2007), it is tempting to speculate that the resistance of soya 
fed animals to exhibit the ‘anti-depressant’ like effect induced by AB treatment may be due to a 
gut microbiota independent effect of soymorphines, which may have contributed a protective 
effect against behavioural changes induced by AB treatment.  These results indicate a soy effect 
on behaviour which warrants further investigation.  
The excretion of urinary metabolites were studied using NMR based metabonomics in order to 
investigate the metabolic impact of diet  (milk casein exposure beyond the normal age of weaning) 
and AB treatment in early postnatal life on the host metabolic profile. Pairwise PCA models were 
built to identify metabolic variation between the different study groups. This included: the effect 
of casein consumption alone on host metabolic profile, the effect of AB treatment alone on host 
metabolic profiles, the effect of AB and casein rich treatment and finally the effect of AB treatment 
and casein free treatment on host metabolic profiles. Loading plots were generated from each 
pairwise PCA model showing the metabolites   (1H NMR chemical shifts) responsible for any 
separation witnessed in the PCA scores plot.  The corresponding loading plots indicated that the 
most significant metabolic differences induced by AB and casein treatment were related to 
disruptions in the metabolism of choline and energy homeostasis as well as differences in 
microbial-derived metabolites (Summarized in Table 3.1).  
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Metabolic Alterations Caused by Casein Intake 
 
A decrease in the excretion of betaine was observed in the urine of casein rich animals compared 
to the control group (see Figure 3.10). This may be related to a decrease in endogenous choline 
metabolism by the host or may suggest an increase in bacterial choline degradation in the gut. 
Choline is a micronutrient found in food and serves as the precursor for the biosynthesis of the 
phospholipids, phosphotadylcholine and sphingomyelin which are essential constituents of 
membranes and play key roles in normal brain function and development (Zeisel, 1981, 2006). 
Moreover, choline is needed for the synthesis of the neurotransmitter acetylcholine which plays 
an important role in influencing the structure and organization of brain regions, neurogenesis, 
myelination and synapse formation (Wessler et al., 2008). Choline is metabolized within liver 
mitochondria and converted into betaine by two enzymes betaine aldehyde dehydrogenase and 
choline dehydrogenase. Alternatively, dietary choline can be metabolized by the gut microbiota to 
trimethylamine (TMA). TMA is subsequently absorbed from the gut and oxidized in the liver to 
form trimethylamine-N-oxide (TMAO) before being excreted in the urine. Interestingly, casein 
rich treated animals excreted lower amounts of TMAO compared to the control group. Taken 
together with the lower excretion of betaine, these observations suggest that animals receiving 
casein rich milk until PND26 obtain less choline from the diet then the control animals 
 The reduced excretion of betaine could be indicative of disruption to the metabolism of choline. 
This is consistent with the findings of  Farshim et al., (2016) who  reported that animals who were 
delayed weaned on PND25 excreted decreased levels of betaine compared to animals who were 
normally weaned on PND21 and also displayed a depressive phenotype in the FST (Farshim et al., 
2016). These observations indicate that prolonged consumption of milk caseins beyond the normal 
age of weaning disrupt choline metabolism and could potentially be linked to the depressive 
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phenotype observed in casein rich treated animals. Indeed a series of studies conducted by Zheng 
and colleagues have shown alterations in TMAO and betaine in depressive states in both human 
and rodent models (Zheng et al., 2011, 2013; Huang et al., 2015). For example, Zheng et al., 
(2013) showed that urinary levels of betaine and TMAO were significantly decreased in patients 
with major depressive disorder compared to healthy controls (Zheng et al., 2013). These findings 
further reinforce that disruptions to choline metabolism may indeed be linked to the depressive 
phenotype observed in casein rich treated animals observed in our study. Interestingly, data 
obtained in results Chapter 2 showed that animals fed casein rich milk excreted higher amounts of 
betaine compared to casein free counter parts. This is in conflict with the current results and may 
requires further investigation.   
Casein consumption appears to have caused alterations in metabolites associated with energy 
metabolism. Urinary excretion of three tricarboxlic acid (TCA) cycle associated metabolites, 
citrate, succinate and 2-oxoglutarate were shown to be excreted at lower levels in the urine of 
casein rich treated animals compared to control and casein free groups, thus highlighting a casein 
effect on energy metabolism (see Figures 3.9 and 3.10).  Decreased levels of succinate, citrate 
and 2-oxoglutarate in casein rich animals are indicative of a dysfunction in the TCA cycle induced 
by casein, which may in turn be associated with the depressive phenotype observed in this group.  
In line with this  Zheng et al., (2010) carried out a study to look at urinary metabolic changes in 
chronic unpredictable mild stress model of depression and observed  decreased citrate and 2-
oxoglutarate in the urine of the depressed rats compared to control (Zheng et al., 2010). 
Furthermore Farshim et al., (2016) also reported decreased levels of citrate, succinate and 2-
oxoglutarate in the urine of rats who were delayed weaned on PND25 and displayed depressive 
like behaviour compared to animals weaned normally on PND21 (Farshim et al., 2016). Taken 
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together these findings suggest that exposure to milk caseins beyond the normal age of weaning 
results in disruptions to the TCA cycle and this may be linked to the development of the depressive 
phenotype observed. The lower levels of TCA cycle metabolites observed in casein rich animals 
indicate energy deficiencies and fatigue, which is in line with the increased immobility times 
observed in casein rich rats, as well as the behavioural data from chapter 2, where a significant 
decrease in active swimming and climbing behaviours was observed in casein rich treated animals 
during the FST. It should also be noted that energy deficiencies or fatigue are amongst the most 
popular reported symptoms of depression. 
Creatinine is another metabolite associated with energy metabolism, which was found to be 
increased in casein rich treated rats compared only to the casein free group and not control. 
Creatinine is a non-protein nitrogenous compound derived from creatine and phosphocreatine 
metabolism. The creatine-phosphocreatine system acts as an energy transport system which carries 
high-energy phosphates from mitochondrial production sites to energy utilization sites, 
particularly in tissues with high energy demands like skeletal or cardiac muscle as well as the brain 
(Wyss et al., 2000). Excretion of creatinine in the urine represents the endpoint of endogenous 
energy transfer from stored adenosine triphosphate (ATP) in cells. It is becoming increasingly 
evident that endogenous creatine plays a critical role in a range of cognitive functions including 
emotion (see Allen, 2012). In fact, there is evidence to show that supplementation with 4% creatine 
for five weeks in male rats results in increased depressive like behaviour in the FST (Allen et al., 
2010). Moreover, this is also in accordance with findings from Farshim et al. (2016) who reported 
increased creatinine excretion in animals who were exposed to mothers milk for 5 extra days  
compared to animals weaned normally on PND21. Together these findings further implicate casein 
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consumption in influencing energy metabolic products, which may be linked to the depressive 
phenotype observed in the casein rich group 
 
Metabolic Alterations Caused by Microbial Suppression 
 
In order to assess the metabolic impact of AB treatment all AB treated animals were compared 
against animals which did not receive AB. Consistent with the FISH results showing a suppressed 
gut microbial profile in AB treated rats, PCA analysis of urine samples collected from all six 
treatment groups revealed differential metabolic patterns of clustering between AB-free and AB 
treated groups (See Figure 3.11). The corresponding loadings plot showed metabolites involved 
in energy metabolism such as glucose and citrate were increased in AB treated animals as well as 
an increase in choline metabolism as indicated by increased TMAO and betaine in AB treated 
urine. Meanwhile bacterial metabolites such as hippurate and 4-HPPA were decreased in 
comparison to control AB-free treated groups. These findings suggest that treatment with a 
combination of penicillin/streptomycin for a period of 10 days was indeed sufficient in causing 
disruption to the gut microbiome and subsequently host metabolic profile.  
In order to assess the metabolic impact of AB treatment alone independent of milk type on host 
metabolic profiles, a pairwise comparison between control and control AB treated animals was 
performed. An increase in the excretion of the metabolite DMA was observed in control AB 
animals compared to the control group. TMA can be further demethylated by the gut microbiota 
to DMA. The fact that we see an increase in DMA following AB treatment is surprising, however 
this metabolic function may be ubiquitous amongst the gut microbial species. Hence, AB-
associated disruption of the gut microbiota may reduce the specific functionalities associated with 
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a particular bacterial group and increase the general traits of the communities left behind. 
Furthermore, we observed an increase in the excretion of 2-oxoglutarate in control AB treated 
animals, which is a TCA cycle associated metabolite. An increase in this metabolite indicates 
increased energy release. Indeed, this is in line with the behaviour observed in control AB treated 
animals who displayed an antidepressive-like effect as shown by a drastic increase in swimming 
behaviour in the FST compared to the control AB-free group.  
 
Metabolic Alterations Caused by Microbial Suppression in Casein Rich Rats 
 
Pair wise comparisons were made between casein rich, casein rich AB, control AB and control 
treatment groups to study the effects of AB treatment in rats exposed to a casein rich milk diet. 
Consistent with bacterial suppression post AB treatment in control animals and not casein free 
animals, the gut microbial metabolite hippurate was excreted in lower amounts in casein rich AB 
animals when compared to control (see Figure 3.13), and in the urine of control AB animals when 
compared to casein rich (see Figure 3.12). Moreover, the gut microbial metabolite 3-HPPA which 
arises through bacterial hydrolysis of dietary derived cholinergic acid and subsequent bacterial 
reduction by caffeic acid was also decreased in control AB animals compared to casein rich 
animals, together these results suggest that AB treatment independent of casein suppresses gut 
microbial activity resulting in a reduction of the excretion of gut microbial metabolites which 
suggests lower gut activity may be linked to the anti-depressive like effect seen in control and 
casein rich AB animals. 
The excretion of amino acids alanine, and taurine were increased in casein rich AB treated animals 
compared to control and casein rich groups. These findings are in accordance with Swann et al., 
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(2011) who reported similar increases in these amino acids following 8 days of 
streptomycin/penicillin treatment in the drinking water.  The increase in excretion of these 
metabolites could be due to the loss of bacterial activity in the gut, which would typically be 
responsible for the degradation of these metabolites, thus improving their bioavailability and 
subsequent excretion in the urine. Indeed, increased excretion of taurine in the urine is a 
characteristic feature of germ-free and acclimatizing germ-free rodents (Nicholls et al., 2003; 
Claus et al., 2008). An increase in these metabolites provides further evidence for the effectiveness 
of the antibiotic regime in suppressing bacterial abundance as well as activity in casein rich 
exposed rats.  
Moreover, the urinary extraction of betaine was seen to be greater in casein rich AB treated rats 
compared to conventional casein rich animals. This indicates increased choline metabolism in 
casein rich animals following AB treatment. Together these findings reinforce that AB treatment 
alone, independent of casein, affects choline metabolism. This is in agreement with Swann et al., 
(2011) who reported an increase in urinary extraction of betaine and DMG in the urine following 
8 days of AB treatment in rats suggestive of increased choline metabolism. Although choline can 
be synthesized in the liver most choline is obtained from the diet. It is feasible that AB treatment 
suppresses the microbial metabolism of dietary choline in the gut, thus increasing its availability 
for the host. This could explain why products of endogenous choline metabolism are increased in 
the urine following AB treatment. Consistently, DMA (a microbial metabolite of choline) was 
excreted in lower amounts by the casein rich AB group compared to the AB-free casein rich group.  
Interestingly, when comparing casein rich AB to the casein rich group, we observed higher 
excretion of DMA in casein rich animals. This indicates that casein rich milk treatment also has 
an effect on choline metabolism independent of AB treatment (as discussed above). It appears 
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casein rich milk exposure decreases choline excretion which is accompanied by a depressive-like 
phenotype in the FST, while AB treatment appears to increases choline excretion while eliciting 
an anti-depressive like effect in casein rich rats, therefore it is possible to suggest that disruptions 
to the metabolism of choline maybe implicated in driving the behavioural differences observed 
between these two treatment groups. Further studies are required to understand the importance of 
choline metabolism in the diet-associated behavioural changes reported in this study.  
Casein rich AB treated animals excreted higher levels of the TCA energy cycle metabolite citrate 
when compared to casein rich animals. This suggests casein increases citrate excretion, which is 
further exacerbated by AB treatment. This may reflect changes in energy metabolism, which is 
further supported by lower glucose excretion in the casein rich animals compared to the control 
AB treatment group. These findings are consistent with the increased mobility and swimming 
behaviours observed in control AB and casein rich AB treated animals.  
 
Metabolic Alterations Caused by Microbial Suppression in Casein Free Rats 
 
Casein free AB animals excreted higher amounts of TMAO compared to control and casein free 
animals (see Figures 3.14 and 3.15). This indicates that casein free milk exposure alone 
independent of AB results in higher TMAO excretion, which is then further exasperated by AB 
treatment. Choline can be metabolized to glycine through a strictly mammalian pathway or it can 
be metabolized via bacteria in the gut to produce trimethylamine (TMA), which in turn is oxidized 
in the liver to produce TMAO (al-Waiz et al., 1992). An increase in TMAO excretion in casein 
free AB animals points towards an increased flux towards bacterial metabolism of choline. 
Furthermore, as we did not observe an increase in betaine, an endogenous choline metabolite, in 
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the urine of casein free AB animals, it is further indication of an increase in bacterial choline 
metabolism in this group, despite AB treatment. As this increase in TMAO was not observed in 
control and casein rich animals following AB treatment, it suggests that the gut microbiome of 
casein free AB animals may indeed have differed to the other AB groups and thus provide an 
explanation for the behavioural phenotype observed in casein free AB treated animals. 
Furthermore, it was observed during the running of the experiment, that casein free AB animals 
were calmer and easier to handle compared to the other AB subjects and did not show any signs 
of aggression. 
As observed in control AB and casein rich AB we also observed a decrease in the excretion of the 
gut microbial metabolites hippurate and 3-HPPA in casein free AB treated animals compared to 
the casein free group. This result indicates that AB treatment was indeed successful in suppressing 
the gut microbial activity in these animals independent of milk type. This is further supported by 
the FISH analysis results, which showed a reduced total bacterial count in casein free AB animals 
in line with the other AB treatment groups.  Without enumeration of individual bacterial groups it 
is not possible to tell if the gut microbiome of the casein free AB group may have differed from 
the other AB treatment groups. Furthermore, in line with the other AB treatment groups, casein 
free AB animals excreted higher amounts of the amino acid taurine, which is characteristic of a 
reduced gut microbiome. Taken together these findings show that AB treatment in casein free 
animals resulted in a similar reduction of gut microbial activity as seen in control and casein rich 
AB animals, however due to the increase in TMAO it can be speculated that the gut microbiome 
was more active in this treatment group compared to control AB and casein rich AB. Moreover, 
the casein free AB group showed a reduction in the excretion of succinate, which is another product 
of energy metabolism, compared to both casein free and control treatment groups. This may 
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suggest that energy metabolism was not increased in casein free AB treatment groups to the same 
extent that it was increased in the other AB animals.  
In summary this research chapter demonstrated that AB treatment was indeed successful in 
reducing both bacterial abundance and activity. It was also shown that not only does AB treatment 
ameliorate the depressive-like effect induced by casein rich milk consumption, but also AB 
treatment alone independent of casein induces an anti-depressive like effect as observed in control 
animals. However, this antidepressive-like effect was not observed in casein free treated animals 
following AB treatment, indicating casein free milk played a protective role against the 
behavioural changes induced by AB treatment. Taken together, these results clearly demonstrate 
AB treatment in early postnatal life effects behaviour independent of casein consumption and 
highlights the need for further investigation into the use of AB in early postnatal life. Furthermore, 
the metabolic effects induced by casein treatment alone, antibiotic treatment alone and casein or 
casein free treatment combined with AB were explored and revealed alterations to choline 
metabolism, energy metabolism and bacterial metabolism which warrant further investigation into 
their association with the behavioural changes observed.  
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4.1 Introduction  
 
The studies performed in Chapters 2 and 3 provide evidence showing exposure to milk caseins 
beyond the normal age of weaning results in a depressive-like phenotype as well as dysregulations 
to the opioid and oxytocinergic systems in rats compared to control animals and animals provided 
with casein free milk beyond the normal age of weaning on PND21. Furthermore we have shown 
that the gut microbiota appears to play a role in mediating behaviour as knock-down of the gut 
microbiota dramatically reduced immobility time in the FST in rats who consumed casein rich 
milk as well as control treated animals at an early developmental stage. This chapter aims to 
determine the genetic variant of milk casein responsible for the depressive phenotype observed 
following consumption of milk caseins beyond the normal age of weaning.  
As discussed in Section 1.2 – 1.3 there has been an increasing interest in recent years regarding 
the consequences associated with the consumption of milk casein derived beta casomorphins for 
extended periods of time on health.  These include increased risk of neurological diseases such as 
autism and schizophrenia, cardiovascular diseases, type 1 diabetes, gastrointestinal dysfunction 
and immune/inflammation related disorders and which have been attributed to a group of peptides, 
particularly BCM-7, derived from the proteolysis of beta casein, (see ul Haq et al., 2014). 
Beta casein is expressed as 13 genetic variants in cows (Kamiński et al., 2007) resulting from 
single nucleotide polymorphisms in the casein beta gene (CSN2)  (Caroli et al., 2009).  Out of 
these, A1 and A2 are the most common forms in cattle breeds making up around 20% of the total 
protein content in cow’s milk (Kamiński et al., 2007). Depending on the individual cow’s genetic 
makeup, cows can be homozygous for one type, or heterozygous resulting in both A1 and A2 types 
being expressed. According to the literature, A2 beta casein is recognized as the original beta 
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casein variant expressed in cows before the appearance of the A1 variant in some European herds 
5000-10,000 years ago (Farrell et al., 2004). The appearance of the A1 variant is believed to have 
arisen due to a CSN2 gene mutation which occurred in Holstein cows and was then passed on to 
many other cow breeds due to breeding practices, by which Holstein cows were used to genetically 
improve the production of other breeds (The A2 Milk Company, 2014 
https://thea2milkcompany.com/). Over time the A1 beta casein variant became the dominant form 
expressed in milk in Europe. While dairy herds in much of Asia, Africa and parts of southern 
Europe remain naturally high in cows producing A2 milk, making the A1 version of the protein 
common in cattle in the western world (The A2 Milk Company, 2014 
https://thea2milkcompany.com/). 
BCM-7 is uniquely derived from the digestion of the A1 β-casein but not the A2 β-casein type. 
These two variants differ in their protein structure owing to a substitution of the amino acid at 
position 67. A2 β-casein and related sub-variants contain a proline amino acid at position 67, 
whereas A1 β-casein and related sub-variants contain a histidine at this same position. This 
histidine within A1 is susceptible to proteolytic cleavage, which allows the preceding seven amino 
acid residues to be cleaved, yielding BCM-7 (see Figure 1.2) (Jinsmaa et al., 1999). Beta casein 
expressed in human, goat, sheep and buffalo milk though not strictly of the A2 type, are classed 
as “A2-like”. However, evidence suggests human milk does indeed release BCM-7, which is of a 
differing amino acid sequence to bovine BCM-7 (Jarmołowska, Sidor, Iwan, Bielikowicz, 
Kaczmarski, Elzbieta Kostyra, et al., 2007; Kost et al., 2009; Wada and Lönnerdal, 2015).  
As discussed in Section 1.3, literature shows that BCM-7 possesses opioid like activity due to the 
N-terminal amino acid sequence Tyr-Pro-Phe-Pro that gives it preferential MOPr agonist activity 
(Brantl et al., 1981). MOP receptors are found primarily in the central nervous system and the 
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gastrointestinal tract and play an important role in responding to stress and pain as well as in 
controlling food intake (Teschemacher, 2003). The first site of action of BCM-7 following 
digestion are the MOPr in the gut. Indeed when injected into animals, BCM-7 was shown to slow 
gastrointestinal motility similar to the effect of morphine (Shah, 2000) and this observation was 
also replicated in humans (Andiran et al., 2003; Ho et al., 2014). In a direct comparison of A1 and 
A2 milk fed to Wistar rats, gastrointestinal transit time was significantly longer in the A1 group 
compared to rats fed A2 beta casein. Furthermore co-administration of naloxone decreased 
gastrointestinal transit time significantly in the A1 group but not in the A2 group indicating the 
greater gut transit time reported in the A1 group is mediated by a MOPr dependant mechanism 
(Barnett et al., 2014). 
Furthermore, this group reported that rats fed A1 β-casein showed an increase in a range of markers 
of intestinal inflammation compared to the A2 group and this was inhibited by naloxone treatment  
(Barnett et al., 2014) again indicating a MOPr mediated increase in markers of inflammation 
caused by A1 β-casein.  Similarly in mice, dietary consumption of β-casein isolated from A1/A1 
or A1/A2 Indian Karan Fries cows resulted in increased IL-4, IgE, IgG concentrations in the 
intestinal fluid compared to groups provided with beta casein extracts from A2/A2 cows or 
controls  (ul Haq et al., 2014). In a second study by the same research group in which mice received 
BCM-7 or saline by gavage for 15 days, similar increases in indicators of inflammation were 
reported compared to saline control. Taken together these studies indicate that A1 beta casein and 
its bioactive breakdown product BCM-7 are responsible for the reported gastrointestinal and 
inflammatory effects.  
Notably, human studies have  gone on to confirm that consumption of milk containing A1/A2 beta 
casein results in an increase in inflammation related biomarkers as well as a longer gut transit time 
 221 
compared to milk containing A2/A2 beta casein (Jianqin et al., 2015). It is therefore evident 
consumption of A1 derived BCM-7 results in gastrointestinal effects and is proinflammatory. 
Whether the proinflammtory effects are due to a direct inflammatory response to BCM-7 or an 
indirect consequence of delayed gut transit time influencing other biological processes is still 
unclear.  
Moreover, some studies have reported effects of BCM-7 on the CNS following perinatal 
administration in animal models. Brantl et al., (1981) were amongst the first to report analgesic 
activities of BCMs after i.c.v injections in rats, and that this analgesic effect can be antagonized 
by naloxone indicating a MOPr mediated mechanism of action. Another study has reported that 
consumption of milk containing both A1/A2 variants resulted in minor impairments to cognitive 
function, which were linked to the increased serum inflammation-related markers associated with 
consumption of milk containing A1/A2 relative to control milk containing only A2 beta-casein 
variant. Indeed elevated levels of circulating inflammatory markers have been linked to significant 
impairments in memory, attention and mood (Dantzer et al., 2008; Myers et al., 2008; Heringa et 
al., 2014). 
Given the health effects associated with consumption of milk containing the A1 variant of  β-
casein, recently bovine milk that is free of A1 has been made available commercially in the United 
Kingdom amongst other countries (The A2 Milk Company, 2014 
https://thea2milkcompany.com/). Also infant formula containing casein but free of A1 is now 
marketed in China and Australia. This chapter aims to compare the effect of consumption of milk 
containing A1/A2 variants against milk containing only the A2 variant during early developmental 
period on mood. Moreover the effect of A1/A2 vs A2/A2 milk consumption on motor function 
was also assessed. Furthermore, metabonomic analysis was carried out on the frontal cortex region 
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of the brain in order to assess any metabolic changes associated with A2 versus A1/A2 milk 
consumption. The frontal cortex was selected as it has been identified as a key region in the 
regulation of emotions, in particular it has been linked to depression (Drevets, 2000). There is also 
evidence to suggest that diet can elicit a profound effect on frontal cortex neurochemistry 
(Sandoval-Salazar et al., 2016) and was thus selected as a key region for metabonomic analysis.   
Hypothesis: 
 Rats provided with A2 milk beyond the normal age of weaning will not display a depressive 
phenotype due to a lack of the bioactive peptide BCM-7 compared to rats provided with 
A1/A2 milk. Moreover, neither A2 nor A1/A2 milk will have an effect on motor activity. 
Due to the differing post weaning diets, metabolic profiles of A2 animals A1/A2 and 
control will differ significantly.  
Aim: 
 To investigate the variant of β-casein in milk responsible for mediating the depressive-like 
phenotype observed in animals provided with casein rich milk from PND21 until PND26. 
Objectives: 
 To provide animals with milk containing only A2 β-casein or milk containing both A1/A2 
from PND21 until PND26 and assess motor activity. 
 Assess depressive-like behaviour using the FST  
 Asses for metabolic changes in the frontal cortex region of the brain using NMR based 
metabolomics.  
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4.2 Methodology 
 
4.2.1 Animals and Experimental Conditions   
 
Male, Wistar Albino rats were purchased from Charles River UK Limited, Kent. All rat pups and 
their cross-fostered mother arrive at the Biological Research Facility (BRF) on PND7, where day 
of birth is PND0.  These animals were maintained in litters of 8 pups with their mothers at all 
times. Pups were left to acclimatize to their new environment for 11 days, after which point they 
were handled and weighed daily by the experimenter. All groups were weaned on PND21, a 
process where the mother is simply removed from the cage (Cramer et al., 1990).  All rats were 
placed in a 12 hour light-dark cycle (lights on 6 AM – 6 PM) with free access to a standard rat 
chow diet (purchased SDS, Kent UK) and tap water and kept at a constant temperature of 22°C ± 
1 °C, humidity of 45-55%. All experimental procedures were conducted in accordance with the 
U.K Animal Scientific Procedures Act (1986).  
4.2.2 A2 Milk Study 
 
Three experimental groups were generated, with each group containing 8 pups caged together. 
Group one were weaned by having their mothers removed at 10.00 am on PND21. This group 
acted as the control and were provided with free access to rat chow and water until the completion 
of behavioural testing on PND26. Group two, the conventional cow’s milk group (A1/A2 group) 
were weaned on PND21 and provided with a bottle containing Tesco’s whole milk from PND21 
until PND26, as well as continued provision of rat chow and water.  Group three, the A2 milk 
group, were also weaned on PND21 and provided with a bottle containing A2 milk daily from 
PND21 until PND26 as well as continued provision of rat chow and water.   
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The groups provided with either conventional cow’s milk or A2 milk, were provided with 100 ml 
of fresh milk in bottles with ball bearing nozzles twice a day once between 9:00-10:00 AM and 
then again between 5-6 PM. Milk consumption was also recorded on a daily basis. Milk bottles 
were heated for 30 seconds in a microwave before being provided to the animals.  Table 4.1 shows 
the nutritional composition of the A2 full fat milk used and Tesco’s whole milk, which was used 
to represent A1/A2 milk. 
A2 Whole Milk Formula  
Parameter  Analysed  Units  Results Fresh Weight 
Moisture % 87.6 
Crude Fat % 3.62 
Crude Protein % 3.25 
Crude Fibre % 0.0 
Ash raw % 0.7 
NFE (Nitrogen Free extract)  % 4.83 
Tesco Milk Formula  
Parameter Analysed  Units  Results Fresh Weight 
Moisture % 87.5 
Crude Fat % 3.57 
Crude Protein % 3.19 
Crude Fibre % 1.3 
Ash raw % 0.7 
NFE  % 5.04 
Table 4.14: Table showing the nutritional content of A2 whole milk formula and Tesco’s (A1/A2) 
whole milk formula.  
 
 
4.2.3 Body Weights and Milk Consumption  
 
To monitor the general health of the animals, body weights were recorded daily from PND14 until 
the end of behavioural testing on PND26 as well as on the day of sacrifice. Milk consumption per 
cage was also recorded daily from PND21 until PND26.  
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4.2.4 Behavioural Tests 
 
4.2.4.1 The Forced Swim Test  
 
The forced swim test was performed between 10 am and 2 pm when all animals reached the age 
of PND25. The FST is run over two consecutive days as described in Section 2.2.3.1.  
4.2.4.2 Locomotor Activity  
 
Locomotor activity of each rat was measured for 20 minutes 1 hour prior to the FST (9:00 AM) 
on PND25 in locomotor chambers (40cm x 20cm x 20cm; Linton Instrumentation, Norfolk, U.K). 
Each chamber had two lines of 16 photocells located at right angles to each other, projecting 
horizontal infrared beams 2.5 cm apart and 6 cm above the cage floor to measure horizontal and 
vertical activity, respectively.  Activity was recorded as the number of sequential infrared beam 
breaks, every 5 mins in the space of 20 minutes. 
4.2.5 Tissue Dissection  
 
Animals were killed using cervical dislocation on PND27 following acute exposure to CO2. Intact 
brains were dissected and rapidly frozen in isopentane at -20°C for 30 seconds and then stored at 
-80°C for metabonomic analysis.  
4.2.6 Data Analysis  
 
Body weight differences, milk consumption and behavioural data from the FST were analysed 
using a one-way ANOVA. Locomotion data was analysed using Two-way ANOVA for factors 
‘time’ and ‘diet. Where ANOVA revealed a significant difference an LSD post-hoc analysis was 
carried out.  All data were expressed as means ± SEM, n = 8 per group. A p value of less than 0.05 
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was accepted as significantly different. All statistical analyses were performed on GraphPad Prism 
7. 
4.2.7 Metabolomics 
 
As described in Section 2.2.6. Metabonomic analysis was conducted by Simone Zuffa at Imperial 
College London. 
4.2.7.1 Sample Preparation-Brain Samples  
 
Prior to the start of the experiments, brains were removed from -80°C freezer and placed on ice. 
Using a scalpel, the frontal cortex (~30 mg) was removed and weighed. The frontal cortex from 
each brain sample was homogenized using 6-7 zirconium beads and 300 µl of  
chloroform:methanol, which was made up in a 2:1 ratio. Samples were placed into a homogeniser 
and homogenised at 5500 rpm for 20 seconds. This step was repeated twice for each sample. The 
homogenate was then combined with 300 µl of demineralized water and vortexed to mix. Samples 
were spun at 8000 g (rcf) for 10 minutes at 4°C to separate the organic (upper) and aqueous (lower) 
phases. These phases were separated into two Eppendorf tubes using a pipette. The organic phase 
was left overnight in a fume hood to allow the chloroform to evaporate and then stored at -40 °C. 
The aqueous phase was dried overnight in a vacuum condenser (Speedvac) at 40 °C. Once the 
samples were dried they were reconstituted in 700 µl of phosphate buffer (pH 7.4) containing 10% 
D2O and 1 mM 3-trimethylsilyl-1 [2,2,3,3-2H4] propionate (TSP). Samples were vortexed 
thoroughly, centrifuged at 8000 g (rcf) for 10 minutes at 4 °C and then 600 µl of the supernatant 
was transferred to 5 mm internal diameter Norell® NMR tubes. The sample were run on the NMR 
machine as described in Section 2.2.5.2.    
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4.2.7.2       Multivariate Data Analysis  
 
As described in Section 2.2.6.4 
4.2.7.3     Principal Component Analysis  
 
As described in Section 2.2.6.5  
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Figure 4.1: Experimental timeline showing key points in the methodology for antibiotic 
dosing study. 
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4.3 Results  
 
4.3.1 Milk Consumption & Weight Change  
 
No differences in milk consumption were observed between rats provided with A2 milk and those 
provided with A1/A2 milk from PND21 until PND26.  Furthermore, no differences in weight gain 
were observed between control, A2 milk and A1/A2 milk treatment groups between PND14 until 
day of culling on PND27 (Figure 4.2 A, B respectively). 
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Figure 4.2: Effects of A2 milk versus A1/A2 Milk on milk consumption from PND21 until PND26 and 
weight change from PND14 until PND27. 
Male Wistar albino rats were provided with no milk (control), A2 milk or A1/A2 milk from PND21 until 
PND26. (A) Milk consumption for A2 and A1/A2 treatment groups. (B) Weight change in grams for 
control, A2 milk and A1/A2 milk from PND14 until day of culling on PND27. No difference in either milk 
consumption or weight change were observed. Data are expressed as mean ± SEM (n=8 per group). One 
way ANOVA followed by LSD post-hoc test. 
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4.3.2 Locomotion  
 
Locomotion testing was carried out on PND25 1 hour prior to the FST. Animals provided with no 
milk (control), A2 or A1/A2 milk were placed into the aforementioned locomotor chambers for 20 
minutes and total horizontal or vertical beam breaks were measured.  Two-way repeated measures 
ANOVA for factors ‘time’ and ‘diet’ showed a significant ‘time’ only effect on both total 
horizontal activity and total vertical activity [F (3,21) = 65.23); p< 0.01] and  [F (3,18) = 15.43); p< 
0.01] respectively (Figure 4.3 A, B).  LSD post-hoc analysis revealed A2 milk consumption 
significantly reduced horizontal activity at 10 minutes (p < 0.05) compared to the control group 
and increased total vertical activity compared to the A1/A2 treatment groups (p < 0.01). 
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Figure 4.3: Effect of A2 milk versus A1/A2 milk consumption from PND21 until PND26 on locomotor 
activity. 
Male Wistar albino rats were provided with no milk (control), A2 milk or A1/A2 milk from PND21 until 
PND26. (A)Total horizontal activity and (B) Total vertical activity were measured on PND25 1 hour prior 
to the forced swim test in 5 min bins for 20 minutes. A decrease in total horizontal activity was seen in A2 
treated animals at 5-10 minutes compared to control animals, and an increase in total rearing activity was 
seen in A2 treated animals compared to A1/A2 animals at 5-10 minutes. Data are expressed as mean ± SEM 
(n= 7-8 per group). Two-way ANOVA followed by LSD post-hoc test was used and a p value of less than 
0.05 was accepted as significantly different. *p<0.05, **p<0.01. 
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4.3.3 Forced Swim Test  
 
The FST was used to assess depressive-like behaviour in rats provided with no milk (control), A2 
milk or A1/A2 milk from PND21 until PND26. The total immobility time was scored from the 
‘test’ session on PND26 (Figure 4.4). The quantification from the ‘test’ times were then used in 
the assessment of depressive-like behaviour as described by (Cryan et al., 2005).  Quantification 
of the results from the ‘test’ swim session showed that rats fed both A2 and A1/A2 milk displayed 
an increase in depressive-like behaviour as shown by a marked increase in immobility time 
compared to control treated animals (p < 0.05 and p < 0.01 respectively).  
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Figure 4.4: Increase in depressive-like behaviour caused by consumption of both A2 and A1/A2 Milk 
from PND21- PND25. 
Male Wistar albino rats were provided with no milk (control), A2 milk or A1/A2 milk from PND21 until 
PND26. Then subjected to behavioural testing using the FST. Immobility time during the 6 minute test 
session was measured on PND26. Data are expressed as mean (± SEM) obtained from manual video analysis 
by one independent observer. An increase in immobility time was seen in both A1/A2 and A2 treated 
animals compared to control animals indicating an increase in depressive-like behaviour.  One-way 
ANOVA followed by LSD post-hoc test was used and a p value of less than 0.05 was accepted as 
significantly different. *p<0.05, **p<0.01. 
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4.3.4 Metabonomic Analysis of Brain samples  
 
4.3.4.1 PCA of Frontal Cortex: All data  
 
PCA was first used as an unsupervised multivariate statistical analysis method to give an insight 
into metabolic variation in the frontal cortex samples from the brains of control, A2 milk and 
A1/A2 milk treatment groups. The percentage of variance described by each PC (R2 ) is shown for 
each axis. To aid the visualisation of any trends associated with the treatment groups, individual 
animals are colour coded in the scores plot to indicate their class membership. Following initial 
PCA modelling of all frontal cortex data, clear separation along PC1 can be seen between the 
A1/A2 profiles and those from control animals and the A2 group (Figure 4.5 A). This indicates 
that A1 β-casein exposure from PND21 until PND 26 is responsible for the largest source of 
variation in the metabolic data. Pair-wise PCA models (Figure 4.5 B-C) further demonstrate this 
metabolic variation between A1/A2 samples and those from the control and A2 groups. No 
variation was observed in the frontal cortex metabolic profiles from control and A2-treated 
animals. 
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A B 
C D 
Figure 4.5:  PCA of frontal cortex samples from Control, A1/A2 and A2 treated animals. 
PCA scores plot constructed on the brain metabolic profile of: (A) All groups (R2 = 78.5%) showing 
separation along PC1 between control/A2 milk and A1/A2 milk, (B) control and A1/A2 group, (R2 = 78.8%) 
showing separation along PC1 between the two groups, (C) A1/A2 and A2 milk group, (R2 = 81.3%) 
showing separation along PC1 between the two groups, (D) Control and A2 milk group, (R2 = 74.3%) 
showing no separation between the two groups. Frontal cortex metabolomics samples were run and 
analysed by Simone Zuffa at Imperial Collage London. 
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4.3.4.2 OPLSDA of Frontal Cortex 
 
OPLS-DA was used to further investigate the effect of exposure to A1 β-casein on animal 
metabolic profiles. This supervised method allows the metabolic variation specifically associated 
with class membership (control, A1/A2, A2) to be identified. To identify the metabolites in the 
frontal cortex that differed between control, A2 milk and A1/A2 milk treatment groups, pair-wise 
OPLSDA models were constructed using milk type as the Y predictor as explained in Section 
2.2.6.6. Models with strong predictive ability (Q2Y) were returned for comparisons. The pairwise 
comparison between control and A1/A2 milk groups can be seen in Figure 4.6 and the pairwise 
comparison between A2 and A1/A2 milk groups can be seen in Figure 4.7. Both models had a 
strong predictive ability (Q2Y = 0.356 and Q2Y = 0.483 respectively), which were found to be 
significant after permutation testing (p = 0.041 and p = 0.022 respectively; 10,000 permutations). 
From the correlation coefficients plot extracted from the OPLS-DA model comparing control and 
A1/A2, it was found A1/A2 rats had  higher amounts of  aspartate, N-acetyl groups, glutamine, 
succinate, glutamate, gamma-amino butyric acid (GABA), acetate, alanine, lactate, ascorbate, 
inosine, myo-inositol, creatine, threonine, O-phoshphocholine, taurine, O-acetylcholine, choline, 
adenosine monophosphate (AMP), inosine monophosphate (IMP), nicotinurate/niacinamide, 
adenosine, uridine monophosphate (UMP), phenylalanine, histidine, S-adenosylhomocysteine, 
GTP, and tyrosine/tyramine than the control group rats. Comparing A2 and A1/A2 profiles 
identified that A1/A2 rats had higher amounts of creatine, GABA, asparate, N-acetyl group, 
glutamine, succinate, glutamate, acetate, alanine, lactate, ascorbate, myo-inositol, threonine, O-
phosphocholine, taurine, choline, O-acetylcholine, niacinamide/nicotinurate, IMP, AMP, tyrosine, 
GTP and UMP compared to the A2 rats. The predictive performance of the OPLS-DA model 
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comparing control and A2 milk treatment groups was poor (Q2Y = -0.29) indicating no metabolic 
differences between these samples. This was also seen in the PCA scores plot comparing these the 
two groups. 
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Figure 4.6: The effect A1/A2 milk from PND21 until PND26 on rat frontal cortex metabolites 
compared to control treatment:  OPLS-DA Plots.  
OPLS-DA model generated from frontal cortex 1H-NMR spectra from control and A1/A2 treated animals. 
The OPLS-DA correlation coefficients (R2 0.723) plot illustrating all metabolites responsible for driving the 
separation between the two groups. Labelled peaks are the metabolites which are increased in the respective 
groups (A1/A2 milk at the top and control at the bottom) (Q2Y =0.356). For the list of metabolites and peak 
shifts refer to Table 4.2. Frontal cortex metabolomics samples were run and analysed by Simone Zuffa 
at Imperial College London. 
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Figure 4.7: The effect of A2 or A1/A2 Milk types from PND21 until PND26 on rat frontal cortex 
metabolites:  OPLS-DA plots.  
OPLS-DA model generated from frontal cortex 1H-NMR spectra from A2 and A1/A2 treated animals. The 
OPLS-DA correlation coefficients (R2 0.799) plot illustrating all metabolites responsible for driving the 
separation between the two groups. Labelled peaks are the metabolites which are increased in the respective 
groups (A2 milk at the top and A1/A2 milk at the bottom) (Q2Y =0.483). For the list of metabolites and peak 
shifts refer to Table 4.2. Frontal cortex metabolomic samples were run and analysed by Simone Zuffa 
at Imperial College London. 
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    Metabolite                                                                                   Chemical Shift (Multiplicity)                                                                      Sample   
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
 
 
 
 
Aspartate 
N-Acetyl Group 
Glutamine 
Succinate 
Glutamate 
GABA 
Acetate 
Alanine 
Lactate 
Ascorbate 
Inosine 
Myo-Inositol 
O-Phosphocholine 
Taurine 
O-Acetylcholine 
Choline 
AMP 
 
1.48 (d), 3.76 (q) 
2.02 (s), 2.50 (q), 2.69 (q), 4.39 (q)* 
2.14 (m), 2.46 (m), 3.77 (t), 6.86 (s) 
2.41 (s) 
2.1 (m), 2.35 (m), 3.76 (q) 
1.9 (m), 2.3 (t), 3.01 (t) 
1.92 (s) 
1.48 (d), 3.77 (q) 
1.33 (d), 4.11 (q) 
3.74 (m), 4.02 (m), 4.52 (d) 
4.28 (q), 4.44 (t), 6.10 (d), 8.25 (s), 8.35 (s) 
3.29 (t), 3.54 (q), 3.63 (t), 4.07 (t) 
3.04 (s), 3.93 (s) 
1.33 (d), 3.59 (d), 4.25 (m) 
3.22 (s), 3.59 (m), 4.16 (m) 
3.27 (t), 3.42 (t) 
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Metabolite                                                                                       Chemical Shift (Multiplicity)                                                                   Sample   
 
 
 
 
 
 
 
 
 
 
 
 
 
IMP 
Nicotinurate/Niacinamide 
Adenine 
UMP 
Phenylalanine 
Histidine/Histamine 
Adenosine 
S-Adenosylhomocysteine 
GTP* 
Tyrosine/Tyramine 
4.48 (q), 6.14 (d), 8.20 (s), 8.53 (s) 
7.60 (q), 8.25 (m), 8.72 (q), 8.94 (d) 
8.15 (s), 8.22 (s) 
4.34 (t), 4.41 (t), 5.99 (m), 8.11 (d) 
7.33 (d), 7.38 (t), 7.43 (t) 
7.10 (s), 7.89 (s) 
4.44 (q), 6.08 (d), 8.25 (s), 8.35 (s) 
4.32 (m), 4.44 (t), 6.10 (d), 8.27 (s), 8.35 (s) 
5.94 (d), 8.14 (s) 
6.91 (d), 7.19 (d) 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk 
A1/A2 milk and A2 milk 
A1/A2 milk and A2 milk 
A1/A2 milk 
A1/A2 milk 
 
 
 
 
 
 
Table 4.2: Full 1H- NMR chemical shifts for metabolites identified in frontal cortex samples of A1/A2 treated rats. Key: s, singlet; d, doublet; t, triplet; 
q, quadruplet. *not confirmed. Abbreviations: GABA: gamma-amino butyric acid; AMP: adenosine monophosphate; IMP: inosine monophosphate; UMP: 
uridine monophosphate; GTP: Guanine triphosphate 
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4.4 Discussion 
 
The aim of this study was to determine the genetic variant of milk casein responsible for the 
depressive-like phenotype observed following consumption of milk caseins beyond the standard 
age of weaning. To achieve this, one group of animals was provided with milk containing only the 
A2 variant of casein (A2 milk) while another group was provided with milk containing a mixture 
of A1/A2 β-casein again from PND21-PND26 and then assessed for depression using the FST. 
The effect of A2 or A1/A2 milk consumption on motor activity was also investigated. Furthermore 
brain (frontal cortex) metabolic profiles were also compared between control, A2 and A1/A2 
treated animals. 
Interestingly, animals provided with both A2 milk and A1/A2 milk types displayed an increase in 
depressive-like behaviour compared to the control group as indicated by a significant increase in 
total immobility time (Figure 4.4).  It was originally hypothesised that only milk containing the 
A1 variant of casein (A1/A2 milk)  would result in a depressive phenotype as A1 beta casein  has 
been shown to release the bioactive peptide BCM-7 (Kamiński et al., 2007) and a large body of 
evidence has linked BCM-7 exposure with a number of negative health effects including 
neurological diseases (see ul Haq et al., 2014). However, the results obtained show that A2 milk 
which is devoid of the A1 variant, also elicited a depressive phenotype in animals despite the lack 
of BCM-7 presence. This indicates that there are other bioactive components in milk, besides the 
A2 beta casein derived casomorphins which may be driving the behavioural changes associated 
with prolonged milk consumption. However as behavioural results from Chapters 2 and 3 have 
shown that consumption of casein-free milk for 5 extra days beyond the normal age of weaning 
did not result in a depressive-like phenotype. Taken together with the current results, this indicates 
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that the depressive-like behaviour is driven by casein but not specifically A2 beta casein derived 
BCM-7 as originally hypothesised.  
Indeed, the α variant of casein (α casein) is also known to contain fragments with opioid receptor 
activity. These are termed α casein exorphins and they are released from α casein by pepsin 
digestion  (in bovine milk it is the αs1 casein which releases these peptides) (see Teschemacher, 
Koch and Brantl, 1997; Nyberg et al., 2013). These α casein exorphins exhibit DOPr activity. 
Human α casein was found to give rise to the opioid antagonist casoxin D which was shown to 
exhibit low DOPr affinity. Similarly, peptic and tryptic digestion of bovine Ƙ casein gives rise to 
casoxins A, B and C which were all found to behave as opioid receptor antagonists, exhibiting a 
low affinity for both MOPr and KOPr (see Teschemacher, Koch and Brantl, 1997). Thus, it is 
feasible that biologically active opioid peptides besides BCM-7 arising from proteolytic cleavage 
of A1 and A2 beta casein, aswell as bioacive break down products from other varients of casein 
are responsbile for driving the behavioural changes observed in the FST.  
In order to assess that the  behavioural changes observed in the FST were not driven by a change 
in locomotor function,  total horizontal and total rearing activies were assessed for 20 minutes  in 
control, A2 and A1/A2 treated animals 1 hour proir to the FST on PND25. The data show no 
significant effect of diet on either parameter of locomotion (Figure 4.3). The first 5 minites in the 
locomotion chamber is used to score exploration of a novel environment (Crawley, 2008). Upon 
first exposure to a novel open field environment, rodents display marked behavioural activation in 
the form of exploratory behaviour, which usually includes sniffing, walking/running and hind leg 
rearing (Drai et al., 2001). In agreement, the present data showed that during the initial 5 mins 
both vertical and horizontal activities were high in all rats indicating no difference in exploratory 
behaviour between all three treatment groups in the first 5 minutes. This reinforces that the changes 
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observed in the 6 minute FST are unlikely to be driven by a difference in motor activity or 
exploratory behaviour and is indeed indicative of a true depressive-like phenotype.  
Over time, all groups showed a significant decrease in their total horizontal and vertical activity 
over the 20 minute test period (time effect). This is an effect of behavioural habituation, a basic 
form of learning (Thiel et al., 1998) whereby repeated or prolonged exposure to an environment 
renders it less novel and thus reduces exploratory behaviour which is then replaced by 
grooming/cleaning behaviour and eventually hibernation.  
Interestingly, post-hoc analysis revealed that at 5-10 minute time bin, a significant decrease in 
horizontal activity was observed in A2 treated animals compared to control animals. This may 
indicate that A2 treated animals habituated quicker to their new environment and hence stoped 
exploring the novel environment sooner. However, a significant increase in total time spent rearing 
was also observed in A2 treated animals at 5-10 minute time bin compared to A1/A2 exposed rats, 
this may explain the decrease in horizontal activity as A2 animals spend more time rearing ( 
vertical activity), perhaps exploring other aspects of their new environment. Although the FST 
data suggest that consumption of both A2 milk ( no BCM-7) and A1/A2 milk (containing BCM-
7) result in depressive like behaviour, there appears to be some modulation of other behavioural 
phenotypes mediated by BCM-7 exposure which require further investigation.  
Metabolomic analysis was carried out on the frontal cortex, a key region in emotional regulation, 
in order to assess the neurochemical effect of BCM-7 exposure through the consumption of A1/A2 
milk compared to the lack of exposure to BCM-7 through the consumption of A2 milk or no milk 
(control animals). A clear difference in metabolic profile was observed in animals exposed to 
BCM-7 through A1/A2 milk consumption compared to control and A2 treated animals. PCA 
analysis showed  animals who had no exposure to BCM-7 clustered together  (control and A2 
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treatment groups) while BCM-7 exposed animals ( A1/A2 treatment group) separated in metabolic 
profile (Figure 4.5) OPLS-DA analysis further highlighted these metabolic differences confirming 
that exposure to BCM-7 from PND21-PND26  altered the neurobiochemical profiles.    
A significant increase in a number of neurotransmitters in the frontal cortex of A1/A2 treated 
animals was observed in comparison to both control and A2 animals (Figure 4.6 and 4.7), 
including GABA, glutamate (Glu) and glutamine (GLn) (together GLx).  GABAergic and 
glutamatergic neurotransmitter systems are the major inhibitory and excitatory neurotransmitters 
in the mammalian central nervous system (Fonnum, 1984) and are thereby involved either directly 
or indirectly in most aspects of normal brain function, including mood regulation. A large body of 
evidence shows that GABAergic and glutamergic neurtotransmission are central to the 
pathophysiology of depression (Hasler, 2010). Indeed a number of clinical and preclinical studies 
show that major depressive disorder (MDD) and stress exposure are associated with an increase in 
the abundance of glutamate in the prefrontal cortex (see Popoli et al., 2011). Although it is not 
possible to determine the causal association between increased glutamate and GABA levels 
observed in the frontal cortex of rats exposed to BCM-7 through A1/A2 milk ingestion and the 
observed depressive-like phenotype, it is unlikely that this is driving it as the depressive phenotype 
was also observed in A2 animals who were not exposed to BCM-7. Nonetheless, the data clearly 
indicate a profound effect of BCM-7 exposure through A1/A2 milk on brain neurochemistry. 
The current data clearly suggests the presence of BCM-7 in the A1/A2 treated animals is driving 
the increase in GABAergic and glutamergic metabolites in the frontal cortex. Although it appears 
no studies have measured the release of these neurotransmitters following BCM-7 treatment, this 
argument is supported by evidence that shows acute and chronic morphine treatment (a MOPr 
agonist similar to BCM-7 albeit of a higher potency) results in significant alterations to 
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extracellular concentrations of glutamate and GABA in a number of brain regions including the 
prefrontal cortex (Hao et al., 2005; Gao et al., 2007).  In the study by Gao et al., (2007) metabolic 
changes in the prefrontal cortex of rats were measured following 10 days of morphine injections 
using 1H NMR spectroscopy. They showed repeated morphine treatment induced a progressive 
change in a number of cerebral metabolites including an increase in GABA concentration and a 
decrease in Glu concentrations in the prefrontal cortex. The observed changes are believed to be 
an adaptive response of cerebral metabolism to ongoing morphine exposure and perhaps the 
development of morphine tolerance and dependence (Gao et al., 2007). Although this in agreement 
with the higher amount of GABA metabolites observed in the current study, it is not consistent 
with the lower Glu reported. This could reflect differences in potency between BCM-7 and 
morphine and also the length of exposure to both agonists (only 5 days of exposure in the current 
study versus 10 days of exposure in Gao et al.,( 2007) study). The metabolic pathways regulating 
the synthesis and cycling of GABA and glutamate are tightly coupled. Gln is the primary precursor 
for both neuronal Glu and GABA (Pascual et al., 1998). Therefore, any changes to this shared 
pathway will affect levels of both associated metabolites. The current data show an increase in Gln 
accompanied by a concomitant increase in both Glu and GABA. These findings indicate that 
similar to the effect of morphine, sustained BCM-7 exposure from PND21- PND26 alters the Glu, 
Gln and GABA content of the brain. In line with this, morphine-induced activation of MOPr has 
been shown to enhance GABAergic neuronal activities in the prefrontal cortex (Mansour et al., 
1987), however this has been shown to provide an inhibitory influence on glutamatergic neurones 
(Cowan et al., 1994). Thus given the opposing excitatory and inhibitory roles of both of these 
neurotransmitter systems, more evidence is needed to pin-point the exact mechanisms underlying 
the reported increased concentrations in the frontal cortex following BCM-7 exposure. 
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Metabonomic analysis of the prefrontal cortex also showed an increase in a number of other 
metabolites including myo-inositol and taurine. Both of these metabolites are markers of astrocytic 
activity and play important roles in regulating intracellular osmoloarity of astrocytes (Isaacks et 
al., 1994). This suggests an increase in astocytic activity in the frontal cortex following BCM-7 
exposure through ingestion of A1/A2 milk. Increased astrocytic activity has been implicated in the 
regulation of glutamergic and GABAergic neurotransmission amongst other roles such as supply 
of energy metabolites for synaptic function (see Miguel-Hidalgo, 2009). Therefore an increase in 
astrocytic activity may be linked to the increase in GABA and glutamate neurotransmission 
following exposure to BCM-7 through A1/A2 milk consumption. In support of the concept of 
BCM-7 induced astrocytic activity, chronic treatment with morphine has been shown to result in 
an increase in astrocytic activity as measured by glial fibrillary acidic protein (GFAP), a key 
component of the astrocytes cytoskeleton, in a number of brain regions including the frontal cortex 
(see Miguel-Hidalgo, 2009;Song and Zhao, 2001; Alonso et al., 2007).   
The current data also shows an increase in N-acetyl groups (NAG) which has a spectrum very 
similar to N-acetylaspartate (NAA) in the frontal cortex of BCM-7 exposed rats through the 
ingestion of A1/A2 milk.  NAA is a putative marker of neuronal activity. It is localised within 
neurons and is involved in synaptic processes (see Miller, 1991). NAA levels have been shown to 
be elevated in several degenerative neurological conditions and high concentrations have been 
shown to behave like a neurotoxin (see Miller, 1991). A greater amount of NAA in the frontal 
cortex following BCM7 exposure could indicate enhanced or disturbed neuronal activity caused 
by BCM-7 exposure. This notion is supported by evidence that suggests NAA is responsible for 
the elimination of metabolic water formed in large quantities especially during high neuronal 
activity (Baslow, 2003). Increased neuronal activity is indeed implicated in A1/A2 treated rats as 
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indicated by an increase in a number of neurotransmitter metabolites including glutamate, GABA, 
and acetylcholine. Furthermore, Deng et al., (2012) showed an elevated level of NAA 
concentrations as measured by 1H NMR spectroscopy-based metabonomics in the prefrontal cortex 
of monkeys treated with an escalating dose of morphine for 90 days. Together these findings 
suggest BCM-7 exposure is causing increased neuronal activity in the frontal cortex and possibly 
resulting in neuronal damage/dysregulation as indicated by increased levels of NAA a neuronal 
marker of neural damage.  
Metabonomic analysis also revealed differences in a number of energy metabolites between 
control, A2 and A1/A2 treated animals. Creatine has a role in both energy homeostasis and 
osmoregulation in the brain (Bothwell et al., 2001). It is a high energy compound necessary for 
the transport of phosphate groups and for maintaining appropriate ATP levels (Andrus et al., 1998) 
. In this study, creatine was found to be higher in the prefrontal cortex of A1/A2 treated animals 
indicating that the presence of BCM-7 is causing alterations in brain energy metabolism.  In 
support of this, Deng et al., (2012) also reported increased prefrontal cortex levels of creatine 
following chronic treatment with morphine in monkeys (Deng et al., 2012). Moreover the current 
study showed an increase in adenosine, IMP and AMP in both A1/A2 and A2 treatment groups 
which are all linked to energy homeostasis. ATP is rapidly broken down to adenosine, inosine or 
inosine monophosphate (IMP) (see Figure 4.8).  
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Figure 4.23: Diagram showing the interconversion between ATP, AMP, IMP and Adenosine. 
Abbreviations:ATP: Adenosine 5’-triphosphate, AMP: adenosine monophosphate, IMP: inosine 
monophosphate. 
 
 
Indeed, together these findings suggest both milk types alter energy metabolism which is likely to 
be linked to the depressive phenotype observed in both A1/A2 and A2 treatment groups. This is 
further supported by findings from result chapter 3 which showed casein-rich exposed rats who 
displayed and increase in depressive-like behaviour showed metabolic alterations in products of 
energy metabolism in urine.  
Moreover, both A1/A2 and A2 treated animals showed changes in levels of the metabolite s-
adenosylhomocysteine which is involved in DNA methylation. DNA methylation is a reaction 
involving the addition of a methylgroup to DNA and is a major factor in epigenetic changes and 
subsequent gene expression (see Trivedi et al., 2014). DNA methylation is carried out by a class 
of enzymes called DNA methyltransferases, which depend on the level of S-adenosylmethionine 
(SAM) (Trivedi et al., 2014). The activity of SAM is dependent on the redox status of the cell 
(Hondorp et al., 2004). SAM acts as a methyl donor for over 200 methylation reactions and is then 
converted to s-adenosylhomocystine (SAH) an inhibitor of methylation reactions. Higher SAH in 
both A1/A2 and A2 treated animals could indicate increased DNA methylation reflecting increased 
ATP AMP Adenosine
Inosine IMP 
ADP
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SAM to SAH conversion or decreased DNA methylation as SAH is an inhibitor of this process. 
Nevertheless,  recent studies have shown abnormal DNA methylation patterns have been reported 
in schizophrenia (Jakovcevski et al., 2012) and ASD (Schanen, 2006). The current results indicate 
disrupted DNA methylation maybe a driving factor in the observed depressive like behaviour 
displayed in both A1/A2 and A2 treated animals. Furthermore, bovine BCM-7 has been shown to 
increase genome wide DNA methylation (Trivedi et al., 2014). At the transcriptional level, bovine 
BCM-7 decreased expression of nine genes including genes involved in cysteine uptake which is 
associated with intracellular antioxidant GSH and also SAM levels (Trivedi et al., 2014).  As A2 
treated animals who were not exposed to BCM-7 also showed changes in SAH it is possible 
bioactive compounds derived from other variants of casein found in A2 milk maybe acting via a 
similar mechanism to BCM-7 to induce changes in cell redox potential and DNA methylation. 
Taken together these findings indicate potential antioxidant and epigenetic effects of bovine milk 
consumption which may contribute to the depressive-like phenotype observed in animals provides 
with A1/A2 and A2 milk from PND21 until PND26. 
Whether the observed changes in brain activity and neurotransmitter levels observed in the A1/A2 
group drive the alterations in behaviour remains to be elucidated. There is some evidence to 
suggest an association between proteolytic products of casein such as BCM-7 and increased risk 
of neurological diseases such as autism and schizophrenia. However the current data suggests it is 
unlikely that BCM-7 in milk is driving the depressive-like behaviour observed as A2 milk treated 
animals without BCM-7 exposure also displayed a similar depressive phenotype.  
In summary, the current results provide evidence that consumption of milk containing either the 
A2 variant of casein or both A1/A2 variants from PND21 until PND26 resulted in an increase in 
depressive-like behaviour in comparison to control animals as assessed by the FST. This finding 
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indicates BCM-7 is not the component in milk responsible for mood regulation. At least as 
assessed by the FST. However, differences in potential anxiety-like behaviour were observed 
between the A2 and A1/A2 treatment groups as assessed by the open field test, indicating that the 
presence of BCM-7 may indeed have an influence on aspects of behaviour which may not have 
been reflected in the FST. Both A1/A2 and A2 treated animals showed changes in energy 
metabolites in the frontal cortex a region of the brain key in emotional regulation, as well as 
important changes in metabolites involved in epigenetic regulation which are likely driving the 
depressive-like behaviour observed in these animals especially as epigenetic changes have been 
implicated in other neurological disorders such as ASD and schizophrenia, indicating a BCM-7 
independent mechanism of action in milk induced mood regulation. Moreover, the presence of 
BCM-7 was found to induce neurochemical changes including higher abundance of a number of 
neurotransmitters and energy metabolites in the brains of A1/A2 treated animals compared to 
control and A2-fed rats, whether these metabolic changes are responsible for driving behavioural 
effects remains to be elucidated. All together these results provide novel and intriguing insights 
into the health effects of milk consumption in early postnatal life.  
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Chapter 5 
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5   General Discussion  
 
The first two years of life represent a period of unique sensitivity during which the CNS undergoes 
the most rapid development and is particularly plastic to environmental influences such as diet. 
Milk is the main source of nutrition for infants during this sensitive period and in recent years 
awareness has increased regarding the potential health risks associated with the consumption of 
bioactive breakdown products of milk proteins. The mechanisms underlying the influence of 
nutritional factors on brain development in early postnatal life and the subsequent effect on 
behavioural outcomes are undoubtedly complex and remain to be fully understood. However, over 
the last two decades an increasing number of studies have begun to show that the gut microbiota 
can modulate brain development and behaviour. Such work has demonstrated the existence of the 
gut-brain axis, a bi-directional communication network between microbes in the gut and the brain. 
Interestingly, the opening of some critical periods in CNS development have been found to 
coincide with the time of weaning in a number of species including humans. In addition, it has 
been demonstrated that the process of stopping breast feeding is one of the major determinants for 
the assembly of a healthy adult like gut microbiome, with post weaning diets rapidly altering the 
composition of commensal bacteria (see Tognini, 2017). The impact of milk rich diets beyond the 
standard age of weaning on host behavioural, microbial and metabolic profiles was investigated in 
this thesis using a multidisciplinary approach. This approach was used to explore the potential role 
of the gut-brain axis in modulating brain neurochemistry and behaviour and its relationship with 
weaning time. 
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5.1  Behavioural Effects of Casein Exposure  
 
The behavioural results obtained in this thesis provide clear evidence that manipulations to diet 
during the weaning period in the form of prolonged exposure to milk caseins in rats results in 
emotional impairments. The depressive-like phenotype which was caused as a result of 
consumption of milk containing casein for 5 extra days post-weaning was observed and replicated 
across all three results chapters, making it a consistent and reliable finding. Moreover, contrary to 
the original hypothesis of this thesis, it was shown that A1 beta casein derived BCM-7 is not the 
only casein-derived component which could be mediating behavioural alterations reported, as 
animals provided with A2 milk devoid of BCM-7 also displayed increased depressive like 
behaviour. Indeed, casein exists in other variants besides beta casein, which have also been shown 
to produce bioactive breakdown products (Teschemacher et al., 1997; Nyberg et al., 2013). These 
bioactive peptides alongside A2 beta casein derived BCM-7 are likely to be responsible for the 
emotional deficits reported following prolonged exposure to milk caseins in early postnatal life. 
Such findings have wide reaching implications in regards to infant feeding. In today’s society 
prolonged breastfeeding is promoted as advantageous to child development with no clear 
guidelines as to when a mother should completely stop breastfeeding her young. The World Health 
Organization recommends that infants should be exclusively breastfed for the first 6 months of life 
(WHO, 2018). The American Academy of Paediatrics recommends breastfeeding for at least 12 
months (Moretti, 2012). Recently the Academy of Nutrition and Dietetics also stated that 
breastfeeding with complementary foods from six until at least 12 months of age is the ideal 
feeding pattern  for infants (Lessen et al., 2015). However, the casein content in human milk has 
no fixed ratio and has been shown to increase in proportion to whey protein during late lactation 
(Kunz et al., 1992). Therefore, given the evidence presented in this thesis, prolonged breastfeeding 
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periods warrant a closer look due to casein exposure and its potential health effects to the 
developing infant.  
Moreover, infant formulas are often used post weaning or as a replacement/supplement to 
breastfeeding and provide a means of extending or increasing exposure to milk caseins in early 
postnatal life. Globally, only 38% of infants are exclusively breastfed. In the United States for 
example, by 3 months of age 67% of infants rely on infant formula for some portion of their 
nutrition (Moretti, 2012). Although infant formulas are intended as an effective 
substitute/supplement for infant feeding, the production of formula milk identical in composition 
to breast milk has not been achieved. This is despite much research into mimicking the profile of 
human breast milk for normal growth and development. Cow’s milk or soymilk are the most 
commonly used bases for infant formulas. Given the health implications of prolonged exposure to 
bovine caseins provided in this thesis, the use of infant formulas based on bovine protein in early 
postnatal life requires attention. Moreover, the studies in this thesis used soy protein as a 
replacement for casein in ‘casein free’ milk, which was intended to be the control milk type. 
However rats fed casein free milk (containing approx. 20% soy protein) for 5 extra days post 
weaning displayed significant neurochemical changes in a number of brain regions despite not 
eliciting behavioural changes as assessed by the FST. Indeed soy protein has been found to release 
soymorphins, which like beta casomorphins released from casein have an affinity for opioid 
receptors. These findings raise the need to consider the health effects associated with the release 
of soymorphins from soy based infant formulas on brain development in early life. Collectively 
the behavioural results from this thesis highlight a need for the development of safer infant 
formulas, which do not contain potent bioactive protein break down products, which may elicit 
and effect on brain development and subsequent behaviour in early life.  
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Furthermore, currently A2 milk is marketed and sold in the United Kingdom amongst other 
developed countries, as the safer alternative to standard cow’s milk as it does not contain A1 beta 
casein derived BCM-7 (Woodford, 2007; The A2 Milk Company, 2014). However, the 
behavioural findings from results Chapters 2, 3 and 4 together suggest prolonged casein 
consumption, independent of A1 or A2 variants, result in behavioural impairments. Over the past 
two years there has been a substantial decline in cow’s milk consumption globally, this is reflected 
in increasing consumption of plant based milk beverages such as coconut and almond milk, with 
worldwide sales of non-dairy milk alternatives more than doubling between 2009 and 2015  
(Whipp and Daneshkhu, 2016). This shift has largely been due to health risks associated with the 
cow’s milk exposure such as gastrointestinal problems from lactose intolerance (Thorning et al., 
2016). The data obtained in this thesis add to the health concerns linked to dairy-milk consumption, 
highlighting the potential development of neurological disorders. Together, such evidence 
reinforces the push for plant based infant formulas as a safer alternative or supplement to 
breastfeeding.  
5.2 Effect of Casein Exposure on Neurochemistry 
 
Neurochemical analysis using autoradiographic binding techniques in results Chapter 2 showed 
significant alterations in brain neurochemistry in the form of downregulations to both OTr and 
MOPr in key regions of the brain associated with mood regulation as a result of casein consumption 
beyond the standard age of weaning, which were concomitant with the increase in depressive like 
behaviour observed. The exact mechanisms by which casein exposure is causing the behavioural 
and neurochemical changes reported still remain to be fully elucidated. However metabonomic 
data from Chapter 4 revealed critical clues in the form of an increase in the metabolite SAH in the 
frontal cortex of rats provided with milk rich diets from PND21 until PND26 compared to control 
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animals weaned normally on PND21. SAH is a key component involved in DNA methylation, a 
major factor in epigenetic changes and subsequent gene expression (see Trivedi et al., 2014). This 
finding suggests mechanisms of epigenetic gene regulation are likely to be involved in mediating 
the down regulation of MOPr and OTr reported following prolonged casein exposure. Indeed, this 
theory is further reinforced by  recent evidence which suggests that food derived opioid peptides 
such as BCM-7 can induce genome wide DNA methylation and hence are able to exert epigenetic 
changes (Trivedi et al., 2014, 2015; Deth et al., 2016). This may be of particular importance during 
early postnatal development when the brain is sensitive to environmental influences.  Moreover, 
abnormal DNA methylation patterns have been reported in neurodevelopmental disorders such as 
ASD (Schanen, 2006), further supporting a casein induced epigenetic mode of action in mediating 
the neurochemical and emotional impairments observed. Moreover, these findings corroborate 
clinical studies showing a positive effect associated with  casein-free diets on children suffering 
from neurodevelopmental disorders such as autism (Whiteley et al., 2010). 
5.3 Behavioural Modulation by Gut Microbiota  
 
The gut-brain axis is a communication system which includes neural, immunological and 
hormonal signalling between the gut microbiota and the brain, providing a potential route by which 
intestinal bacteria and their metabolites can influence the brain and subsequent behaviour. The 
literature cited in Chapter 1 (Section 1.5.4) provide strong evidence showing the ability of the gut 
microbiota in influencing brain development and behaviour. Indeed results obtained in this thesis 
demonstrate that the casein induced increase in depressive like behaviour was concomitant with a 
significant increase in bacteria belonging to C. histolyticum group. This group of bacteria are 
recognised as toxin-producing bacteria that can exert systemic effects. Moreover, results Chapter 
3 demonstrated that AB induced knock-down of the gut microbiome during the weaning period 
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resulted in significant alterations to behaviour as assessed by the FST, confirming that the gut 
microbiota does indeed play a key role in mediating behaviour.  
These findings are fascinating and raise concerns regarding the use of AB in early postnatal life in 
infants. Currently, research regarding the use of AB in infants and its effect on behavioural 
development is lacking. Antibacterial agents are frequently prescribed worldwide in infants 
(McCaig et al., 2002) despite a substantial number of expert guidelines advocating more limited 
use due to antibiotic resistance (Finkelstein et al., 2003; Thompson et al., 2008).  Furthermore, 
with growing appreciation regarding the role of the gut microbiome in many aspects of human 
physiology including metabolism and immune responses, knowledge of the importance of the 
microbiome in human development raises new issues about antibiotic use in infants as such 
exposures may disrupt the normal development of microbial ecology (Bedford et al., 2006). Unlike 
the microbiota of adults which appears to be relatively stable, the microbiota of infants is 
considerably more variable and more vulnerable to antibiotic perturbation. Indeed, increased risk 
from childhood AB exposure to atopic dermatitis, asthma as well as inflammatory bowel diseases 
has been reported. The results obtained in Chapter 3 add to this growing body of evidence and 
raise concerns regarding AB exposure in infants and its potential effects on behaviour.  
5.4 Metabolic Impact of casein Exposure  
 
A systems biology approach using NMR-based metabonomics was used to highlight metabolic 
variations associated with casein rich milk diets as well as AB exposure in early postnatal life. The 
data obtained shows changes in a number of metabolites associated with bacterial metabolism, as 
well as choline and energy metabolism following prolonged casein exposure, most of which have 
been identified as biomarkers of depressive disorders. Moreover, consistent with changes in 
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microbial composition following AB treatment in Chapter 3, the use of NMR-based metabonomics 
techniques demonstrated significant changes in a number of gut microbial metabolites, further 
implicating the role of gut microbiota and its metabolites in mood regulation during the critical 
developmental period in early life. This is consistent with studies showing an association between 
gut conditions such as IBS and mood alterations (Gros et al., 2009). Whether the metabolic 
pathways found to be disrupted in these studies are a direct cause of the emotional changes reported 
or a product of them remains unknown. Nonetheless, these findings provide useful evidence of 
potential metabolic pathways involved in the aetiology of CNS disorders, which in future may 
enable the design of drugs that specifically target these pathways. 
Interestingly, metabolic analysis also revealed that BCM-7 exposure through consumption of milk 
containing the A1 variant of casein induced higher neuronal activity in the frontal cortex, compared 
to animals provided with A2 milk containing no BCM-7 and control treated animals.  This was 
shown in the form of increased GABAergic and glutamergic metabolites as well as higher 
expression of a marker of neuronal damage (Baslow, 2003) which has been shown to be elevated 
in several degenerative neurological disorders (see Miller, 1991) in BCM-7 exposed rats. These 
findings are interesting and support evidence from parents of children suffering from ASD who 
have reported improved symptoms following consumption of A2 milk. This indicates that A2 milk 
may indeed confer some health benefits over the standard milk type found in western countries 
today.  
 
 
5.5 Study Limitations  
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 The FST was the only behavioural test used for depression in this thesis. Depression is a 
complex phenotype, other tests such as the tail suspension test could be used to confirm 
depression.    
 Although consumption of casein free milk did not elicit an increase in depressive-like 
behaviour as assessed by the FST, the neurochemical changes induced by casein free milk 
may be driving other behavioural phenotypes such as anxiety or social interaction which 
were not measured. 
 Although no difference in depressive-like behaviour was observed between A1/A2 and A2 
treated animals, differences in brain metabolic profiles between the two groups could be 
driving other behavioural differences such as sociability or anxiety which were not tested. 
 As locomotion was not assessed prior to the FST in results Chapter 3, it is not possible to 
exclude the possibility that the increase in swimming behaviour observed in the FST 
following AB treatment is not driven by differences in motor activity. 
5.6 Future Studies  
 
 It would be beneficial for future studies to measure the persistence of the observed 
behavioural deficits following prolonged casein exposure into adulthood either after 
cessation of casein consumption following delayed weaning or following continued 
consumption of milk caseins into adulthood in rats, which is more reflective of milk 
drinking practices in most western societies today. Especially as studies show that 
environmental influences in early life can have long lasting effects into adulthood including 
development of neuropsychiatric conditions. 
 Given the role of the immune system in mediating communication between the gut brain 
axis, future studies should measure inflammatory markers following casein and AB 
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exposure in early life to shed light on potential mechanism by which the gut and the brain 
could be communicating in mediating behavioural alterations.  
 The exact casein breakdown products driving the behavioural neurochemical metabolic 
and microbial changes observed in these studies are yet to be identified. Measurement of 
behaviour using a battery of behavioural tests following i.v injections of BCM-7 and other 
casein derived breakdown products could help answer this question. 
 The findings in this thesis highlight the need for human studies to answer the effect of 
prolonged casein exposure on the gut microbiome and behaviour. One proposed study 
could assess behavioural and microbial differences in infants from countries like China 
which typically do not use milk beyond the age of weaning compared to infants in western 
countries in which milk rich diets are popular. Also, epidemiological studies assessing 
durations of breast feeding and associated behavioural development would be of interest. 
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5.7 Conclusion 
 
In summary the findings from this thesis provide strong evidence that dietary manipulation during 
the sensitive developmental period in early postnatal life result in behavioural, neurochemical, gut 
microbial and metabolic alterations and raise concerns regarding early life factors and their 
potential harmful effects on mood disorders. In particular, it was shown that prolonged 
consumption of milk caseins beyond the normal age of weaning results in emotional impairments 
and has important public health implications regarding exposure to milk caseins in infancy either 
in the form of prolonged breastfeeding durations or provision of cow’s milk as strong 
environmental factor influencing mood disorders. These public health considerations should 
include comprehensive guidelines on weaning practises, consumption of cow’s milk and other 
food products such as soy which may release bioactive breakdown products, as well as exposure 
to antibiotics in early postnatal life, all of which have been shown to have potential implications 
in the pathogenesis of paediatric psychiatric illnesses.  In utilising a multidisciplinary approach the 
work described here demonstrates that brain development and subsequent mood are influenced by 
changes in gut microbial profile and metabolic pathways as well as potential epigenetic alterations.  
Future work should aim to investigate direct mechanisms by which the microbiome-gut-brain axis 
communication influences behaviour during early life development as well as direct mechanisms 
by which casein could be causing alterations to the gut microbiome and brain neurochemistry.  
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